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Abstract 
Introduction: The prevalence of overweight and obesity is increasing worldwide. It has been 
estimated that every kilogram of weight gain during adulthood represents a 3% to 6% risk increased 
of cardiovascular disease. There are some studies showing an inverse relationship between calcium 
intake and body weight. Overweight and obese women are advised to lose weight before conception, 
however the evidence on how to achieve this is scarce. No studies have investigated the effect of 
calcium supplementation on weight management before conception or during pregnancy. 
Aims and objectives: The overarching purpose of this project was to provide information and enrich 
the body of evidence of the effect of calcium intake on body weight. The first aim was to evaluate 
the effect of calcium intake on body weight of fertile or pregnant women; secondly to investigate the 
pre-pregnancy weight status, weight gain during pregnancy and adequacy of dietary intake of 
pregnant women participating in the Calcium and Pre-eclampsia (CAP) trial. The third aim was to 
perform a systematic review of studies evaluating the effect of calcium intake on body weight. 
I was part of the core research team throughout the CAP trial duration and also lead the nutritional 
component. The trial sample size included 540 pregnant women recruited between 2012 and 2017 in 
South Africa, Zimbabwe and Argentina. Women were randomized pre-pregnancy to receive 500 mg 
of elemental calcium or placebo until 20 weeks´ gestation, whereafter they received 1500 mg. Weight 
was measured pre-pregnancy and at 8, 20 and 32 weeks’ gestation. Diet was assessed at 20 weeks´ 
gestation. Ethical approval was obtained from appropriate national and institutional ethical review 
bodies as applicable for each study site. 
Results: There was a high proportion of women who started their pregnancy overweight or obese 
(73.7% in South Africa and 60.2% in Zimbabwe). Most women had an inadequate intake of 
micronutrients at 20 weeks pregnancy. For the most basic micronutrients like iron, calcium, folate 
and zinc, the percentage of women with intakes below requirements was above 90%.  
Although there was no effect of calcium supplementation on body weight in the sample of the CAP 
trial, the calcium group had a no statistically significant smaller increase in body weight during 
pregnancy especially in those who were obese at the start of the trial. The systematic review shows a 
small but statistical effect of calcium supplementation in body weight (Mean Difference (MD) -0.33 
kg, 95% CI -0.57 to -0.09); (p=0.007); 819 participants; 15 studies) and in BMI (MD -0.17, 95% CI 
-0.21 to -0.13); p < 0.00001; 695 participants; 10 studies). 
Conclusion: We found a high prevalence of obesity found together with the micronutrient 
inadequacy which show a very poor nutritional status of women who have the possibility of getting 
pregnant again. This needs to be addressed so that maternal and perinatal outcomes are improved. 
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There is a need to implement nutritional counselling preconceptionally to these women before they 
fall pregnant. The results of this thesis show a no statistically significant smaller increase in body 
weight in women supplemented with calcium, opening a promising area of research for weight 
management including the study of the mechanisms involved. Before making clinical 
recommendations further studies are needed with higher sample size to have the power to detect 
clinically significant effects. 
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Chapter 1  - Introduction 
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1.1 Introduction and Motivation 
Poor nutrition is one of the main contributors to burden of disease.1,2 Nutrient intake before and during 
pregnancy, and weight gain during pregnancy are the main influencing factors to pregnancy outcomes 
and early child health.3–7 It is well known that women who start a pregnancy in optimal nutrition 
status have lower risk of developing complications such as pre-eclampsia, gestational diabetes 
mellitus, gestational hypertension, depression, foetal macrosomia, stillbirth, preterm birth, birth by 
caesarean section and infant mortality.8–13 Furthermore, high maternal body mass index (BMI) has 
been associated with delayed breastfeeding, post-natal weight retention and in women with 
gestational diabetes, a higher risk of developing chronic diseases later in life.12  
Excessive weight gain during pregnancy and failure to get back to pre-pregnancy body weight also 
bear consequences later in life, as it increases the risk of obesity and cardiovascular disease.14 Weight 
gain during pregnancy seems to be a better predictor of later obesity than pre-pregnancy BMI.15,16 
Interest in pre-conceptional interventions to reduce risk factors during pregnancy is growing, 
although their effectiveness on pregnancy outcomes is less certain.17 
Inter-pregnancy interval is also an important moderating factor, as it may influence maternal 
availability of nutrients, especially in those populations with existing micronutrient deficiencies.18 
In many low and middle-income countries (LMICs) undernutrition and overnutrition coexist in the 
same population.19 Obesity rates are increasing while micronutrient deficiencies still persist, 
particularly in the most vulnerable groups such as women and children.20 Inter-pregnancy interval 
has been shown to be an important moderating factor of nutritional status in pregnant women and 
pregnancy outcomes, as it may influence maternal availability of nutrients, especially in those 
populations with existing micronutrient deficiencies.18 Furthermore, excessive weight gain during 
pregnancy and failure to return to pre-pregnancy body weight also has consequences later in life, as 
it increases the risk of obesity and cardiovascular disease.14 
Interest in pre-conceptional interventions to reduce risk factors for complications during pregnancy 
is growing, although their effectiveness on pregnancy outcomes is less certain.17 While many 
treatment options exists for obesity, with varying degree of effectiveness, weight loss in obese women 
during pregnancy is not recommended. Calcium intake has been receiving interest due to its role in 
the management of blood pressure during pregnancy and weight in adults. A systematic review of 
dietary intake of pregnant women carried out in 2004 indicates a low calcium intake in African and 
Latin American populations.21 The study reported a median intake of 481 mg a day for Argentina and 
567 mg a day for South Africa, although the number of women assessed was very few and no data 
were reported for Zimbabwe. It is thus likely that calcium intake of pregnant women in LMICs is 
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much lower than recommended daily calcium intake during pregnancy, which is around 1000 to 1300 
mg a day.22 Furthermore, for the prevention of pre-eclampsia, the WHO guidelines state that pregnant 
women at high risk of pre-eclampsia, including those who previously had pre-eclampsia and those 
from areas of low calcium intake, should take 2000 mg of calcium a day from 20 weeks´ gestation.1 
This recommendation was based on a systematic review of thirteen randomised trials which included 
15730 women and showed that 2000 mg of calcium supplementation starting at 20 weeks of 
pregnancy resulted in the risk of pre-eclampsia being reduced by more than half when compared to a 
placebo (Relative Risk (RR) 0.45 95%, Confidence Interval (CI) 0.31-0.65).23 
Davies et al. 2000 indicated that a decline in calcium intake is associated with an increase in 
population weight gain, even in people of normal weight.24 A systematic review of the effect of 
calcium supplementation on weight management indicated a small reduction in body weight, however 
the included studies had a short intervention period of around 6 months and the effect during 
pregnancy was not assessed. 25 This evidence is questionable despite being by all randomised 
controlled trials because the risk of bias was not properly described. Although the individual clinical 
relevance of this hypothetically small weight reduction hypothetically proposed for women at 
childbearing age seems marginal, at a population level it could help to prevent the observed obesity 
global trends. 26  
The WHO Calcium and Pre-eclampsia (CAP) trial is a double blind randomised control trial that was 
carried out in South Africa, Zimbabwe and Argentina. The aim of the trial was to determine whether 
calcium supplementation before conception and during the first half of pregnancy reduces the 
incidence of recurrent pre-eclampsia more effectively than supplementation starting at 20 weeks, 
which is the current WHO recommendation. 27 In the CAP trial, non-pregnant women with a history 
of pre-eclampsia or eclampsia in their most recent pregnancy and with the possibility to become 
pregnant again were invited to participate. Eligible women were randomised to receive calcium or 
placebo, from admission to the trial, before pregnancy. Blinded supplementation continued pre-
pregnancy and up until the 20th weeks of pregnancy if they become pregnant. After the 20th week of 
pregnancy, participants received calcium supplements in compliance with WHO guidelines on 
pregnancy supplementation.1,28 The WHO CAP double blind randomised control trial gave an unique 
opportunity to assess the effect of calcium supplementation on the weight of women of fertile age 
and in pregnant women using data from a well-designed and monitored on-going trial. 27 
The current thesis uses data of the CAP trial to evaluate the effect of calcium on the weight of 
non-pregnant women and then separately in those women who became pregnant. Also, taking into 
account the scarcity of information related to dietary intakes in pregnant women in South Africa and 
Zimbabwe, a description of the dietary intake status of the CAP trial participants is justified. Lastly, 
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building on the flaws of the previous systematic review that was conducted in 201125 which showed 
a small effect of calcium supplementation on weight, I proposed to update the evidence by performing 
a good quality systematic review and meta-analysis of studies on the effect of calcium 
supplementation on weight in different population groups. This review was important as it 
incorporated new studies published after the last review in 2011, as well as population groups that 
were not included before, such as pregnant women. 
Evaluating the effect of calcium intake on weight is essential to better understand the impact that a 
population-based strategy could have on pregnant women for the prevention of overweight and 
obesity and their consequences. 
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1.2 Aim and Objectives 
 
The overarching purpose of this project was to provide information and enrich the body of evidence 
of the effect of calcium intake on body weight through three specific aims. 
Aim 1: To evaluate the effect of calcium intake on body weight of fertile or pregnant women with a 
history of pre-eclampsia or eclampsia participating in the WHO Calcium and Pre-eclampsia (CAP) 
trial: nested study of the CAP trial RCT. 
Aim 2: To investigate the pre-pregnancy weight status, weight gain during pregnancy and the 
adequacy of dietary intake of pregnant women in the CAP trial. 
Aim 3: To perform a systematic review of studies evaluating the effect of calcium intake on body 
weight and summarise the evidence available. 
 
Objectives related to aim 1 - CAP trial nested-study: 
- Primary objective 1.1: To assess the effect of calcium supplementation on body weight of women 
in reproductive age. 
- Primary objective 1.2: To assess the effect of calcium supplementation on women body weight 
gain during pregnancy and on the birth weight of newborns. 
Secondary Objectives: 
• To estimate energy intake during the second trimester of pregnancy. 
• To compare the energy intake of women assigned to calcium and placebo groups. This will allow 
for the exploration of a potential mechanism of action for the effect of calcium supplementation 
on body weight. 
• To estimate mean daily calcium intake during the second trimester of pregnancy. 
• To explore calcium and energy intakes by age and parity. 
• To assess the effect of total calcium intake (supplementation plus food) on maternal body weight 
during pregnancy. 
• To estimate the proportion of women participating in the CAP trial during their second trimester 
of pregnancy with usual dietary intakes of calcium below 800 mg of calcium per day. Estimates 
were analysed separately for Argentina and African countries. To attain this objective, a 
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subsample of women enrolled in the CAP trial underwent a second dietary recall upon reaching 
20 weeks of pregnancy. 
• To assess the effect of calcium supplementation on maternal body weight according to dietary 
calcium intake levels. 
• To assess the effect of calcium supplementation on weight gain during pregnancy according to 
Body Mass Index (BMI) groups at the start of the pregnancy. 
 
Objectives related to aim 2 – dietary intake adequacy during the second trimester - CAP Trial. 
• To assess and describe preconception weight according to WHO BMI classification. 
• To assess and describe weight gain during pregnancy. 
• To assess and describe the dietary intake of energy, macronutrients and micronutrients. 
• To compare actual energy intake with current dietary standards for pregnant women e.g. the 
estimated energy requirements (EERs). 
• To compare the actual intakes of carbohydrates, proteins, vitamins and minerals with current 
dietary standards for pregnant women e.g. estimated average requirements (EARs) and 
adequate intakes (AIs). 
• To calculate and describe the macronutrient distribution as a percentage of total energy intake; 
• To compare the macronutrient distribution as a percentage of total energy intake with the 
recommended macronutrient distribution ranges. 
Objectives related to aim 3 - Systematic review and meta-analysis:  
Primary objective 3.1: To evaluate the effect of calcium supplementation on body weight in 
individuals of different ages. 
Systematic reviews are the best approach available to describe the evidence of health interventions. I 
proposed the title “Calcium supplementation for weight reduction” to the Cochrane Metabolic and 
Endocrine Disorders Group and it was consequently accepted and registered in September 2015 
(Cochrane Registered Title number: T150806) 
CAP trial nested-study 
Hypothesis  
- Hypothesis 1: Daily calcium supplementation with 500 mg of elemental calcium reduces the 
body weight of women of reproductive age.  
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- The hypothesis was only postulated for Aim 1 and on the effect of calcium on the body weight 
of non-pregnant women, as it was not expected that pregnant women would lose weight. For 
pregnant women the objective was to evaluate safety by comparing maternal body weight 
gain and birth weight of the baby between calcium and placebo groups to explore if there was 
any difference. 
1.3 Contribution of candidate 
I conceptualized and coordinated the nutritional component of the CAP trial in the three countries 
where it was performed (South Africa, Zimbabwe and Argentina). Within this role I conceptualized 
the protocol for my PhD thesis. I designed the 24-hour questionnaires, as well as trained and 
supervised the personnel for data collection and data management in the three countries of interest. I 
was also in charge of reviewing all data and managing queries and data quality. For this I travelled to 
the sites in each country annually. Finally, I performed the data analysis and interpretation. I was a 
member of the Steering Committee of the CAP trial which allowed me to use the data immediately 
after the trial was closed (See ANNEXURE A). I am also part of the Argentinean Cochrane Centre 
that provided the support to perform the systematic reviews. I proposed and wrote all protocols 
analyzed in this thesis and performed the analysis with the support of my supervisors. I had written 
agreement with the WHO study coordinator and co-supervisor Dr. Ana Pilar Betrán Lazaga, to 
implement this project proposal.  
1.4 Definition of terms 
Usual dietary calcium intake: Calcium intake distribution adjusted by the within person variability 
calculated from 2 non-consecutive 24 hour recalls from each individual of the subsample.29 
Pre-eclampsia: pregnancy-specific syndrome was diagnosed when a pregnant woman had increased 
blood pressure and proteinuria after 20 weeks of pregnancy.30 Gestational hypertension (diastolic BP 
>90 mmHg on two occasions 4 hours apart, or >110mmHg once, and/or systolic BP >140 mmHg on 
two occasions 4 hours apart, or >160mmHg once, after 20 weeks’ gestation) and gestational 
proteinuria (2+ or more on urine dipstick, or >300mg/24 hours, or >500mg/L or urinary 
protein/creatinine ratio >0.034g/mmol, after 20 weeks’ gestation. 
Body Mass Index: index of weight-for-height defined as the weight in kilograms divided by the 
square of the height in metres (kg/m2).32 
Birth weight: body weight of the baby at birth as measured by each clinic. 
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1.5 Outline of thesis 
Chapter Two of this thesis contains a review of literature covering the current state of overweight and 
obesity and their effects on health, the existent evidence of the relationship between calcium intake 
and body weight, the global status of calcium intake and finally a description of the use of the 24-
hour recall methodology. Chapter Three focuses on the methods used throughout the sub-studies. 
Chapter Four includes the article “Effect of calcium supplementation on body weight of women in 
reproductive age” and further analysis to respond to aim 1: To evaluate the effect of calcium intake 
on body weight of fertile or pregnant women with a history of pre-eclampsia or eclampsia 
participating in the WHO Calcium and Pre-eclampsia (CAP) trial. Chapter Five includes the article 
“Pre-pregnancy weight status, weight gain during pregnancy and adequacy of dietary intake of 
pregnant women in the CAP trial” and further analysis to respond to aim 2: To investigate the 
pre-pregnancy weight status, weight gain during pregnancy and the adequacy of dietary intake of 
pregnant women in the CAP trial. Chapter Six includes a systematic review evaluating the effect of 
calcium intake on body weight and summarising the evidence available. The final chapter summarises 
these findings, discusses the potential implications, and suggests future lines of study related to the 
topic. 
Due to the structure followed for this thesis it is inevitable that there will be overlap in content. This 
is particularly conspicuous in the methodology chapter and the chapters that contains articles, where 
the methods are more concisely described as per requirements for a journal publication. 
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Chapter 2 - Literature Review 
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2.1 Introduction 
 
In this literature review I describe the overweight and obesity trends globally. Thereafter I focused 
on the literature available for South Africa, Zimbabwe and Argentina as women from these countries 
where included in the CAP trial. This review also provides a description of the literature available of 
the dietary intake of women in these countries. Furthermore, the review gives a broad overview of 
the causes, consequences and treatment of obesity especially during pregnancy. Finally this chapter 
provides a more detailed description of the role of calcium in body weight, as it was the background 
information required to formulate the aims of this thesis. 
 
2.2 Overweight and Obesity 
 
The prevalence of overweight and obesity is increasing worldwide and in different age groups.33–35 
According to the World Health Organization (WHO), the prevalence of obesity doubled between 
1980 and 2008 and it is increasing more rapidly in lower-middle income countries.36 There is also 
evidence that obesity is increasing more than overweight rates. In the adult population, obesity is 
more prevalent in women than in men. Between 23% and 29% of women are obese in the European, 
the Eastern Mediterranean and American Regions.37 Obesity is also a problem in adolescents. A 
systematic review of 23 studies reporting national data shows that in 21 countries the prevalence of 
adolescent overweight and obesity was higher than 20%.38 The prevalence of overweight and obesity 
in children has shown a remarkable increase over the last decades, representing a public health 
challenge as they tend to track into adult life. 39,40 
The South African National Health and Nutrition Examination Survey (SANHANES-1) performed 
in 2012 reports a prevalence of overweight and obesity of 24.8% and 39.2% for females and 20.1% 
and 10.6% for males, respectively.41 More recently, the 2016 South African Demographic and Health 
Survey shows a slightly higher prevalence of overweight and obesity of 68% in women where one in 
five women was considered severely obese.42 On the other hand, the prevalence of overweight or 
obesity in men was 31%, less than half of that of women. The overweight rate in children was 13% 
percent according to their weight-for-height measurements.  
The Argentina National Health and Nutrition Survey performed in 2004 shows a prevalence of 24,9% 
overweight and 19,4% obesity in females, while no data were collected for men. The National Health 
and Nutrition Survey has not been repeated since then. However, in 2013 a National 
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Non-Communicable Disease Survey of Risk Factors was carried out.43 While this survey included a 
general population aged 18 years or older living in cities with more than 5.000 inhabitants and has 
probabilistic sampling; weight was reported rather than measured. There were 32.365 people 
interviewed on the telephone with a response rate of 70.7%. The overweight prevalence was 43.3% 
for women and 31.3% for men and the prevalence of obesity was 22.9% for women and 18.8% for 
men. It seems that the obesity and overweight figures are increasing in Argentina, however it should 
be borne in mind that the National Health and Nutrition Survey used direct measurements of weight 
and height while the National Non-Communicable Disease Survey of Risk Factors used self-reported 
measurements. Recently a review of 21 studies and including 18.749 women showed some evidence 
that in women of reproductive age, self-reported weight and height differs slightly from direct 
measures.44 The review reported an underestimation of weight by -0.94 kg (95% CI -1.17 to -0.71 kg) 
in the overall sample and an overestimation of height by 0.36 cm (95% CI 0.20-0.51), values that are 
not considered acceptable for clinical purposes. Considering however the extremely high prevalence 
of overweight and obesity, the data can be used to give an overall trend of the situation. Even more, 
taking into account the differences between self-reported weight and height shown in the review, 
where women under report weight and over report height, the prevalence’s shown in the National 
Non-Communicable Disease Survey of Risk Factors for women in Argentina could be even higher. 
Data from Zimbabwe comes from the Demographic Health Survey funded by the United States 
Agency for International Development and shows that the prevalence of overweight and obesity for 
women has increased from 23% in 1994 (17.3% overweight and 5.7% obesity) to 35% in 2015.45–47 
On the other hand the prevalence of overweight and obesity for men has increased in much lower 
rates, from 9% in 2010 to 12% in 2015, although for men there is no earlier data. For both women 
and men, the overweight and obesity prevalence in Zimbabweans increased with age, wealth and 
education. Also, those living in urban areas had a higher overweight or obesity prevalence than those 
living in rural areas, 46% and 28% respectively for women and 21% and 7% respectively for men.45,48 
According to the Non-Communicable Disease Risk Factor Collaboration that holds data on obesity 
prevalence of 200 countries, South African women are ranked 23rd for obesity and 16th for severe 
obesity, whereas South African men are ranked 112th for obesity and 65th for severe obesity. 49 On 
the other hand women in Argentina are ranked 56th for obesity and 54th for severe obesity, whereas 
for men, Argentina is ranked 28th for obesity and 29th for severe obesity. Zimbabwe is ranked 88th for 
women obesity and 81rst for severe obesity, whereas for men, Zimbabwe is ranked 158th for both 
obesity and severe obesity. 49 Overweight and obesity are more prevalent in women than in men in 
South Africa and Zimbabwe and the opposite in Argentina. Also some literature reports that obesity 
has more deleterious effect in women than in men.50 A report evaluating the impact of obesity states 
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that an obese man is 5 times more likely to develop type 2 diabetes and 2.5 times more likely to 
develop high blood pressure than a healthy weight man, whereas compared to a healthy weight 
woman, an obese woman is thirteen times more likely to develop type 2 diabetes four times more 
likely to develop high blood pressure.51  
Obesity represents a major and challenging public health problem as it increases the risk of 
developing high blood pressure, insulin resistance, heart disease, diabetes, osteoarthritis, sleep apnea 
and in pregnant women increases the risk of adverse pregnancy outcomes such as macrosomia, 
gestational hypertension and gestational diabetes.9–11,36,46 It has been estimated that every kilogram 
of weight gain during adulthood increases the risk of cardiovascular disease by 3.1 to 5.7% and for 
pregnant women every 5 to 7 kg/m2 increase in BMI doubles the risk of pre-eclampsia. 8,52 A 
systematic review of the economic burden of obesity worldwide estimated that those who are obese 
have 30% greater medical costs compared to normal weight individuals. 53 
Although the information on overweight and obesity rates specifically during pregnancy is scarce in 
South Africa, Zimbabwe and Argentina, there is evidence suggesting that a great number of women 
are reaching pregnancy with excess weight. A recent study in Johannesburg showed that 55% of the 
538 participants presented excessive weight gain during pregnancy.54 In Argentina the National 
Nutritional Survey of 2005 shows that 19.7% of pregnant women were overweight and 24.4 were 
obese.55 
 
2.3 Causes and treatment of obesity 
 
Obesity is the excessive accumulation of fat mass in the body, however obesity aetiology is complex 
as it is influenced by environmental and social factors, genetics, epigenetics as well as prenatal and 
early life influences.56 Environmental and social factors are very important as they impact on diet and 
physical. This is evident by the rapid increase of obesity that cannot be due to genetics only. This is 
also shown by the nutritional transition with the rapid increase of obesity in urban areas where people 
have more access to energy-dense foods and fewer opportunities to maintain physical activity.19,56 
Although obesity is the accumulation of fat mass in the body, there are many physiological 
mechanisms put in place that impair easy weight reduction by merely restricting energy intake.57 
Consequently, there is no single treatment for obesity and a broad approach taking into account many 
risk factors should be implemented. Pregnant women are advised to have a healthy diet and to keep 
physically active during pregnancy, however it is recognised that most of the research on healthy 
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eating and exercise comes from high income countries, and less evidence is available on low and 
middle income countries.4 
Despite being recognised by WHO as a disease in 1948, it was not until the year 2000 that obesity 
started being accepted as one of the main health risk factors.58 Just recently countries started to 
recognise obesity as a disease, which is crucial for the broad approach it requires.59 
  
2.4 Weight gain during pregnancy 
 
In order to improve pregnancy outcomes, overweight and obese women are advised to lose weight 
before conception, however there is lack of evidence on how to manage their weight during 
pregnancy. 60,61 as dieting during pregnancy may increase the risk of ketosis that is harmful for the 
foetus, it is recommended that women not lose weight but rather gain weight at a reduced rate. The 
current weight gain recommendations for pregnancy specify that women classified as normal weight 
are advised to gain from 11.5 to 16 kg; those classified as overweight are advised to gain from 7 to 
11.5 kg and those classified as obese are advised to gain from 5 to 9 kg.62 The WHO Guidelines also 
report that women receiving counselling on diet and/or exercise are less likely to experience excess 
weight gain during pregnancy. 
 
2.5 Calcium intake and body weight, postulated mechanisms 
 
There are some studies showing an inverse relationship between calcium intake and body weight. 63 
A systematic review in 2011, that included seven studies with 794 overweight or obese participants, 
showed that calcium supplementation compared to placebo produced a mean body weight-loss of 
0.74 kg (CI -1.00 to -0.48).25 Six of the included studies had a duration of six months with a dose of 
1000 mg of elemental calcium a day and one study had a duration of 24 months with a dose of 1500 
mg of elemental calcium a day. 
Three mechanisms in which calcium could affect body weight have been postulated. The first one is 
linked to the regulation of the parathyroid hormone that is required to maintain specific calcium 
concentrations in extracellular fluids (See Figure 2.1).64,65 Serum calcium is tightly regulated and 
small reductions stimulate parathyroid hormone and 1-25 vitamin D secretion to increase calcium 
resorption from the bones, kidneys as well as absorption in the intestine. However, higher levels of 
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parathyroid hormone and 1-25 vitamin D also stimulate calcium influx into different cell types, 
including the adipocyte. 63In the adipocyte, this increase of intracellular calcium stimulates fatty acid 
synthase and consequent lipogenesis, and could thus lead to weight gain.64 Low calcium diets have 
also been linked to insulin resistance and high blood pressure through similar collateral effects. 66,67 
Likewise, higher levels of parathyroid hormone and 1-25 vitamin D increase intracellular calcium 
uptake into the vascular smooth muscle cell and consequently increase muscle reactivity and 
peripheral vascular resistance which contribute to a higher blood pressure. 68,69 In summary, hormones 
like parathyroid hormone, that are released to compensate for low serum calcium levels could 
increase of blood pressure and body weight as collateral effects.66 
 
 
Figure 2-1: Cellular effects of a low calcium diet. From Mechanisms Involved in the Relationship between Low 
Calcium Intake and High Blood Pressure. Villa-Etchegoyen C, Lombarte M, Matamoros N, Belizán JM, Cormick G. 
Nutrients. 2019 May 18;11(5). 
 
A second postulated mechanism is associated with the reduction of fatty acid absorption in the 
intestine. Higher calcium intakes could bind to bile acids or fatty acids impairing their absorption and 
decreasing available energy. 70,71 One randomised control trial found that individuals assigned to 
cocoa butter fortified with 900 mg of calcium daily for one week had increased excretion of fatty 
acids whereby total absorbable energy decreased as compared to those assigned to non-fortified 
cocoa. 72 
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Finally a third postulated mechanism is related to appetite regulation, although this has not been much 
studied. One randomised controlled trial (RCT) found an increase in postprandial gastrointestinal 
peptides such as glucagon-like peptide-1 (GLP) and glucose-dependent insulinotropic peptide in 
healthy individuals after receiving calcium supplementation.73 An increase in gastrointestinal 
peptides has been associated with reduced appetite. 74,75 
2.6 Other effects of calcium supplementation on health 
 
Besides the postulated effect of calcium supplementation on weight, other evidence indicates that 
calcium may also reduce blood pressure, pre-eclampsia (PE) and hypercholesterolemia.  
 
A systematic review that included 13 RCTs and 15.730 women estimated that calcium 
supplementation compared to placebo reduced the risk of PE by 55% (RR 0.45, 95% CI 0.31 to 
0.65).23 There is also evidence that calcium supplementation also reduces systolic blood pressure in 
adults by 1.14 mmHg with doses of calcium 1000 to 1500 mg a day and by 2.79 mmHg with doses 
of calcium equal to or over 1500 mg a day.76 In this review it was found that calcium supplementation 
had the greatest effect in young adults of less than 35 years as their systolic blood pressure was 
reduced by 2.11 mmHg. Reduction of blood pressure is one of the mechanisms by which it is believed 
that calcium reduces the incidence of pre-eclampsia. 
 
Furthermore, a systematic review on calcium supplementation and lipid metabolism reported that 
calcium supplementation reduced low density lipoproteins (LDL) cholesterol [-0.12 mmol/L (95% 
CI, -0.22 to -0.02)] and increased high density lipoproteins (HDL) cholesterol [0.05 mmol/L (95% 
CI, 0.00 to 0.10).77  
 
There is also evidence that calcium supplementation during pregnancy has a modelling effect on the 
offspring. Calcium supplementation with 1.5 grams after 20 weeks´ gestation showed a 27% 
reduction on the risk of children of supplemented mothers when they were 12 years of age in 
developing dental caries.78 Furthermore, a systematic review shows that children whose mothers 
received calcium supplementation had a reduction of -1.92 mm Hg (95% CI -3.14 to -0.71) in 
systolic blood pressure at age 1 to 9 years.79 
 
Metabolic syndrome is diagnosed by the presence of multiple risk factors, such as 
hypertriglyceridemia, low HDL cholesterol, hypertension, essential hypertension, abnormal fasting 
glucose levels, and abdominal or visceral obesity.80 Calcium may have implications in three of these 
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risk factors -high blood pressure, cholesterol and excess body weight- which lends support to the need 
for further efforts to implement strategies to improve calcium intakes.  
 
2.7 Calcium supplementation adverse events 
 
Calcium supplements and myocardial infarction  
Calcium supplements are commonly used to prevent fracture in postmenopausal women.81,82 In a 
narrative review by Bolland et. al. the use of calcium supplements in postmenopausal women was 
discouraged based on a previous secondary analysis of randomised controlled trials (RCTs) showing 
a potential increase of adverse events such cardiovascular health disease as atherosclerotic vascular 
disease in women from New Zealand receiving calcium supplements.83 Despite having several 
methodological limitations, such as self-reported events, the dissemination of the findings had a high 
public health impact producing a 66% decrease in monthly prescriptions of calcium supplements in 
New Zealand.84  
Subsequently, Lewis et al. published a systematic review and meta-analysis that included 18 RCTs 
involving 63.564 participants, all reporting cardiovascular events clinically verified by hospital 
records or death certificate.85–87 Seventeen trials contributed all-cause mortality data with pooled RR 
of 0.96 (95% CI, 0.91-1.02; p = 0.18). Five trials contributed CHD events with pooled relative RR of 
1.02 (95% confidence interval [CI], 0.96-1.09; p = 0.51). The RR for myocardial infarction was 1.08 
(95% CI, 0.92-1.26; p = 0.32). The authors concluded that current evidence does not support the 
hypothesis that calcium supplementation with or without vitamin D increases coronary heart disease 
or all-cause mortality risk in elderly women. 
Calcium supplements and iron intake  
There has been a concern related to the effects of calcium supplements on iron absorption. There are 
some studies showing that calcium supplements inhibit iron absorption by 28% to 55%.88 However, 
more recent evidence studying the long-term consequences of taking calcium supplements showed 
no effect on iron status showed.89–94 
Calcium supplements and renal stones  
The link between renal stones and calcium supplement intake is not of concern if calcium intake is 
maintained within the recommended levels as dietary calcium restriction is not recommended for 
stone formers with nephrolithiasis on the contrary diets with more than a gram of calcium a day could 
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be protective against stone formers.95 It is believed that the calcium that remains in the intestine would 
impede the absorption of products that could produce risk of renal lithiasis such as oxalates.96 For 
this reason there are studies that postulate that the intake of calcium supplements during meals would 
decrease the absorption of oxalates and thus decrease the formation of stones. 
 
2.8 Calcium intake review 
Calcium is the most abundant mineral in the human body. It is available in estimated quantities of 1.2 
kg. Ninety-nine per cent of calcium is found as calcium hydroxyapatite in the skeletal system and is 
essential for the creation, rigidity and maintenance of bones.97 The remaining one per cent is 
distributed between the intra- and extracellular fluids where it is involved in the majority of metabolic 
processes as well as in muscle contraction, nervous system transmission, enzymatic activation, and 
hormonal function.66 Calcium serum levels are regulated by the parathyroid hormone, vitamin D, and 
calcitonin. All of these control calcium bowel absorption, its bone resorption and its renal excretion. 
98 
Calcium requirements are high during all stages of life. Dietary recommendations for individuals over 
19 years of age vary from 1000 mg to 1300 mg, depending on the reference guidelines.99,100 
Requirements increase in specific periods of life especially during pregnancy.66 There is no consensus 
regarding the recommended intake during pregnancy. While most guidelines acknowledge the 
increased demand of calcium during pregnancy, some guidelines increase recommendations during 
pregnancy up to 1300 mg a day to achieve a positive balance while others state that metabolic 
adaptations during pregnancy compensate the required calcium demand. 101–105 
In most low- and middle-income countries, daily calcium intake is well below recommendations 
however, low intakes are also observed in certain age groups, such as adolescents, in high-income 
countries.21,106–108 Whereas calcium intake seems to be below 600 mg a day in low- and middle-
income countries, reports from high-income countries show that the intake is above 900 mg a day 
depending on age groups.97,109 A review of studies reporting dietary intakes of pregnant women from 
low- and middle-income countries shows consistently low calcium intakes across Asian, African and 
Latin American countries. 21,108 
2.9 Sources of calcium 
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Calcium intake is usually associated with the intake of dairy products such as milk, yoghurt and 
cheese, which are rich sources of calcium. However not all population have the same food patterns 
and dietary intakes. Whereas dairy products represent around 14% of total dietary energy intake in 
developed countries, in developing counties dairy products represent only around 4% of total energy 
intake.110 Some reports show that Asian countries have a higher proportion of total calcium intake 
from non-animal foods such as vegetables, legumes and grains, though they also have much lower 
calcium intake overall.110 In the United states 72% of calcium comes from dairy products and in 
China only around 7% of total calcium intake comes from dairy products while 30% comes from 
vegetables and 17% from legumes 81,111 
Calcium supplements can also provide a great proportion of calcium requirements. Some calcium 
supplements that are available over the counter have upto 1000 mg of calcium per pill which 
represents most of the nutritional recommendations for an adult. However, the use of supplements 
also varies between countries. In the United States and Canada around 40 percent of the adult 
population reported taking calcium supplements in the last month and 70 % of older women. 
Supplements in these countries can increase the average calcium intakes in about 10%.81 On the other 
hand in Argentina very few women reported taking calcium supplements, even during 
pregnancy.55,112 Due to new technology fortified foods such as cereals and juices can also become 
important sources. 
 
2.10 Dietary intake requirements during pregnancy 
 
Dietary reference values are established to account for the needs of growth, development, functioning 
and maintenance of health of healthy people and as references to plan and assess diets.82 The 
Estimated Average Requirements (EAR) are established for healthy individuals by sex, age and 
lifecycle stage. Requirements are estimated to account for the needs of half of the population they are 
aim at. Afterwards the Recommended Daily Allowances (RDA) are derived from the EARs and are 
set to account for the needs of most of the individuals in the age and life stage specific group, more 
specifically 97 to 98 percent of the group.113,114 The RDAs are calculated as the EARs plus two 
standard deviation. Whereas the RDAs are used to guide the diet of individuals the EARs are used to 
evaluate the diet of populations. In the case of energy, requirements are calculated using the Estimated 
Energy Requirement (EER) that is the average dietary energy intake predicted to maintain energy 
balance in a healthy adult by age, gender, weight, height and level of physical activity. Recommended 
dietary intakes for pregnant women vary according to different institutions.4,82,102–106,115,116 In South 
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Africa and Argentina adequacy of dietary intake is usually measured using the United States dietary 
reference intakes. 22,41,55,117  
Energy protein and nutrient intakes requirements and recommendations for pregnancy are shown in 
Table 2.1. During pregnancy, these requirements are increased to account for the extra needs of foetus 
and maternal tissue deposition to support pregnancy.118 For energy, it is estimated that a woman need 
a total of 80,000 kcal (334720 kiloJoules (kJ)) in a full-term pregnancy, however no extra energy is 
required during the first trimester.118 As such pregnant women are only advised to increase energy 
intakes only during the second and third trimester. 
Table 2.1: Summary of Energy, protein and nutrient Dietary Reference Intakes for pregnant women 
according to the Institute of Medicine and National research Council of the National Academies 
  EAR RDA 
Energy 2nd 
trimester kjoules/day EER*+ 1400 NA 
Energy 3nd 
trimester kjoules/day EER*+ 1400 NA 
Protein g/day 50 71 
Calcium  mg/d 800 1000 
Iron mg/d 22 27 
Folate μg/d 520 600 
Vitamin B12 μg/d 2.2 2.6 
Vitamin A μg/d 550 770 
Vitamin D IU 400 600 
 
* Estimated Energy Requirement (kcal/day) EER = 354 - (6.91 × age [years]) 
+ PA × [(9.36 × weight [kg]) + (726 x height [meters])] from NAP Weight 
Gain During pregnancy 
PA= Physical Activity 
EAR= Estimated Average Requirement 
RDA= Recommended Daily Allowances 
 
The upper limit for calcium intake, the level above which there is risk of adverse events, is 1000 mg 
a day for 0 to 6 months,1500 mg a day for 6 to 12 months, 2500 mg a day for 1 to 8 years, 3000 mg 
a day for 9 to 18 years, 2500 mg a day for 19 to 51 years, and 2000 mg a day for older than 51 years. 
For pregnant women upper limits are 3000 mg a day for those aged 14 to 18 years and 1500 mg a day 
for those that are older. Despite these recommended levels, the WHO guidelines for the prevention 
of pre-eclampsia and antenatal care for a positive pregnancy recommend calcium supplementation 
dose for pregnant women from areas of low calcium intake is 1500 mg a day as the evidence shows 
that this reduces the risk of PE.1,81 
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2.11 Nutritional status and dietary intake of pregnant women from South 
Africa, Zimbabwe and Argentina 
 
There are very few published studies related to dietary intake of pregnant women in South Africa and 
Zimbabwe. A PUBMED search retrieved only one can be retrieved from year 2000 onwards. 119 This 
was confirmed by a systematic review on dietary intake in African countries that included only one 
article from South Africa and none from Zimbabwe. 120 The article included in the systematic review 
shows the nutritional status of pregnant women in one community of Western Cape Province in South 
Africa revealing that more than 50% of all pregnant women in that community were below the 
Estimated Average Requirement (EAR) for vitamins A, D, E, and C, thiamine, riboflavin, vitamin 
B6, folate, calcium, magnesium, iron, and zinc. Calcium intake in this group was 362 mg a day (SD 
±165). The rest of the information comes from Limpopo Province. A study in rural areas of Limpopo 
Province shows a high prevalence of iron, vitamin B12 and folate deficiency in 262 pregnant women 
50.9%, 16.4% and 10.3% respectively. 121 A smaller study also in rural areas of Limpopo Province 
shows deficiencies particularly of calcium, iron, zinc, niacin, folate, and vitamins A, C, E, and B6 in 
a sample of 46 women under 40 years of age during their second trimester of pregnancy. 122 
Information from adolescent pregnant women population from Polokwane Municipality in Limpopo 
Province shows high inadequate intakes of iron (98%), folate (96%) and vitamin 12 (56%).123,124 The 
results from another article were excluded here as the sample only included pregnant women with 
high alcohol intakes and therefore not representative of the general population. 125 
In Argentina the National Nutritional Survey of 2005 shows that most women had insufficient intakes 
of energy (64.3%) calcium (88.5%) and iron (59.3%). Very few women reported taking iron (24.4%) 
or folic acid (21.2%) supplements and only 1% took calcium supplements. 
In conclusion, there are not many studies on diet intake in South Africa, none in Zimbabwe, and one 
nationally representative study in Argentina that has not been repeated in the last 10 years. The current 
studies show poor nutrient intake, although there is a need for more nationally representative 
information including biochemical assessment. 
 
2.12 Interventions to address inadequate nutrient intakes during pregnancy 
 
There are three broad approaches to improve dietary intake, one is behavioural intervention that 
although ideal, it relies on personal habits and ability; the second one is supplementation that targets 
individuals and the third one is fortification that aim to improving dietary intakes of the whole 
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population. Recommendations to improve dietary calcium intake increasing the consumption of 
healthy foods and/or take supplements, have been around for many years, however, these 
recommendations show limited impact in low and middle-income countries (LMICs). Unfortunately, 
many women are contacted too late in pregnancy, find it difficult to follow the advice to improve 
their diet due to economical constraints, find it difficult to take supplements daily, or live in areas 
without access to supplements.23 Implementing this recommendation relies on healthcare workers 
contacting pregnant women.  
 
Micronutrient supplementation  
Interventions, such as calcium supplementation or food fortification, have been used for many years 
as strategies to increase calcium intake.  
The World Health Organization published in 2016 recommendations for a positive pregnancy that 
included micronutrients supplementation for the improvement of maternal and infant outcomes.126 
The guidelines recommend supplementation with iron and folic acid to all pregnant women, and with 
calcium and vitamin A to women in certain areas that have a high prevalence of deficiency.126 In 
populations where calcium intake is low, the WHO recommends supplementation with 1.5–2.0 g 
elemental calcium/day from 20 weeks´ gestation until the end of pregnancy for the prevention of 
pre-eclampsia.  
However, the applicability of this recommendations is of concern as supplements are frequently 
consumed in high-income countries; however reports show that this is an uncommon practice in low- 
and middle-income countries.97 Due to the lack of timely access to health care systems, difficulties 
in supplement distribution, and patient non-adherence, women in LMIC’s struggle to consume the 
recommended supplements. In our recent research trial of calcium supplementation commencing 
pre-conceptionally and continuing up to 20 weeks´ gestation it was shown that around only 50% of 
women had a good compliance (>= 80% of tablets taken) with the supplementation.127 This indicates 
that even in the context of a research trial it is very difficult to achieve a good calcium intake and that 
strategies other than supplementation, such as fortification should be develop. 
Micronutrient fortification  
Fortification has been used in high-income countries for more than 80 years, yet despite this vast 
experience; food fortification products are not readily accessible to low socioeconomic groups.128 
Experiences in food fortification as public health measures in order to reach a whole population exist 
with diverse results as not all have been properly evaluated. Mandatory food fortification has 
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contributed to health improvement by lowering the incidence of goitre, beriberi and pellagra. 
Currently more than 130 countries have mandatory fortification of salt, and around 85 have 
mandatory fortification of wheat flour. The WHO evaluation of food fortification nutrition 
interventions recommends as food fortification vehicles the use of maize flour fortified with iron and 
folic acid; salt fortified with iodine and iron containing powders for children in areas where 
prevalence of anaemia is 20% or higher.129–135 There are successful experiences improving zinc, 
vitamin A, folic acid, vitamin D and calcium deficiencies at population level fortifying other staple 
foods. Experiences from high-income countries also show positive results. A Danish study found that 
calcium fortification of flour reduced the number of adults with low calcium intakes from 22% to 6 
%.136 In the UK fortification of white flour with calcium has been mandatory since 1943 and calcium 
fortified cereals and bread are the major contributors to calcium intake in children. 128,137 Studies 
looking at consumption of ready to use cereals fortified with calcium found that they help to reach 
adequacy of calcium intake in populations from France, Ireland, Spain and Northern Ireland. 138–140 
It is also acknowledged the restoration of micronutrients naturally present in foods that are removed 
during industrialization processes, such as vitamin B complex in maize flour.128 There are also 
experiences in drinking water fortification that include fortification of public water supplies with fluor 
to prevent dental cavities that have been implemented for more than 50 years in more than 25 
countries, however as these are public health policies that were already established, most evidence 
comes from observational studies.141,142 There are some experiences in Asia with iodized water, 
however as iodine has limited stability it is not always cost-effective.128 Iron and ascorbic acid water 
fortification to prevent iron deficiency anaemia have been explored and although successful they are 
still under investigation. 143,144 
Fortification interventions need to be further evaluated and new fortification vehicles should be 
explored. Some of the mandatory fortification is on foods such as salt and staple foods like flour as 
the majority of the population eats them. Exploring fortification vehicles that are part of a healthy 
diet should be part of the research agenda in los and middle income countries. Stakeholders may wish 
to consider culturally appropriate fortification vehicles that are part of a healthy diet. There is a need 
to investigate on the technical feasibility of fortification vehicles culturally acceptable and then to 
develop and test strategies to provide the fortified food in a diversity of existing or novel distribution 
systems. 
There is a need to explore other minerals and such as calcium that can be added to water in order to 
increase its nutritional values. Water is part of a healthy diet and water intake should be reinforced, 
so adding minerals to public drinking water that is of free access could improve some mineral intake. 
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Water with high calcium content is present in some mineral waters and also in sources of hard water 
in some populations. More recently the water retailed industry has through marketing increased the 
sales of different type of water. In the United States although calcium content of piped water is very 
low, there are several brands of bottle water with calcium content above 200 mg/l and upto 400 
mg/l.145 Increasing calcium content of water, could represent an important source of calcium to 
improve diet quality. Increasing the calcium content of water could become an important source of 
calcium that improves diet quality. Water enriched with calcium could improve calcium intake not 
only through direct consumption as drinking water, but also through increasing the calcium content 
of foods cooked in this water. This would include boiled foods, juices, and soups, among others. 
Calcium in water is present in the ionic form, with a high bioavailability similar to milk.146A review 
shows that the pooled data from 4 studies indicates a mean absorbability ratio for calcium in water 
and in milk of 1.084 ± 0.043.147 
Calcium content of water can vary negligent to values similar to some dairy products. Data from 
Canada and the US show that tap water have between 8 to 135 mg of calcium per liter.148 A study in 
Spain shows calcium values from 0.5 to more than 337 mg/l of water. However higher values such 
as 523 mg/l have been reported in Algeria.149 
It has been estimated that in LMICs, urban areas have a high coverage to improved drinking water 
(92%) and 70% of the urban population has access to piped water within the household. In contrast, 
in rural areas, only 25% of the population has access to piped water.150 The implementation of water 
fortification would need to be adapted to the situation of drinking water access of the population of 
interest. 
Dietary reference values are established to account for the needs of growth, development, functioning 
and maintain health.102 For each nutrient, requirements are calculated based on a selected health 
outcome, in the case of calcium, requirements are based to maintain bone health.  
Other effects of calcium on health were not taken into account to establish the recommendations. In 
1997 the Institute of Medicine (IOM) considered there was not enough evidence at the time to set 
recommendations and published adequate intakes for calcium for all life stage groups.99,106,151 
Calcium and Vitamin D recommendations were reassessed in 2010 for the US and Canadian 
population.22 The report mentions that recommendations were based on the calcium content of human 
breast milk for infants, balance studies for ages 1–50 years, and observational and clinical trial for 
those older than 50 years. However this time the evidence it was also concluded that there was still 
not enough evidence to include other outcomes besides bone health.152 However, since then almost 
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ten years have passed and more evidence on the role of calcium has emerged and thus it could be a 
time to update the recommendations.  
In South Africa fortification of certain types of maize meal with vitamin A, thiamine, riboflavin, 
niacin, pyridoxine, folic acid, iron and zinc and wheat flour (excluding crushed wheat, pearled wheat, 
semolina, self-raising flour and flour with an ash content <0.60% db) is mandatory following the 
promulgation of R504 Regulations since 2003.153 In Zimbabwe a fortification strategy was launched 
in 2016 for mandatory fortification of sugar with vitamin A; cooking oil with vitamin A and D; and 
wheat flour with vitamin A, thiamine, riboflavin, niacin, pyridoxine, vitamin B12, folic acid, iron and 
zinc.154 Argentina has mandatory fortification of wheat flour with iron, folic acid, thiamine, riboflavin 
and niacin since 2001. The three countries have mandatory salt fortification with iodine South Africa 
since 1994, Zimbabwe since 1993, and Argentina since 1967. 153–155 
 
2.13 Dietary methodology: assessment of dietary intake during pregnancy 
Different tools such as food frequency questionnaires, dietary records and 24-hour recalls, can be 
used to measure dietary intake. Each method has it advantages and disadvantages. Briefly, food 
frequency questionnaires require that the interviewed person recalls an average of all food and drinks 
taken in during a period of time that usually last weeks or months. They are expensive to prepare but 
economical to run and they require that the interview person performs several calculations. Diet 
records requires that the interviewed person writes all the foods and drinks just after they are 
consumed, so the participants need to be literate and highly motivated as the interviewed person can 
modified their diet so as to simplify the task. Lastly 24-hour recalls required that the interviewed 
person recalls all the foods and drink consumed in the previous day and as this is the methodology 
used in the thesis it is described in more detail below. 
24-hour recall methodology  
The 24-hour recall is a subjective dietary assessment tool and as any subjective method is prone to 
recall bias derived from the participant's experiences and perceptions.156 However the advantages of 
this type of methods are that they have lower cost, are easier to use, can be adapted to different 
scenarios and are feasible to be used in large studies as compared to objective methods. It has been 
suggested that 24-hour recalls is subject to less recall bias than other subjective dietary assessment 
methods, such as diet histories or food frequency checklists.157 Quantified food frequency 
questionnaires usually require use of generic memory and higher numeracy skills in the population 
interviewed to quantify average food intakes over a period of time.158 A major advantage of the 
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24-recall method is that high literacy of the respondent is not required and that inter-observer 
differences are minimised.156  
Within-person variance of the energy and nutrient intake  
A single day, 24-hour dietary recall is a reliable methodology to assess individual intake on the day 
recalled with the purpose of estimating the population mean. However, as food intakes have a wide 
day-to-day variability, an intake result obtained on one single day is not sufficient to measure usual 
intake or to assess nutrient inadequacies. Extrapolating one single recall assessment to make 
conclusions on the usual intake would lead to a biased estimate of the fraction of the population with 
intakes above or below some standard.29 
Different approaches to estimating usual intake  
A conceptual definition of usual intake is the average of several daily intakes of a person or a 
population.159 It has been described that the measurement of single day intake is a deviation of usual 
intake, and that deviation is called a measurement error.160 However, it has been postulated that the 
average of several recalls would not lead to a correct measurement of usual intake.29,159 Applying 
several dietary recalls to the whole population is economically impractical when the sample is large, 
and there is some evidence that the results are likewise biased due to participant tiredness, low quality 
of reported information and response burden.161,162 In this way the first interview is believed to be 
more accurate that the following ones and it is shown to usually lead to higher intake estimates than 
the following interviews. Although FFQs tend to measure longer periods of time and have been used 
as a measurement of usual intake they have more systematic errors than 24 hour recalls. 29,163 Besides 
there is evidence that the energy intake measured with FFQ does not correlate with doubly labelled 
water and that for quantitative assessments FFQ performance is poor.164,165 24-hour recalls adjusted 
for person to person variability leads to distributions much more closely to biomarkers than the 
distributions estimated from FFQs. 29 
Usual intake has a day-to-day variability (or within person variability) and a person-to-person 
variability. The within person variability if measured in a restricted number of days, as it is commonly 
the case in research, is usually larger than the real day-t-day variability and also usually larger than 
the person-to-person variability, making the distribution curve having a longer tails than the real 
distribution.163 When the objective is to measure the proportion of individuals below or above a 
certain threshold value, for example below the EAR or above the UL, if there is more variability than 
in reality, the proportion estimated will be unrealistically large. As explained above, it is not feasible 
and it also introduces bias averaging multiple recalls, however there are some statistical methods 
developed to mitigate this problem.  
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Statistical models have been developed to improve estimation of usual intakes obtained from the 
24-hour recalls by adjusting the distribution by within-person variance.128 In this way, by adjusting 
the distribution, these statistical models reduce the within-person variability so that the main 
variability left is the person-to-person (between persons) variability. The adjustment can be done with 
an external variance from a similar population or by repeating the dietary recall to a subsample of the 
study population. 
 
Dodd et al. described and compared four approaches that have been developed to estimate usual 
intake.29 The first of these methods was the National Research Council method, that is useful only 
for data with close to normal distributions, however it does not produce standard errors for estimated 
parameters, does not adjust for day of the week or interview order and it is not useful for nutrients or 
foods that are not frequently consumed. 
The second method is the Best Power method is similar to the National Research Council method, 
that is also useful only for data with close to normal distributions. However, the National Research 
Council method produces standard errors for estimated parameters and adjusts for day of the week or 
interview order. 
The National Research Council and the Best Power methods assume that the nutrient intake 
distributions are nearly normal, however dietary intakes are frequently not normally distributed as 
individuals can have intakes away from the mean to the right of the distribution but the same is not 
possible to the left of the distribution as the values cannot be negative. 29  
The third method is the Iowa State University (ISU) method that can be applied to complex surveys, 
can produce standard errors for estimated parameters, adjusts for day of the week or interview order, 
however it is not useful to assess the usual intake of nutrients or foods that are not frequently 
consumed. For this thesis I selected the ISU method as there is evidence it produces good estimates 
of usual intake distributions of most nutrients.163,164,166 The ISU method for estimating usual intake 
analytically assesses and removes the within-person variation. The ISU method for estimating usual 
intake can correct some characteristics of dietary intake data such as within person variability in 
intakes, correlation of intakes reported over consecutive days, effect of day of week, recall order, 
nonnormality of reported intakes and survey nonresponse.163,164 However the ISU method has some 
limitations as well as it assumes that a 24 hour recall is an unbiased estimate of the day measured for 
that individual. 29 Besides, when duplicate recalls are made in very few individuals the estimated 
intake of some micronutrients can be less accurate than that for macronutrients or those consumed 
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more frequently. Furthermore, less frequently consumed foods such as oysters and nutrients such as 
lycopene, beta- cryptoxanthin and alfa-carotene may require more than two 24-h recalls. 164  
 
The fourth and last method reviewed by Dodd et al. is the Iowa State University Food method. Its 
most distinguishable characteristic is that it can be used to assess the usual intake of nutrients or foods 
that are infrequently consumed, however similar to the ISU method, one limitation of this method is 
that if the repeated sample is too small the estimation of usual intake might not be accurate.  
Although with different approaches, these methods can correct the errors related to within-person 
variability. On the other hand, reporting bias of specific foods or errors in the food composition 
databases are not contemplated with any of these methods and none of them allow estimating the 
individual usual intake of a single individual. 
2.14 Concluding remarks  
Overweight and obesity prevalence is high in South Africa, Zimbabwe, and Argentina. More 
particularly in women, obesity prevalence in women doubles the obesity prevalence in men in several 
countries. These statistics on obesity prevalence thus indicate that many women in SA, Zimbabwe 
and Argentina may enter pregnancy when already overweight and obese and this may result in severe 
health outcomes for both the mother and offspring. Besides, as obesity treatment is complex and is 
beyond individual will, women struggle to lose weight in the postpartum.  
Calcium supplementation may help to achieve calcium recommendation intakes as well weight 
management. A systematic review of calcium and weight in 2011 shows a small reduction in body 
weight however there are new studies since then and this warrants to be updated. None of the included 
studies in the systematic review were on pregnant women. The effect of calcium supplementation on 
preconceptional weight and weight gain during pregnancy has never been investigated. Thus a study 
that investigates weight change in a large number of women that were followed from before 
conception and during pregnancy is essential, as it will provide novel insights on the effects of 
calcium supplementation on the mother and their infants.  
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Chapter 3 - Methodology 
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3.2 CAP trial methodology (Aims 1 and 2) 
Study design  
The CAP trial was a multi-centre randomised, double-blind placebo-controlled clinical trial of women 
from South Africa, Zimbabwe and Argentina to assess the effect of calcium on pre-eclampsia. This 
nested study used the same design and population to assess the effect of calcium on body weight. 
Women were recruited before pregnancy and were requested to return to the clinic every 12 weeks 
for follow up health check-ups and resupply with study tablets. For those who became pregnant, visits 
were scheduled at weeks 8, 20, and 32 of gestation (Figure 3.1). Outcomes of pregnancy were 
recorded, as well as the mother and baby’s general health status at 6 weeks after delivery to ensure 
safety of participating women and their babies. Weight and height were recorded at admission and 
weight was also recorded at 8, 20 and 32 weeks of pregnancy. Dietary assessment was conducted at 
20 weeks of pregnancy (See Figure 3.1).  
Figure 3.1: Study flow chart 
 
I- Methods and Procedures 
Target Population: Participants were all women recruited in the CAP trial with no other specific 
requirement for this proposal. CAP trial participants were parous women whose most recent 
pregnancy had been complicated by pre-eclampsia/eclampsia and who were intending to become 
pregnant, women were not eligible if they were less than 18 years old; were pregnant; were taking 
calcium supplementation; had chronic hypertension with proteinuria; had a history or symptoms of 
urolithiasis, renal disease or parathyroid disease; were not in a sexual relationship; were using 
long-term contraception or were not willing to give informed consent. 
Women were recruited from 5 hospitals in South Africa, two hospitals in Zimbabwe and 3 hospitals 
in Argentina. Study sites for the CAP trial were selected from locations where populations have a 
known low calcium intake.112,167,168 ha Individual calcium intake level cut-off was not included as 
eligibility criteria, as this was a pragmatic study looking at the effect in pregnant women. However, 
as part of the Steering Committee of the CAP trial, I proposed and designed the dietary assessment 
described below to all CAP trial pregnant women reaching 20 weeks of pregnancy with the purpose 
of confirming the low calcium intake. 
Randomisation	to	calcium	or	placebo	 	Calcium	supplementation	 Post	partum	
Pre-pregnancy	visits	(every	12	weeks) Pregnancy	visits	(every	12	weeks)
Admission Visit	1 Visit	2 8	week	visit 12	week	visit 20	week	visit 32	week	visit End	of	pregnancy 6	week	phone	call
		 						/
			24	hour	recall
Suplementacón	con	calcio	o	placebo Suplementación	con	calcio
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Sample Size: The sample size calculated for the CAP trial was 540 women with a pregnancy of more 
than 20 weeks. Figure 3.2 shows the CAP trial Consort Diagram that was designed for the CAP trial 
protocol to plan the participants flow and ensure reaching the desired sample size. This was the 
sample size available to evaluate pregnancy body weight (Objective 1.2). It was estimated that the 
sample size to evaluate pre-pregnancy body weight (Objective 1.1) would be slightly higher, around 
600, as those having miscarriages between 8 to less than 20 weeks will only provide data for objective 
1.2.  
This sample size enabled to detect a difference of 1.2 kg between the calcium and placebo groups 
with a type 1 error of 0.05 and a power of 80%. Although smaller weight reductions are also clinically 
relevant at a population level, this trial was not powered to detect them. However as the proposal was 
to update the body of evidence performing a meta-analysis, these results added to the results of other 
studies and increase the sample size to detect smaller changes. 
The trial started in 2011 and ended in 2017. The CAP trial was a unique study that recruited women 
before they become pregnant; therefore it was not possible to predict the representation of hospitals 
or even countries in the final sample of pregnant women. 
Argentinean sites joined the trial at a later time; they had a smaller number of pregnancies, relative 
to the African sites. Therefore, if the number of women who fell pregnant was too small in Argentina 
by the time the CAP trial was closed, there was a possibility that we will not been able to perform a 
separate country-specific analysis. 
 43 
Figure 3.2: Consort Diagram of the expected number of participants at each step of the study. This diagram was 
part of the CAP trial proposal 
 
Inclusion criteria: the trial recruited women with history of pre-eclampsia or eclampsia in the 
immediately previous pregnancy, older than 18 years of age and not pregnant, could become pregnant 
again within the trial period and who were willing to give informed consent to participate. 
Pre-eclampsia was defined as gestational hypertension (diastolic BP >90 mmHg on two occasions 4 
hours apart, or >110mmHg once, and/or systolic BP >140 mmHg on two occasions 4 hours apart, or 
>160mmHg once, after 20 weeks’ gestation) and gestational proteinuria (2+ or more on urine dipstick, 
or >300mg/24 hours, or >500mg/L or urinary protein/creatinine ratio >0.034g/mmol, after 20 weeks’ 
gestation. Eclampsia was defined as occurrence of generalized seizures in women with pre-eclampsia. 
Exclusion criteria: women with chronic hypertension and proteinuria, history or symptoms of 
urolithiasis, renal disease of parathyroid disease, or those taking calcium supplements. 
Location of the research: the study was carried out in South Africa, Zimbabwe and Argentina. 
The South African sites included Groote Schuur hospital and Mowbray Maternity hospital in Cape 
Town; East London Hospital Complex, which comprises Frere and Cecilia Makiwane Hospitals; and 
Chris Hani Baragwanath Academic Hospital, Soweto, Johannesburg. Cape Town, Johannesburg and 
East London are all large cities situated in three different provinces in South Africa. East London has 
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71% of the population Black African, 35% Coloured and 14% White. Cape Town has 39% of the 
population Black African, 42% Coloured and 15% White. Johannesburg has 77% of the population 
Black African, 4% Coloured and 14% White.169 The sites in Zimbabwe were Harare Maternity and 
Mbuya Nehanda Maternity Hospitals, both in Harare city. Sites in Zimbabwe and South Africa were 
public secondary or tertiary referral hospitals serving urban, peri–urban and rural lower-income 
populations who reside in formal and informal housing and do not have private medical insurance.170 
According to the Demographic survey Zimbabwe has 98.3% of its population of African origin 
mainly speakers of Shona	 and	 Ndebele.171	 In Argentina the sites were “Nuestra Señora de las 
Mercedes” Maternity Hospital in San Miguel de Tucumán that is the referral public hospital of 
northwest Argentina serving a lower socioeconomic population and Hospital Italiano and CEMIC 
(Centro de Educación Médica e Invetigación Clínica) in Buenos Aires a private hospital used by the 
population whose health care is provided by labour union insurance funds or the private sector. 
Subject recruitment: Participants were identified retrospectively by checking hospital records of 
women who had pre-eclampsia or eclampsia and also prospectively by inviting women attending one 
of the health service facilities mentioned above. Women were then contacted by telephone to inform 
them about the trial and to enquire whether they were interested in learning more about it. Women 
who express interest were invited to attend a special pre-pregnancy clinic at the hospital where they 
are offered routine pre-pregnancy screening and counselling, given detailed information about the 
project, and invited to participate. Those interested were asked about exclusion criteria, and if there 
were no obvious exclusion criteria present, they were invited to attend the trial clinic for further 
discussion of the trial and to confirm inclusion criteria. Only when women had signed the informed 
consent, evaluation of blood pressure, proteinuria and pregnancy test were performed. Soon after 
eligibility was confirmed women were then randomised. Teams trained for the CAP trial were 
involved in the recruitment and follow up of participants. 
Randomisation 
 
The random allocation sequence was created using computer-generated random numbers in balanced 
blocks of variable size, stratified by site. Treatment allocation was centralised and participants and 
personnel were blinded to treatment groups, decreasing the potential risk of bias. Non-pregnant 
women enrolled in the trial were allocated to the next available sequentially numbered pack provided 
by an online randomisation system (ALEA). The ALEA software contained the numbered packs of 
calcium or placebo available at each site. Tablets were packed in 12-week treatment bottles. The 
ALEA also provided the appropriate follow-up pack at each 12-week visit to ensure continuation of 
the same treatment without unblinding while participants remained randomised (See Figure 3.1). 
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Randomisation lasted until 20 weeks´ gestation, from that point all women received unblinded 
calcium tablets until delivery. 
Intervention: 
Study participants were assigned to receive: 
• Calcium group: 1 tablet of 500 mg of elemental calcium a day in the form of calcium 
carbonate. 
• Control group: 1 placebo tablet a day, identical to the calcium tablet. 
Participants were advised to take one tablet a day at least 2 hours before or after meals or other tablets, 
no further info or dietary advice was given. 
Justification of the calcium dose 
A 500 mg dose was decided on based on the information from the study populations suggesting that 
the average daily calcium intake from the diet was around 400 to 600 mg. 27,172 An extra 500 mg a 
day would thus allow reaching dietary calcium recommendations for these populations. 21 
Furthermore, 500 mg of calcium is the maximum level that could be included with food fortification. 
This is important as the intervention of the trial is supplementation before pregnancy and the 
recommendation to supplement all women of fertile age would not be feasible and consequently a 
fortification strategy would be more appropriate. 
Participants received a health check-up by a member of the research team every 12 weeks where they 
were provided with a new bottle of supplements with each visit. At each visit they were requested to 
bring the old bottle of supplements to monitor compliance. The returned supplements were counted 
and registered in the study forms. In those cases where the woman did not bring the bottle, they were 
phoned later on to assess the number of supplements taken. 
In order to maintain women and study personnel blinded to the intervention group, bottles were 
identified with a number and assigned using a web-based randomisation system. 
Outcomes: 
1. Body weight in kg, at admission and at 8, 20 and 32 weeks during pregnancy. 
2. Body Mass Index in kg/m2. 
3. Birth weight in grams. 
4. Maternal energy intake at 20 weeks of pregnancy in kcal per day. 
5. Maternal calcium intake at 20 weeks of pregnancy in mg per day. 
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6. Maternal protein, carbohydrates, fibre, sugars and fat intake in grams per day. 
7. Maternal iron, magnesium and zinc intake in mg per day 
8. Maternal folate, vitamin D, vitamin A intake in mcg per day. 
 
Measurement, assessments and tests 
Information on the women’s weight, height, pregnancy status, dietary information including 
supplement intake, baby´s birth weight and the assigned intervention have been obtained from the 
data collected in the CAP trial. 
Anthropometric measurements: 
Body weight (in kilograms) and height (in centimetres) were recorded at admission and weight was 
also recorded at 8, 20 and 32 weeks of pregnancy. Measurements were taken by each hospital’s 
research team and recorded in the questionnaires designed for the study. Body weight was measured 
using a digital scale to the nearest 0.1 kg. Measurements were taken in light clothing and women 
were asked to remove their shoes. Height was measured to the nearest 1 centimetre using a 
stadiometer while the participant was not wearing shoes. Scales and stadiometers were those provided 
by each hospital but they remained the same throughout the study. 
Body Mass Index (BMI) was calculated for each women at admission and at 8 weeks of pregnancy 
(surrogate of preconceptional weight) as weight (kg)/ height (m2). Women were classified 
prepregnancy according to the WHO BMI standards for adults, defined as underweight (BMI < 18.5), 
normal (18.5 ≤ BMI < 25), overweight (25 ≤ BMI < 30), or obese (BMI ≥ 30). 173 
Birth weight (in grams) was taken by each hospital team and recorded in the questionnaires designed 
for the study. Birth weight was measured to the nearest 1 gram. Baby scales were those provided by 
each hospital and remained the same throughout the study. 
To evaluate the effect of calcium on the body weight of non-pregnant women of fertile age (objective 
1.1) we analysed the difference in the body weight collected at admission from the non-pregnant 
women and the body weight collected at 8 weeks of pregnancy. The weight at 8 weeks of pregnancy 
was used as a surrogate of preconceptional body weight as evidence from a cross-sectional study of 
a 1000 women showed that there is no significant change in mean maternal body weight or BMI in 
the first trimester. 174 Although the time period between admission to the study until evaluation at 8 
weeks of pregnancy varied for each women, this was a randomised controlled trial and it was expected 
that the average supplementation time for the calcium and placebo groups are the same. 
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The effect of calcium supplementation on body weight gain during pregnancy was evaluated using 
the weight difference between week 8 to 20 weeks as all women received calcium supplementation 
from 20 weeks until the end of pregnancy. At 32 weeks of pregnancy it was evaluated if the difference 
found at 20 weeks persisted afterwards when both groups receive calcium supplementation. The 
newborns’ birth weight and maternal body weight was compared between both groups to evaluate 
the safety of the intervention. 
 Dietary intake assessment:  
A 24-hour multiple pass dietary recall method was used to ascertain dietary intake. Dietary data was 
obtained from personal interviews with all pregnant women enrolled in the CAP trial during their 
scheduled trial visit at 20 weeks pregnancy. A sub-sample of women was assessed at a second time 
point during a scheduled pregnancy visit, in order to estimate usual intake. 
The recall took the form of a guided interview lasting approximately 20 minutes and involved 
recording food intake of the previous day on a questionnaire. The questionnaire was adapted from a 
triple pass 24-hour recall developed by the Kings College and pilot tested in South Africa and 
Argentina.29,117 The Dietary assessment Education Kit (DAEK) was used to assist with portion size 
estimation. 175 
CAP trial study staff at the clinics interviewed participants. All women were asked to enumerate all 
foods, drinks and dietary supplements taken on the previous day. Afterwards, detailed information of 
each item was collected to identify the correct portion size and food composition for each item. 
Portion size estimation was done using household measurements and comparison with photographic 
material. At the end of the interview, all items were reviewed in chronological order, prompting for 
additional foods or drinks consumed.  
To minimize possible communication problems, we used the food photographic material to show the 
pictures or portion size of the specific food item. Translators assisted with Xhosa and Zulu speakers 
in South Africa, while all participants in Zimbabwe were fluent in English and in Argentina, all 
interviews and questionnaires were in Spanish. 
Statistical models have been developed to improve estimation of usual intakes obtained from 24-hour 
recalls by adjusting the distribution by within-individual variance. 128 In this way, by adjusting the 
distribution, these statistical models reduce the within-person variability so that the main variability 
left is the person-to-person (between person) one. The adjustment can be done with an external 
variance from a similar population or by repeating the dietary recall to a subsample of the population. 
As there are no published within-person variances for pregnant women in South Africa, Zimbabwe 
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or Argentina, I proposed obtaining this information from a subsample of the population. For this 
thesis I selected the Iowa State University (ISU) method as there is evidence it produces good 
estimates of usual intake distributions of most nutrients.163,164,166 
The Iowa State University method for estimating usual intake analytically assesses and removes the 
within-person variation. The method assumes that a 24 our recall is an unbiased estimate of the day 
measured for that individual. 29 
The method includes four steps: 
1. It adjusts the nutrient intake distribution data to the day of the week the first nutritional 
assessment was performed and to the sequence order of interviews. This adjustment is done 
using the least squares method to minimized the errors that day of the week and order of the 
interview bring to the dietary intake data.  
2. Then the distribution of each nutrient is power transformed to make it a normal distribution. 
Exponents from 1 to 10 are tested in the power transformation and then mapped into the 
normal scale via a cubic spline transformation. The Anderson-Darling test is used to detect 
departures from normality, if the p-value is less than 0.05 the hypothesis of normality is 
rejected. 
3. Next compute the usual intake of nutrients for each individual calculating each individual own 
daily intake variance between the first and the second interviews in the subsample that have 
repeated measures. This method contemplates that individual variances can be different 
between subjects.  
4. The last step is an inverse mean back-transformation to produce a distribution of usual intakes 
in the original scale.166 
 
The recommendations of the Iowa State University method for calculation of the population variance 
require that at least 50 women have a second dietary assessment to be able to assess within person 
variance, otherwise the estimates might not be accurate. 176 Following this, the subsample for second 
recall were all pregnant women recruited in Argentina and 50 pregnant women from South Africa 
and Zimbabwe. In Africa, the attempt was made to perform the assessment in at least 50 consecutive 
women. However, if a woman missed the follow-up visit, the next woman coming in was recruited. 
The ISU method has some constrains, when duplicate recalls are made in very few individuals the 
estimated intake of some micronutrients can be less accurate than that for macronutrients or those 
consumed more frequently. 
Other variables 
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The following variables will also be collected for the purposes of this proposal: 
1. Intervention group: calcium or placebo. This information was available when the study 
finished, data unblinded and database prepared for analysis. 
2. Time of exposure to the intervention: days from admission date (Admission questionnaire, 
question 1) to end of intervention period (20-week questionnaire, question 1). 
3. Compliance: was calculated with the number of supplements returned at each visit (proportion 
taken of expected tablet intake). This information was available in all follow-up visit 
questionnaires. 
4. Age of the woman at admission: this was calculated subtracting admission date (Admission 
questionnaire) minus birthdate. 
5. Age of the woman at pregnancy: this was calculated subtracting pregnancy date (8-week visit 
questionnaire, question 1) minus birthdate. 
6. Parity: Total number of deliveries of gestations of >24 weeks irrespectively of the outcome 
(Admission questionnaire, question 3). 
7. Inter-pregnancy interval (for those that become pregnant during the study): Interval since 
previous pregnancy (Admission questionnaire, question 4). 
8. Months since last birth: for the analysis of non-pregnant women it was calculated as the date 
of the end of the last pregnancy reported at admission of the study, minus admission date. For 
the analysis of women it was calculated as the date of the end of the last pregnancy reported 
at admission of the study minus date at 20 weeks of pregnancy. 
9. Blood Pressure: systolic and diastolic; in mm Hg: defined as the lowest of two blood pressure 
measurements taken three minutes apart. 
10. Pre-eclampsia in current pregnancy: yes or no (Delivery questionnaire, question 22). 
11. Eclampsia in current pregnancy: yes or no (Delivery questionnaire, question 23). 
12. Country of recruitment: South Africa, Zimbabwe, Argentina. Participant screening numbers 
allow identifying recruitment site and country. 
 
Data Collection procedures and quality assurance 
Data Collection 
Weight and height were recorded at admission and weight was also recorded at 8, 20 and 32 weeks 
of pregnancy. Energy and calcium intake were assessed by a 24-hour recall at the clinic during the 
trial visit at 20 weeks pregnancy. If the visit was missed, effort was made to trace women to perform 
the recall at a visit as close as possible to the 20-week of pregnancy (See Figure 1.1).  
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Intervention compliance was measured by counting returned tablets at each visit that was scheduled 
every 12 weeks before pregnancy and at 8, 20 and 32 weeks during pregnancy.  
Data collected at the admission and follow up visits were recorded in standardized questionnaires that 
were developed in English and then tested and translated into Spanish for the participants recruited 
in Argentina. Adverse events were recorded on a separate form. 
Copies of the English version of the admission, pre-pregnancy and pregnancy visits, delivery and 
adverse events forms can be found in Annexure 1. However, all forms were also available in Spanish. 
Data quality assurance 
Data were collected in carbon copy data recording sheets. Double data entry was performed in 
OpenClinica, which allows for detection of inconsistencies and the tracking of changes. The 
OpenClinica system is an open-source web-based software, protected and reliable, totally compliant 
with Good Clinical Practice (GCP) and regulatory guidelines as well as the HRP/WHO Standard 
Operating Procedures (SOPs) for managing clinical trials. These procedures have been used in 
previous international multicentre trials sponsored or coordinated by WHO and proven to be efficient. 
The study was coordinated by the Department of Reproductive Health and Research of the WHO, 
which performed site supervisions of the data collection and maintained the database. 
Fieldworkers 
Interviewers were trained by the PhD candidate to complete 24-hour recalls, dietary assessment 
techniques and portion estimation using a booklet of pictures with locally relevant portion sizes.175 
After each recall, interviewers were asked to complete a question to be able to assess whether it was 
very difficult to take the 24-hour recall due to communication problems that can impair the validity 
of the information reported (See Data Collection Forms: Dietary assessment questionnaire). 
Participants were prompted to report any supplement containing calcium in addition to the study 
tablets. Type and frequency of additional dietary supplement products were recorded. This 
information was used to later review supplement intake during pregnancy and whether the 
supplement product taken contained calcium. The established supplemented amount was added to the 
daily calcium intake calculated from the rest of the participant´s diet. Women participating in the 
study were advice not to take any other type of calcium supplement including those issued by the 
hospital. 
The 24-hour recall data from the interviews were entered into a food classification software by the 
local CAP trial staff at each site. African data were entered using the South African Food Finder III 
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developed by the South African Medical Research Council that uses South African Food composition 
tables and Food Quantities Manuals as no such data exists for Zimbabwe.177 In Zimbabwe we used 
the same food composition database as in South Africa, which includes fortified foods by South 
African law 2003, but not in Zimbabwe, this may produce that the prevalences of inadequate intake 
in Zimbabwe are even higher than those reported for vitamin A, thiamine, riboflavin, niacin, 
pyridoxine, folic acid, iron and zinc. In Argentina, data were entered into an excel spreadsheet for 
later analysis in SPSS. Data from and Argentina were calculated using the Argentinean Ministry of 
Health chemical composition table (SARA). All data were stored in computers used for the CAP trial 
that had restricted access under lock and key for the duration of the study. Daily intakes of energy, 
macronutrients and micronutrients were calculated.  
After data entry of the 24-hour recall, the information from each interview was sent to me and I was 
responsible for reviewing the information. I then performed the analysis to calculate the calcium 
intake of the interviewee. Afterwards I confirmed the results to the sites in order to ensure the quality 
of the data collected. Final values were then entered in OpenClinica for each site. At least twice a 
year I travelled to each site to supervise the information collected and ensure data quality. 
Statistical method and analysis: 
Intention-to-treat analysis was used and the results were reported according to the CONSORT 
guidelines. Baseline characteristics were compared to confirm effectiveness of the randomisation 
process. Participant lost to follow-up was compared between groups to detect any imbalances. 
Numerical data were tested for normality using skewness and kurtosis z-values, the Shapiro-Wilk test 
p-value and visual outputs from histograms, Normal Q-Q plots and box plots. Numerical data with a 
normal distribution were described using mean (±SD) and those with non-normal distribution using 
median (IQR). All categorical data were described using percentages. 
The principal outcome of the study was change in body weight. 
Analysis for objective 1.1: Effect of calcium supplementation on body weight of women on fertile 
age (body weight at 8 weeks used as surrogate of preconceptional weight). 
Analysis for objective 1.2: To assess the effect of calcium supplementation on women body weight 
gain during pregnancy and newborn birth weight. 
Change of body weight from admission to 8 weeks of pregnancy (objective 1.1) and from 8 weeks to 
20 weeks of pregnancy (end of randomisation period) (objective 1.2) was calculated for each woman 
and compared between the calcium and placebo groups.  
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If there were differences at 20 weeks of pregnancy, and in order to evaluate if differences found at 20 
weeks persist at 32 weeks when both groups received calcium supplementation, the change of body 
weight from 20 weeks to 32 weeks of pregnancy (all women were receiving calcium) was calculated 
for each woman. 
In all cases the mean difference (MD) of change was compared between the calcium and placebo 
groups using a T-test. If the distribution of the difference in body weight was not normal the median 
of the differences were compared using a Wilcoxon test. 
The mean birth weight was be compared between the calcium and placebo groups. 
If there were imbalances in baseline characteristic for important prognostic factors, the effect on 
weight was analysed performing a linear regression, adjusting for baseline covariates (age, parity, 
time of exposure, BMI). 
Dietary assessment analyses:  
Data analysis to calculate nutrient intake: each nutrient distribution was tested for normality and 
skewed variables were logged transformed. As nutrient intakes are usually right-skewed, this 
methodology requires a power transformation to make the intake distribution look as close to normal 
as possible. Means and standard deviations were analysed using descriptive statistics in SPSS. 
Data analysis to calculate usual nutrient intake: The usual intake population distribution was 
calculated using the Iowa State University methodology to estimate population variance. After testing 
the distribution for normality, a further step consists of adjusting the distribution to within-person and 
between-person variability. The within-person variability was calculated using the information 
obtained from the repeated interview to the subsample of at least 50 subjects of the population. The 
variance component was estimated using the Software for Intake Distribution Estimation (PC-SIDE, 
version 1.0, 2003; Department of Statistics, Iowa State University, Ames).176 
Descriptive measures of calcium intake (mean, standard deviation) and within- and between-person 
variance component were calculated. Afterwards, the proportion of individuals with calcium intake 
below 900 mg a day was calculated separately for Argentina and Africa. 
The EAR cut-point was used to assess adequacy of intake of macro and micronutrients. The 
percentage women with an intake below the EAR was calculated for each nutrient and compared 
between the intervention and control groups using Chi-square tests. 
All data were cleaned and analysed using SPSS version 22. For all statistical analyses a p-value <0.05 
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indicated statistical significance. 
Ethical considerations 
The WHO protocol A65750: “Long term calcium supplementation in women at high risk of 
pre-eclampsia: A randomised, placebo, controlled trial” which also includes the assessment of 
calcium intake was approved by the Scientific and Ethical Review Group of the 
UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and 
Research Training in Human Reproduction at the Department of Reproductive Health and Research 
of WHO, and the WHO Research Ethics Review Committee, Geneva, Switzerland.27 The trial sites 
also have approvals from their local IRBs. Approval has been obtained from the Faculty of Health 
Sciences, Human Research Ethics Committee (HREC) of University of Cape Town (Ref no 
457/2010, Site Principal Investigator: Dr. Sue Fawcus). Permission to conduct the study have been 
obtained at each site including Mowbray Maternity Hospital (MMH). This nested study was approved 
by the UCT HREC (Ref no. 884/216). 
Protection of Human Subjects 
Human subjects’ involvement and characteristics: Women who meet the inclusion criteria for the 
CAP clinical trial were recruited from the selected hospitals. Women received close, personalized 
follow-up before and during pregnancy, and had telephone access to the research medical officer. 
They were referred promptly for any pregnancy complications, which occur. Their surveillance 
during pregnancy was more closely supervised than in the routine antenatal clinic. They also received 
calcium supplementation from 20 weeks of pregnancy as currently recommended by WHO 
guidelines. 
Source of material: The study data was collected from interviews with the women. All data collected 
was obtained specifically for research purposes. 
Potential risks: It was very unlikely that serious side-effects of the calcium supplementation could 
occur as the intervention dose of this trial was low -500 mg a day -compared to previous studies that 
provided 2000 mg a day. Any adverse events and serious adverse events whether they were thought 
to be related to the trial intervention or not, were recorded by the CAP trial researchers on special 
forms and then submitted to Data Safety and Monitoring Board (DSMB) and the relevant ethics 
committees. 
A Data Safety and Monitoring Board (DSMB) with no direct involvement in the trial was appointed. 
The role of DSMB was to deal with any ethical issues that could have arisen while the trial was in 
progress. Interim analyses were undertaken and the decision on if the trial continued was discussed 
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at the yearly Steering Committee meetings. Reporting and handling of adverse events was in 
accordance with GCP guidelines. 
A part from this there was very little risk to the subjects in this study. The interview might have 
caused psychological discomfort, but timing of the interview was selected to suit subjects’ 
preferences. The interviewers were field workers who had regular contact with the participants for 
follow-up visits, and had, due to the nature of the study, developed trust with the participants. In 
addition, the interviewers were specifically trained to minimise the discomfort. 
Before enrolment, all participants received an explanation of the study including objectives, the 
reason why they were invited, the randomisation process and the time that the activities of the study 
required. It was also highlighted that participation was voluntary and if they accepted they were free 
to withdraw from the study at any time. All participants were provided with a copy of the informed 
consent form and those willing to join the study were asked to sign.  
3.2 Systematic review methodology (Aim 3) 
This systematic review and meta-analysis of randomised control trials had the objective of evaluating 
the effect of calcium, as supplements or food fortification compared to placebo or none fortified food, 
on body weight. The systematic review followed the Cochrane methodology.  
All randomised controlled trials reporting the effect of calcium supplementation on overweight and 
obese individuals including pregnant participants with duration of at least 2 months were included. 
For adults, overweight was classified according to WHO standards as BMI equal or higher than 25 
to less than 30 and obese as BMI equal or higher than 30.178 For children and adolescents validated 
classifications for overweight or obese children or adolescents such as the WHO child growth 
standards for 0 to 60 months, WHO growth references for school aged children and adolescents using 
BMI for age, the International Obesity Task Force child BMI cut offs that are derived from BMI 
centiles at 18 years, and BMI z scores were accepted. 179,180 
The primary outcomes were body weight, health related quality of life as evaluated by a validated 
instrument such as the Centre for Disease Control and Prevention health-related quality of life 
questionnaire and adverse events as hypercalcaemia, hypercalciuria, nephrolithiasis, coronary heart 
disease, secondary hyperparathyroidism, anaemia, gastrointestinal symptoms. Secondary outcomes 
were defined as body mass index (BMI) and waist circumference. 
 I developed the search strategy with the assistance of the Cochrane group and it was then translated 
to include Medline, the Cochrane Central Register of Controlled Trials, LILACS, EMBASED, 
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clinicaltrials.gov and World Health Organization (WHO) International Clinical Trials Registry 
Platform (ICTRP) Search Portal (http://apps.who.int/trialsearch/). 
I screened the title and abstract of all references retrieved by the search strategy and another three 
researchers independently did the second screening. I obtained from PubMed all full texts for those 
articles satisfying the inclusion criteria. Disagreements were resolved with a third opinion. I extracted 
all full texts and co-supervisor Janetta Harbron performed the second extraction independently using 
COVIDENCE in a predesigned form. Both extractions were compared and disagreements were 
discussed and resolved. I listed those trials registered in clinicaltrials.gov and searched for 
publications. If the trials were not finished I listed them separately. Risks of bias were also assessed 
independently using the same system. Risks of bias were defined by Cochrane ’Risk of bias’ 
assessment tool and judged as low, high, or unclear risk.181,182  
I expressed dichotomous data as odds ratio (OR) or risk ratio (RR) with 95% confidence interval (CI) 
and calculated mean differences or standardised mean differences (SMDs) for those trials using 
different measurement scales and 95% CIs for continuous outcome measures. Effect estimates were 
calculated from p values, t statistics or other available statistics.  
Heterogeneity was identified by visually inspecting the forest plots and by using a standard Chi2 test 
with a significance level of α = 0.1 and I2 statistic, which quantifies inconsistency across trials to 
assess the impact of heterogeneity on the meta-analysis; where an I2 statistic ≥ 75% indicates a 
considerable level of heterogeneity.182–184 
I included the pre-specified subgroup analysis: menopausal status: pre- and post-menopausal women, 
age: children, adults, older adults, gender, BMI: obese, overweight, physical activity, calcium 
supplementation, baseline energy intake: restricted energy intake or not, pregnancy status and type of 
diet as co-intervention. 
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Chapter 4 : Article 1 
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Effect of calcium supplementation on body weight of women in reproductive age (Primary 
objective 1.1) 
This article describes the effect of a daily calcium supplementation of 500 mg on body weight of 
women before and during pregnancy.  
4.1. Introduction 
Obesity represents a major and challenging public health problem as it increases the risk of 
developing high blood pressure, insulin resistance, heart disease, diabetes, osteoarthritis and sleep 
apnea.9,36 During pregnancy, obesity increases the risk of adverse pregnancy outcomes.11,185 A review 
shows that obesity before and during pregnancy increases the risks of gestational diabetes and 
hypertension, mental ill health before and after pregnancy, caesarean section, preterm birth, large for 
gestational age, miscarriage, stillbirth and foetal death.10 It has been estimated that a 5 to 7 kg/m2 
higher pre-pregnancy Body Mass Index (BMI) doubles the risk of pre-eclampsia.8,52 Even an increase 
of 1 or 2 BMI units between pregnancies increases the risk of hypertension and gestational diabetes. 
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Several studies have investigated the modulating effect of calcium intake in body weight.25,63,186 In 
animal models changes in lipid metabolism with calcium supplementation have been illustrated.187,188 
Sun and Zemel (2004) reported that after induced weight loss, obese mice on a diet low in calcium 
experienced increased lipogenesis and rapid body weight regain whereas calcium supplementation 
inhibited the weight regain.189 In humans a systematic review in 2011, that included seven studies 
with 794 overweight or obese participants, showed that calcium supplementation compared to 
placebo produced significantly larger mean body weight loss of 0.74 kg (CI -1.00 to -0.48).25 Six of 
the included studies had a duration of six months with a dose of 1000 mg of elemental calcium per 
day and one a duration of 24 months with a dose of 1500 mg of elemental calcium per day. 
 
Three mechanisms in which calcium could affect body weight have been postulated. The first one is 
linked to the regulation of the parathyroid hormone that is required to maintain specific calcium 
concentrations in extracellular fluids.64,65 Low calcium intakes stimulate parathyroid hormone and 
1-25 vitamin D secretion to increase calcium resorption from the bones, kidneys as well as absorption 
in the intestine. However, higher levels of parathyroid hormone and 1-25 vitamin D also stimulate 
calcium influx into different cell types, including the adipocyte. 65 In the adipocyte, this increase of 
intracellular calcium stimulates fatty acid synthase and lipogenesis. 64 Low calcium diets have also 
been linked to insulin resistance and high blood pressure through similar collateral effects. 66 
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Likewise, higher levels of parathyroid hormone and 1-25 vitamin D increase intracellular calcium in 
the vascular smooth muscle cells and consequently increase muscle reactivity, peripheral vascular 
resistance and thus higher blood pressure. 68,69 In this way, hormones that are released to compensate 
for low serum calcium levels could produce as collateral effects an increase of blood pressure and 
lipogenesis. 66 
A second postulated mechanism is associated to the reduction of fatty acid absorption in the 
intestine.190–192 192 This mechanism is linked to the fact that calcium absorption is inefficient, only 15 
to 58% of calcium is absorbed, thus a large proportion of calcium remains in the intestine.192,193 The 
calcium remaining in the intestine has the effect to bind and form soaps with different substances. 
This is the case of calcium binding to oxalate and decreasing stone formation.194 Besides this effect, 
higher calcium intakes could provide more calcium remaining in the intestine and binding to bile 
acids or to fatty acids impairing their absorption and decreasing available energy. 70,71,190,195 This 
same mechanisms was proposed for the effect of calcium on improvement of lipid profile and 
decrease in cardiovascular disease.192 However, as some of the evidence comes from dairy products, 
it is still controversial if the effects seen are due to calcium or to other component of dairy products.190  
Finally, the third and with least evidence mechanism postulated to explain the relationship between 
calcium intake and body weight is the effect on appetite.190,191 Higher calcium intakes have been 
linked to increase of glucagon-like peptide-1 that reduces appetite. 73 On the other hand Tordoff 
described a different pathway.196 Some minerals such as calcium, magnesium and sodium produce a 
phenomenon to crave for foods rich in these minerals. As calcium is present in energy containing 
foods these appetite for calcium would increase energy intake and increase weight.190 
 
In order to improve pregnancy outcomes, overweight and obese women are advised to lose weight 
before conception, however the evidence on how to achieve this is scarce.61 Also, for overweight or 
obese pregnant women there is lack of evidence on how to manage their weight during pregnancy.60,61 
Until more robust evidence is available recommendations are still to gain weight, although at a 
reduced rate, as dieting during pregnancy may increase the risk of ketosis that is harmful for the 
foetus. According to the US Institute of Medicine guidelines women that are overweight should aim 
to gain 7 to 11.5 kg and women who are obese should aim to gain 5 to 9 kg during the entire 
pregnancy.197 With the current high overweight and obesity prevalence among women of 
child-bearing age and low calcium intakes in several low and middle income countries, calcium 
supplementation might aid weight management before and during pregnancy.107,198 
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The Calcium And Pre-eclampsia (CAP) trial was a randomised controlled trial aimed to test the effect 
of calcium supplementation commencing before pregnancy and up to 20 weeks’ gestation on the 
incidence of pre-eclampsia in women with history of pre-eclampsia.168 The aim of this sub-study is 
to evaluate the effect of calcium supplementation on body weight in women of fertile age with 
emphasis in overweight and obesity before they conceive and the effect of the supplementation once 
they became pregnant.  
4.2. Methods 
 
The protocol of the multi-centre CAP trial has been previously published.168 The trial included 
women from South Africa, Zimbabwe and Argentina. 
Participants 
Women were eligible if they had pre-eclampsia or eclampsia in their most recent pregnancy, if they 
were in a sexual relationship, not pregnant, not using contraception and if they provided informed 
consent. Pre-eclampsia was defined as a diastolic BP >90 mmHg on two occasions 4 hours apart, or 
>110mmHg once, and/or a systolic BP >140 mmHg on two occasions 4 hours apart, or >160mmHg 
once and 2+ or more on a urine dipstick, or a urinary protein excretion of >300mg/24 hours, or 
>500mg/L or urinary protein/creatinine ratio >0.034g/mmol, after 20 weeks’ gestation or diagnosed 
by the attending clinicians. Exclusion criteria included: less than 18 years of age; chronic 
hypertension as reported by the women with persistent proteinuria confirmed with a dipstick at 
admission; calcium supplement intake; and history or symptoms of urolithiasis, renal disease or 
parathyroid disease. Women were eligible if they had hypertension with no proteinuria at admission. 
Women were recruited from five hospitals in South Africa (one hospital in Cape Town, one in 
Stellenbosch one in Johannesburg, and two in East London), two hospitals from Zimbabwe (located 
in Harare) and three hospitals in Argentina (one in Tucuman, one in the city of Buenos Aires and one 
in the province of Buenos Aires). Study sites for the CAP trial were selected from locations where 
populations have a known low calcium intake. 21,117,172Individual calcium intake level cut-off was not 
included as eligibility criteria, as this was a pragmatic study looking at the effect in pregnant women. 
 
Intervention  
Women of fertile age were recruited before pregnancy and randomised until 20 weeks´ gestation to 
receive a calcium supplement containing 500 mg of elemental calcium as calcium carbonate per day 
or placebo identical in shape, colour and taste to the calcium tablet. Women were asked to chew the 
tablet during the day, 2 hours before or after taking food or iron supplements. From 20 weeks´ 
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gestation until delivery all women received three tablets of 500 mg of elemental calcium per day (thus 
1500 mg per day) in accordance with WHO recommendations. 1Women did not receive any other 
dietary advise from the team throughout the study period. 
 
Before pregnancy, all women were asked to return every 12 weeks where they were provided with a 
new bottle of supplements. Women who became pregnant were also asked to return every 12 weeks 
during their pregnancy study visits at 8, 20 and 32 weeks´ gestation.  
Sample size 
 
The sample size for the CAP trial was a total of 540 women with a pregnancy of more than 20 weeks. 
This was the expected sample size available to evaluate change in body weight at 32 weeks´ gestation. 
It was also estimated that the sample size to evaluate pre-pregnancy body weight would be slightly 
higher than the one to evaluate weight at 20 or 32 weeks, as those having miscarriages, quit the trial 
or have their weight not registered after 8 weeks will only provide pre-pregnancy data for the analysis. 
The expected sample size at 8 weeks´ gestation was 704 women and at 20 weeks´ gestation 600 
women.  
 
With any of these sample sizes we planned be able to detect a difference of 1.2 kg between the calcium 
and placebo groups with a type 1 error of 0.05 and a power of 80%. Although smaller weight 
reductions are also clinically relevant at a population level, this trial was not powered to detect them. 
However the results could contribute to improve the evidence if combined with other studies in a 
meta-analysis in order to increase the sample size and detect the existence of smaller changes. 
 
Randomisation 
Sequence generation 
The sequence was generated using computer-generated random numbers in a ratio of 1:1 and in 
balanced blocks of variable size, stratified by site.  
Allocation concealment 
Calcium and placebo tablets given throughout the trial were packed in identical bottles containing 84 
tablets each. Before and until 8 weeks´ pregnancy, women were given one bottle of their allocated 
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treatment at each visit. At the 20 and 32 weeks´ pregnancy visits women were given three bottles of 
calcium tablets. Allocation was done using an online service that provided the next available 
treatment for each new participant. During follow up visits the system ensured continuation of the 
treatment allocated at admission without revealing group allocation.  
Blinding 
Participants as well as investigators and outcome assessors were blinded to group allocation.  
Implementation 
Participants were identified retrospectively through reviewing hospital records of women who had 
pre-eclampsia or eclampsia. Women were then contacted by telephone to inform them about the trial 
and to enquire whether they are interested in learning more about it. Women were also contacted 
prospectively by inviting those attending one of the participating sites. Women who expressed interest 
were then invited to attend a special pre-pregnancy clinic, at the hospital where they were offered 
routine pre-pregnancy screening and counselling. At the special pre-pregnancy clinic they received 
detailed information about the project during an individual consult with the site researcher. Those 
interested were asked about exclusion criteria, and if there were no obvious exclusion criteria present, 
they were invited to participate in the trial. Only when women have signed the informed consent 
form, evaluation of blood pressure, proteinuria and pregnancy test were performed to confirm 
eligibility criteria before admission and randomisation. Teams trained for the CAP trial were involved 
in the recruitment and follow up of participants. Participants were admitted from 12th of July 2011 
to 8th of September 2016. 
4.3. Methods for this sub-study 
Participants 
For the analysis of this sub-study our sample included all participants of the CAP trial that had body 
weight registered at 8 weeks of pregnancy, n=457 (230 allocated to calcium and 227 allocated to 
placebo). 
Measurement 
 
Data collected at admission and used for the analysis of this sub-study included maternal age, height 
and weight, number of previous pregnancies and date of birth of last pregnancy complicated with 
pre-eclampsia and country where women lived. For women who became pregnant, body weight was 
measured during pregnancy at 8, 20 and 32 weeks´ gestation during the planned visits. Compliance 
to the study supplements was measured at admission and at each visit. Participants were asked to 
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bring the study bottle to each visit and the supplements left were recorded. In those cases where the 
woman did not bring the bottle, they were phoned later on to assess the number of supplements taken. 
Compliance was calculated as a percentage of the number of used supplements of the total number 
of supplements that should have been taken. 
Research nurses specially trained for the CAP trial assessed all anthropometric and clinical 
assessment at admission and during follow up visits at each participating site. 
Body weight was measured to the nearest 0.1 kg, women were measured in light clothing and they 
were asked to remove their shoes. Height was measured to the nearest 0.1 centimetre using a 
stadiometer while the participant was not wearing shoes. Scales and stadiometers were those provided 
by each hospital and remained the same throughout the study. The CAP trial Manual of Operations 
and the Standard Operating Procedures (SOPs) provided clear instructions on how women should be 
weighed and measured. 
Pre-pregnancy BMI was calculated as weight (kg) divided by the square of the body height (meters) 
using measurements recorded at admission. Women were classified according to the WHO BMI 
standards for adults, defined as underweight (BMI < 18.5), normal (18.5 ≤ BMI < 25), overweight 
(BMI ≤ 25 and <30), or obese (BMI ≥ 30). 173 
Dietary energy and calcium intakes were measured at 20 weeks´ gestation using a triple pass 24-hour 
recall adapted from the method developed by Nelson et. al. and before the first CAP trial interview it 
was pilot tested in Argentina, South Africa and Zimbabwe. 117,156 
Birthweight of infants was recorded from clinical records as women were only followed until 32 
weeks´ pregnancy.  
Statistical analysis 
Baseline data were compared between the calcium and placebo groups for those randomised, became 
pregnant and had weight measurements at 8 weeks´ gestation. We used an intention-to-treat (ITT) 
approach for this analysis as recommended by the Consolidated Standards of Reporting Trials 
(CONSORT) guidelines. 
Continuous variables were described with means and standard deviations and categorical variables 
with percentages. To evaluate the effect of calcium on body weight in women of fertile age we 
analysed the information collected from admission to 8 weeks´ gestation as we did not have further 
weight measurements after admission and before pregnancy. We used weight at 8 weeks´ gestation 
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as a surrogate of preconceptional body weight. Evidence from a cross-sectional study of 1000 women 
shows there is no significant change in mean maternal body weight or BMI in the first trimester. 174 
We evaluated the effect of calcium supplementation on weight at 20 weeks´ gestation in women that 
started calcium supplementation preconceptionally using the difference between weight at admission 
and weight at 20 weeks´ gestation as all women stopped being randomised to calcium or placebo at 
20 weeks. All women received calcium supplementation from 20 weeks´ gestation until the end of 
pregnancy; however we also evaluated if any difference was found at 32 weeks´ gestation. To 
compare continuous variables between intervention and control group a t-test was used and to 
compare categorical values a chi2 test was used. 
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We then performed the same analysis of the effect of calcium supplementation at 8, 20 and 32 
weeks´ gestation for the following three BMI classification groups: underweight or normal, 
overweight and obese. To explore the effect in those that complied with the intervention the 
analysis for those that complied with 80% of the treatment was done separately. 
Finally, as the time between admission and pregnancy was different for each woman we 
evaluated the effect of calcium supplementation from admission to 8 weeks´ gestation by months 
of supplementation. We selected the cut off points reviewing the literature and decided to have 
three groups from 1) 2 to less than 6 months, 2) from 6 to less than 12 months and 3) more than 
12 months, as there are studies showing effect with duration between 2 and 6 months however 
there are no studies with duration of less than 2 months and very few of more than 6 months. A 
p-value of 0.05 was used to define significant differences. 
4.4. Results 
 
A total of 1355 women were admitted to the study and randomised to receive calcium 
supplementation (n= 678) or placebo (n=677) (See figure 4.1). Of those, 630 women conceived 
during the study with 322 in the calcium group and 308 in the placebo and of those 230 allocated 
to calcium and 227 allocated to placebo had information on body weight at 8 weeks´ gestation; 
198 allocated to calcium and 198 allocated to placebo had information on body weight at 20 
weeks´ gestation and 142 allocated to calcium and 139 allocated to placebo had information on 
body weight at 32 weeks´ gestation. None of the participants were taken off calcium or placebo 
groups. 
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Figure 4.1: Women for the analysis of the effect of calcium on weight 
 
 
Baseline characteristics of randomised women, for those who became pregnant in the CAP trial 
and those included in this sub study are illustrated in table 4.1. We did not find any significant 
difference at baseline in any of the variables between those allocated to calcium or placebo in 
any of the groups nor any difference between groups (Table 4.1). 
 
 
 
  
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   Conceived during study (n=308) Conceived during study (n=322) 
32 weeks visit with weight registered (n=142)  32 weeks visit with weight registered (n=139)  
Follow-Up 
Weight not registered at 8 weeks (n=92) 
 
Miscarriage before 20 weeks (n=2) 
Weight not registered at 20 weeks (n=30) 
Weight not registered at 8 weeks (n=81) 
 
20 weeks visit with weight registered (n=198) 20 weeks visit with weight registered (n=198) 
Randomized (n=1355) Enrollment 
Weight not registered at admission (n=30) 
Allocated to calcium (n=678) 
Not conceived during study (n=333) 
 
Allocated to placebo (n=677) 
Allocation 
8 weeks with weight registered (n=230) 8 weeks with weight registered (n=227) 
Lost to follow up (n=1) 
Weight not registered at 32 weeks (n=55) 
 
Before pregnancy 
weight change 
Weight change 
during pregnancy 
Not conceived during study (n=327) 
Weight not registered at admission (n=36) 
Allocated to calcium with weight registered (n=649) Allocated to placebo with weight registered (n=641) 
Miscarriage before 20 weeks (n=2) 
Weight not registered at 20 weeks (n=27) 
Lost to follow up (n=0) 
Weight not registered at 32 weeks (n=59) 
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Table 4.1: Comparison of baseline characteristics of women included in the CAP trial study and women included in this study. Mean values with 
standard deviations (SD) 
 
  BASELINE ALL IN CAP TRIAL BASELINE IN THIS SUB-STUDY 
  PLACEBO CALCIUM 
p value* 
PLACEBO CALCIUM 
p value 
  N Mean SD N Mean SD N Mean SD N Mean SD 
Maternal Age 677 30.4 5.9 678 30.2 5.8 0.518 227 29.0 5.0 230 29.7 5.4 0.145 
Parity 677 2.0 1.1 678 1.9 1.1 0.240 227 1.9 1.1 230 2.0 1.1 0.246 
Weight at ADM** (kg) 641 76.9 18.8 649 76.2 18.5 0.497 227 74.0 16.3 230 75.8 16.8 0.266 
Height at ADM (cm) 613 160.0 6.7 617 160.2 6.3 0.489 215 159.9 6.4 221 160.7 6.4 0.16 
BMI*** at ADM 608 30.1 6.9 610 29.7 7.1 0.347 215 28.9 6.2 221 29.3 6.6 0.530 
Months since last birth with PE§ 648 24.6 36.3 645 22.1 29.7 0.181 212 20.2 26.2 224 20.9 27.3 0.789 
* Differences were tested using a t-test and a p value of 0.05 
** ADM= Admission  
*** BMI= Body Mass Index 
§ PE= pre-eclampsia 
 
The average duration of receiving calcium or placebo from admission at baseline to 8 weeks´ 
gestation was 11.3 (SD± 8.8) months and 11.2 (SD± 9.3) months for those allocated to the 
calcium and placebo groups respectively. The body weight of all women increased during this 
period, however those allocated to placebo had a mean increase in body weight of 1.5 (SD ±6.1) 
kg whereas those allocated to calcium had a mean increase of 1.1 (SD ±5.5) kg although there 
was no statistical difference (Table 4.2). There was no difference between calcium and placebo 
group in body weight change from admission to body weight at 20 or 32 weeks´ gestation (Table 
4.2). From admission to 20 weeks women allocated to placebo had an increase in weight of 4.0 
kg (SD ±7.0) and those allocated to calcium 3.9 kg (SD ±6.0) (p=0.811). From admission to 32 
weeks´ gestation the weight of women allocated to placebo increased by 8.3 kg (SD ±7.3) and 
those allocated to calcium 7.7 kg (SD ±6.6) (p=0.457). 
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Table 4.2: Weight change between admission and 8, 20 and 32 weeks´ gestation by baseline Body Mass Index (BMI) 
  
PLACEBO CALCIUM  
n Mean difference (SD) n Mean difference (SD) p value* 
Weight change at 8 weeks´ gestation 227 1.5 (6.1) 230 1.1 (5.5) 0.408 
   BMI** at ADM*** < 25 72 0.8 (4.2) 70 1.5 (4.4) 0.334 
   25<=BMI at ADM<30 72 1.7 (5.3) 65 0.8 (4.0) 0.261 
   BMI at ADM>=30  83 2.0 (7.9) 95 0.9 (7.0) 0.330 
Weight change at 20 weeks´ gestation 198 4.0 (7.0) 198 3.9 (6.0) 0.811 
   BMI at ADM < 25 62 4.6 (5.7) 60 4.5 4.7) 0.916 
   25<=BMI at ADM<30 63 3.9 (6.6) 53 3.4 (4.4) 0.628 
   BMI at ADM>=30  73 3.7 (8.2) 85 3.7 (7.6) 1.000 
Weight change at 32 weeks´ gestation 139 8.3 (7.3) 142 7.7 (6.6) 0.457 
   BMI at ADM < 25 44 8.2 (5.4) 42 9.2 (5.5) 0.398 
   25<=BMI at ADM<30 50 8.2 (6.6) 37 8.1 (5.0) 0.936 
   BMI at ADM>=30  45 8.6 (9.4) 63 6.5 (7.9) 0.225 
* Differences were tested using a t-test and a p value of 0.05 
** BMI= Body Mass Index 
*** ADM= Admission 
 
Table 4.2 also shows change in body weight from admission to 8, 20 and 32 weeks´ gestation by 
baseline BMI categories. We found that at 8 and 32 weeks´ gestation women who started the trial 
with BMI equal or higher than 30, had a 1 kg (p=0.330) and 2.1 kg (p=0.225) higher increase in 
body weight respectively if they received placebo as compared to calcium however none of these 
differences were statistically significant. On the contrary, we found that women who started the 
trial with a normal BMI, had a 0.7 kg (p=0.334) and 1.0 kg (p=0.398) higher increase in body 
weight at 8 and 32 weeks’ gestation respectively if they received calcium compared to placebo, 
however none of these differences were statistically significant. 
Dietary energy and calcium intake was only measured at 20 weeks´ gestation. At this point the 
average total daily energy intake was 1815.2 kcal (SD ±802.8). There was no significant 
difference (p=0.902) in energy intake between women assigned to calcium (1812.8 (SD ±795) 
kcal) or to placebo (1824.2 (SD ±822) kcal). There was no difference in calcium intake from the 
diet between the groups, those allocated to calcium (n=143) had a mean dietary calcium intake 
of 418.9 (SD ±249.2) mg whereas those allocated to placebo (n=153) had a mean dietary calcium 
intake of 435.7(SD ±348.9) mg.199 
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We found that women of different age or parity had similar energy, however calcium intakes 
were lower in older women. Those aged between 20 to less than 35 years had a mean energy 
intake of 1859.6 kcal (SD ±810) and those aged 35 or more had a mean intake of 1620.1 kcal 
(SD ±775.6) (p=0.046). Those women with 1, 2 or 3 or more previous birth had a mean energy 
intake of 1938.9 kcal (SD ±917.8), 1789.5 kcal (SD ±714.9) and 1675.0 kcal (SD ±729.7) 
respectively (p=0.069). Those aged between 20 to less than 35 years had a mean calcium intake 
of 432.9 mg (SD ±325) and those aged 35 or more had a mean intake of 427.8 mg (SD ±308.2) 
(p=0.922). Those women with 1, 2 or 3 or more previous birth had a mean calcium intake of 
429.7 mg (SD ±331.4), 437.8 mg (SD ±345.6) and 425.1 mg (SD ±274.4) respectively (p=0.825). 
There was no difference in birth weight between those babies born to mothers randomised to 
calcium 2670 grams (SD ±1021) and those to placebo 2686 grams (SD ±846) (p=0.897). 
Table 4.3 shows compliance of women measured at 8, 20 and 32 weeks´ gestation. We did not 
find any difference in compliance between calcium and placebo groups at any point. Only around 
50 to 60 % of women had a compliance of 80% or more with the study supplements. We ran the 
analysis taking into account only those that had complied with 80% of the supplements or more 
and found no differences between the groups (Table 4.4). 
Table 4.3: Participants compliance of 80% or more of the study supplements  
  PLACEBO CALCIUM 
p value*  Compliance (>80% tablets taken) N n % N n % 
From last PPV§ up to before 8 weeks  227 131 57.7 230 122 53 0.363 
From last PPV up to 20 weeks 198 117 59.1 198 118 59.6 1 
From last PPV up to 32 weeks 139 72 51.8 142 79 55.6 0.629 
*Differences were tested using a chi2 test and a p value of 0.05 
§PPV = Pre-pregnancy visit 
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Table 4.4: Weight change between admission and 8, 20 and 32 weeks´ gestation by baseline Body Mass Index (BMI) in those that complied 
with 80% or more 
  
PLACEBO CALCIUM  
n Mean difference (SD) n Mean difference (SD) p value* 
Weight change at 8 weeks´ gestation 131 1.1 (4.4) 122 1.4 (5.4) 0.578 
   BMI** at ADM*** < 25 44 1.1 (4.4) 35 1.5 (4.8) 0.688 
   25<=BMI at ADM<30 42 1.7 (4.1) 39 1.1 (3.2) 0.476 
   BMI at ADM>=30  45 0.5 (4.7) 48 1.6 (7.0) 0.374 
Weight change at 20 weeks´ gestation 117 3.4 (5.7) 118 3.6 (5.6) 0.867 
   BMI** at ADM*** < 25 35 4.5 (6.4) 39 4.1 (4.3) 0.774 
   25<=BMI at ADM<30 41 3.4 (5.3) 29 3.2 (4.2) 0.839 
   BMI at ADM>=30  41 2.5 (5.1) 50 3.3 (7.1) 0.554 
Weight change at 32 weeks´ gestation 72 8.4 (7.8) 79 7.7 (5.6) 0.558 
   BMI at ADM < 25 22 6.6 (5.1) 24 9.2 (3.8) 0.065 
   25<=BMI at ADM<30 27 9.0 (4.9) 20 8.8 (4.3) 0.906 
   BMI at ADM>=30  23 9.4 (11.7) 35 6.2 (6.8) 0.190 
* Differences were tested using a t-test and a p value of 0.05;  
** BMI= Body Mass Index;  
*** ADM= Admission 
 
Finally we analysed the effect of calcium supplementation on body weight by time in the study 
between admission to pregnancy and we did not find any difference between the calcium and 
placebo groups. (Table 4.5) 
Table 4.5: Weight change in kilograms from admission to 8 weeks´ gestation by months of supplementation 
 
PLACEBO CALCIUM 
 
n Mean difference SD n Mean difference SD p value* 
Weight change at 8 weeks´ gestation        
   Time in study < 2 months 6 1.2 2.6 5 -0.2 2.7 0.418 
   Time in study 2 to 6 months 81 0.6 3.9 77 0.3 4.2 0.635 
   Time in study 6 to 12 months 55 1.3 3.7 72 1.3 5.7 0.957 
   Time in study >=12  85 2.5 8.6 76 1.7 6.6 0.511 
* Differences were tested using a t-test and a p value of 0.05 
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4.5. Discussion 
 
In this study we evaluated the effect of a low dose of calcium supplementation on body weight 
change starting preconceptionally and up to 8, 20 and 32 weeks´ gestation in women with high 
risk of pre-eclampsia. To our knowledge this is the first study that investigated the effect of 
calcium supplementation on weight change in pregnant women. We did not find an effect of 
calcium supplementation in reducing 1.2 kg or more of body weight in women with high risk of 
pre-eclampsia, however we observed that the calcium group had a smaller increase in body 
weight at 8, 20 and 32 weeks’ gestation although none of these differences were statistically 
significant. Sub-group analyses indicated that obese women receiving calcium had a lower 
increase in body weight than those who received placebo, however normal weight women 
receiving calcium had a higher increase in weight than those receiving placebo. Although these 
differences were not statistically significant, the finding for normal weight women was 
unexpected. 
We were not able to demonstrate that calcium supplementation decreases body weight as has 
been shown in animal models; it could be that in humans there are other more influencing factors 
affecting body weight.200 Furthermore, our study was not restricted to women who were 
overweight or obese as were the basic studies and the systematic review that showed that calcium 
supplementation decreases body weight.25 Although the mean difference in body weight between 
treatment arms was not statistically significant, the difference is in line with the effect shown in 
a systematic review in overweight and obese women. 25 It is also possible that the Calcium dose 
of 500 mg of elemental calcium a day was too low to influence weight as the systematic review 
included many studies with doses of 1000 mg of elemental calcium or more a day.25 It is also 
likely that the time period that women received supplementation was not sufficient for a large 
number of women in our sample, as 37% of the women had a supplementation time less than 6 
months. The previous systematic reviewed indicated that the minimum time needed to have a 
statistical effect on body weight is 6 months. 25 It should be noted that there were no differences 
in weight change between the treatment groups for different time periods of calcium 
supplementation. Lastly, it must be borne in mind that we conducted this investigation during 
pregnancy, where other physiological or hormonal mechanisms may influence the results. For 
example, intestinal calcium absorption is generally low, around 25%, however during pregnancy 
intestinal calcium absorption doubles or triples to meet foetal requirements. 201 This adaptation 
might have some influence in calcium metabolism. 
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One of the potential mechanisms of action for the effect of calcium supplementation on body 
weight was through the effect of calcium in appetite.65 However, the fact that the energy intake 
at 20 weeks´ gestation was not different between the calcium and placebo groups may indicate 
that calcium supplementation with 500 mg a day has no effect on the total energy intake of 
women. There was also no difference in dietary calcium intake at 20 weeks´ gestation between 
the groups suggesting that women randomised to calcium truly had a higher calcium intake. 
The study showed no difference in birthweight between those babies born to mothers randomised 
to calcium or placebo. This finding precludes the possibility that maternal calcium intake could 
have a role on foetal growth. 
 
Strengths  
This was a randomised controlled trial with standardised procedures used in all sites. Women in 
this study were followed up regularly and weight and height were measured by the same research 
team before and during pregnancy. 
Limitations 
It is important to note that the findings of this study is only applicable to women with a risk of 
pre-eclampsia and not generalizable to all pregnant women. It has been shown that, obesity, 
hypertension and endothelial dysfunction are risk factors of PE. In this way, women in the CAP 
trial might have had an increase occurrence of these diseases compared to the general population 
and therefore different physiological changes. 202,203 Besides women with limited access to 
hospital delivery are not represented in this study. 
Besides the small sample size another limitation was that we had only the admission 
measurement of body weight before pregnancy for each participant and thus we had to use body 
weight measured at 8 weeks as a proxy of pre-pregnancy body weight. 
Although the time period between admission to the study until evaluation at 8 weeks´ gestation 
varied for each woman, the average supplementation time for the calcium and placebo groups 
were similar and time-period on supplementation did not influence the results.  
Other reasons why we did not find any effect could be that the study lacked power to detect 
differences smaller than 1.2 kg, this can introduce a type II error where there is not power to 
 
 
72 
 
  
detect a true effect. and that Besides, in this study compliance was not optimal as only 50 to 60 
% of women took 80% or more of the assigned supplements. 
A further limitation is the fact that we did not use birthweight percentiles when comparing the 
effect of calcium supplementation during pregnancy on the effect of birthweight. 204 
 
4.6. Conclusion 
 
This study shows that it is feasible to recruit women preconceptionally from low and middle 
countries and to follow them up throughout pregnancy.  
We found that a low dose of calcium supplementation of 500 mg of elemental calcium a day had 
no statistically significant effect on body weight in women preconceptionally and during 
pregnancy. The sample size of the study allowed power to detect at 8 weeks´ gestation a 
difference of 1.2kg or higher between the calcium and placebo groups. In this way a clinically 
significant reduction smaller than 1.2 kg could have been missed due to a type II error where 
there is not power to detect a true effect.205,206 Although the results were not statistically 
significant the effect found was in the same direction of previous results. Even though the 
individual clinical relevance of a small weight reduction has been questioned, at a population 
level it could help to prevent the observed obesity global trends. 186 
 
Although the results from this study do not support any implication for practice, it is of interest 
to report this type of study so as to build on the evidence. Future studies with more power are 
desirable to assess if those randomised to calcium had higher body weight increment if their BMI 
was less than 25 at the start of the intervention and a lower body weight increment if their weight 
was BMI 30 or more at the start of the intervention.	
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Pre-pregnancy weight status, weight gain during pregnancy and adequacy of dietary intake 
of pregnant women in the CAP trial  
 
This chapter reports the pre-pregnancy weight status, weight gain during pregnancy and 
adequacy of dietary intake of pregnant women in the CAP trial that is Aim 2 of this thesis. Part 
of the information for this aim was published in open access in the journal BMC Pregnancy and 
childbirth where I describe the anthropometry and dietary intake of women participating in the 
CAP trial during the second trimester of pregnancy. 
“I confirm that I have applied for permission by the University of Cape Town’s Doctoral Degrees 
Board to include the following publication(s) in my thesis, and where co-authorships are 
involved, my co-authors have agreed that I may include the publication(s): 
Cormick G, Betrán AP, Harbron J, Dannemann Purnat T, Parker C, Hall D, Seuc AH, Roberts 
JM, Belizán JM, Hofmeyr GJ; Calcium and Pre-eclampsia Study Group. Are women with history 
of pre-eclampsia starting a new pregnancy in good nutritional status in South Africa and 
Zimbabwe? BMC Pregnancy Childbirth. 2018 Jun 15;18(1):236. 
 
5.1. Abstract 
 
Background: Maternal nutritional status before and during pregnancy is an important contributor 
to pregnancy outcomes and early child health. The aim of this study was to describe the 
preconceptional nutritional status and dietary intake during pregnancy in high-risk women from 
South Africa and Zimbabwe. 
Methods: This is a prospective observational study, nested to the CAP trial. Anthropometric 
measurements before and during pregnancy and dietary intake using 24-h recall during 
pregnancy were assessed. The Intake Distribution Estimation software (PC-SIDE) was used to 
evaluate nutrient intake adequacy taking the Estimated Average Requirement (EAR) as a cut-off 
point. 
Results: Three hundred twelve women who had pre-eclampsia in their last pregnancy and 
delivered in hospitals from South Africa and Zimbabwe were assessed. 73.7 and 60.2% women 
in South Africa and Zimbabwe, respectively started their pregnancy with BMI above normal 
(BMI ≥ 25) whereas the prevalence of underweight was virtually non-existent. 
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The majority of women had inadequate intakes of micronutrients. Considering only food and 
beverage intake, none of the micronutrients measured achieved the estimated average 
requirement. Around 60% of pregnant women reported taking folic acid or iron supplements in 
South Africa, but almost none did so in Zimbabwe. 
Conclusion: We found a high prevalence of overweight and obesity and high micronutrient 
intake inadequacy in pregnant women who had the previous pregnancy complicated with 
pre-eclampsia. The obesity figures and micronutrient inadequacy are issues of concern that need 
to be addressed. Pregnant women have regular contacts with the health system; these 
opportunities could be used to improve diet and nutrition. 
Trial registration: PACTR201105000267371. Registered 06 December 2010. 
Keywords: Nutrient intake, Weight, Pregnancy, Supplement, Obesity, BMI 
5.2. Introduction 
 
Nutrition status of women before and during pregnancy is one of the main contributors to 
pregnancy outcomes and early child health.3 In many low and middle-income countries 
undernutrition and overnutrition coexist in the same population.19 Obesity is increasing while 
micronutrient deficiencies still persist, particularly in the most vulnerable groups such as women 
and children.20 Consequently, women start pregnancy with higher risks to develop complications 
such as pre-eclampsia, gestational diabetes mellitus, gestational hypertension, depression, foetal 
macrosomia, stillbirth, preterm birth, birth by caesarean section and infant mortality.8–13 In 
addition, high maternal body mass index (BMI) has also been associated with delayed 
breastfeeding, weight retention and in women with gestational diabetes, a higher risk of 
developing chronic diseases.8 Inter-pregnancy interval is also an important factor that may 
influence maternal availability of nutrients, especially in those populations with existing 
micronutrient deficiencies.18 
Interest in pre-conceptional interventions to reduce risk factors during pregnancy is growing, 
although their effectiveness on pregnancy outcomes is less certain.17 Current WHO Guidelines 
on antenatal care recommend supplementation with iron and folic acid to all pregnant women, 
and with calcium and vitamin A to women in specific areas with a high prevalence of 
deficiency.126 The WHO guidelines also recommend supplementation with 1.5–2.0 g elemental 
calcium/day from 20 weeks´ gestation until the end of pregnancy for the prevention of 
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pre-eclampsia in those areas where calcium intake is low. The WHO Guidelines also report that 
women receiving counselling on diet and/or exercise are less likely to experience excess weight 
gain during pregnancy, although the evidence on the impact of other pregnancy outcomes is less 
certain.126 
In South Africa, the National Health and Nutrition Examination Survey (SANHANES-1) 
reported a prevalence of overweight (BMI ≥ 25 kg/m2) and obesity (BMI ≥ 30) in women of 
24.8% and 39.2%, respectively in 2012.41 Data from Zimbabwe in 2000 shows a prevalence of 
overweight and obesity in women of 17.4% and 5.7% respectively.46 However information on 
overweight and obesity rates as well as dietary intake during pregnancy is scarce in these 
countries. In South Africa, high levels of micronutrient inadequacy have been reported in a 
sample of alcohol and non-alcohol consumer pregnant women in their second half of pregnancy 
from Cape Town as well as women with gestational diabetes mellitus from Cape Town.125,207 
Nutrient and supplement intake information would be important to better plan and tailor 
interventions to improve pregnancy outcomes.18 
We conducted a randomised controlled trial to evaluate the effect of pre-pregnancy calcium 
supplementation on the incidence of recurrent pre-eclampsia (Calcium and Pre-eclampsia: CAP 
trial).167 This was a multi-country trial conducted in South Africa, Zimbabwe and Argentina. 
This manuscript presents the results of a sub-analysis of the CAP trial with the aim of describing 
the nutritional status of women from South Africa and Zimbabwe that became pregnant during 
the CAP trial. More specifically, we aimed to describe levels of overweight and obesity before 
and during pregnancy, and the adequacy of macronutrient and micronutrient intake during 
pregnancy. 
5.3. Participants and Methods 
 
This was a nested prospective observational study of women from South Africa and Zimbabwe 
recruited in the CAP trial.168 The CAP trial was a multi-centre randomised, double-blind 
placebo-controlled clinical trial with the objective to determine whether calcium supplementation 
before conception and during the first half of pregnancy reduces the incidence of recurrent pre-
eclampsia more effectively than supplementation starting at 20 weeks, which is the current WHO 
recommendation. In the CAP trial, non-pregnant women with history of pre-eclampsia or 
eclampsia in their most recent pregnancy were invited to participate as they are at higher risk of 
developing pre-eclampsia in subsequent pregnancies. Once admitted in the trial, participants 
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were required to attend study sites every 12 weeks for follow up until pregnancy occurred. 
Pregnant women were followed up throughout their pregnancy and trial visits were scheduled at 
8, 20 and 32 weeks´ gestation. Eligible women were randomised to receive either 500 mg of 
elemental calcium daily or placebo from recruitment and blinded supplementation continued 
while participants were non-pregnant or until 20 weeks’ gestation. From 20 weeks’ gestation, all 
participants received calcium supplements in compliance with WHO guidelines.1 The CAP trial 
started in 2011 and recruitment was completed in September 2016. 
Settings and study population 
Participants were recruited from government secondary or tertiary urban referral hospitals with 
large obstetric units serving urban and rural populations. The maternity and obstetric units 
included in the CAP trial were located in Cape Town (1), East London (2) and Johannesburg (1) 
in South Africa; and in Harare (2), Zimbabwe. Women were eligible for the CAP trial if they had 
pre-eclampsia or eclampsia in their most recent pregnancy, if they were not pregnant but in a 
sexual relationship, not using contraception and if they gave informed consent. For admission 
we reviewed the participant clinical records and accepted the clinical evaluation of pre-eclampsia 
or eclampsia reported there. Exclusion criteria included: less than 18 years of age; chronic 
hypertension with persistent proteinuria; calcium supplement intake; and history or symptoms of 
urolithiasis, renal disease or parathyroid disease.168 For a complete list of eligible criteria please 
refer to the published protocol.168 In this analysis, we included women recruited in the CAP trial 
who became pregnant and reached 20 weeks´ gestation between March 2013 to March 2016. 
Anthropometric assessment and clinical data collection 
Variables used for this sub-study included: age, height, pre-pregnancy weight, number of 
previous pregnancies and date of birth of last pregnancy complicated with pre-eclampsia. This 
data were collected at admission and for those that became pregnant, weight was also measured 
during pregnancy at 8, 20 and 32 weeks´ gestation throughout the planned trial visits. Research 
nurses specially trained for the CAP trial assessed all anthropometric, clinical and dietary 
variables at admission and during follow up visits at each participating site. 
Body weight was measured to the nearest 0.1 kg in light clothing and without shoes. Height was 
measured to the nearest 1 centimetre using a stadiometer while the participant was not wearing 
shoes. Scales and stadiometers were those provided by each hospital and remained the same 
throughout the study. The Manual of Operations and the Standard Operating Procedures (SOPs) 
provided clear instructions on how women should be weighted and measured. 
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Pre-pregnancy BMI was calculated as weight (kg) divided by the square of the body height (m) 
using measurements recorded at admission. Women were classified according to the WHO BMI 
standards for adults, defined as underweight (BMI < 18.5), normal (18.5 ≤ BMI < 25), overweight 
(BMI ≥ 25), or obese (BMI ≥ 30).173 
Gestational weight gain was calculated by subtracting the weight at 8 weeks´ gestation from the 
weight at 32 weeks´ gestation, since the participant’s weight at delivery was not assessed. 
Dietary assessment 
The dietary intake of participants was assessed at 20-weeks’ gestation using a triple pass 24-hour 
dietary recall adapted from the method developed by Nelson et. al. Before the CAP trial started 
it was piloted in South Africa and Zimbabwe.156 The 24-hour recall is a guided interview to assess 
food intake of the previous day. CAP trial research nurses were trained in-site in March 2013 to 
administer the triple pass 24-hour recalls and to use the Dietary Assessment Education Kit 
(DAEK) to assist with the portion size estimation.175 Xhosa and Zulu translators were trained at 
the sites that required them. 
Reported food intakes from the 24-hour recall were entered and analysed using the Food Finder 
III computer program, provided by the South African Medical Research Council (SAMRC) to 
obtain daily energy and nutrient intakes for each participant. If properly conducted, a single day 
24-hour dietary recall is a reliable method to assess individual intake on one day and can be used 
to estimate a population mean.29 However, as food and nutrient intakes have a wide day-to-day 
variability, data obtained from one single day is not sufficient to describe the usual intake or to 
assess the proportion of individuals with intakes below certain thresholds (e.g. below 
requirements). Statistical models have been developed to better estimate usual nutrient intakes in 
a population by adjusting for within-individual intake variability.128 These statistical models 
reduce the within person variability adjusting the distribution so that the main variability left is 
the person-to-person one. We used the Iowa State University (ISU) method that produce standard 
errors for estimated parameters, adjusts for day of the week or interview order. The ISU method 
as there is evidence it produces good estimates of usual intake distributions of most nutrients, 
however it is not useful to assess the usual intake of nutrients or foods that are not frequently 
consumed.163,164,166 Therefore, in order to estimate the proportion of women with intakes below 
requirements we used the Intake Distribution Estimation software (PC-SIDE, version 1.0, 2003; 
Department of Statistics, Iowa State University, Ames) that applies the ISU model and requires 
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a sample of at least 50 dietary assessments that are repeated on a non-consecutive day to the first 
assessment.71,176 The ISU method for estimating usual intake can correct some characteristics of 
dietary intake data such as within person variability in intakes, correlation of intakes reported 
over consecutive days, effect of day of week, recall order, nonnormality of reported intakes and 
survey nonresponse.163,164 However the ISU method has some constrains, when duplicate recalls 
are made in very few individuals the estimated intake of some micronutrients can be less accurate 
than that for macronutrients or those consumed more frequently. Besides, less frequently 
consumed foods such as oysters and nutrients such as lycopene, beta- cryptoxanthin and alfa-
carotene may require more than two 24-h recalls. 164 
For these purposes, a second 24-hour dietary recall assessment was administered in a subsample 
of women on a non-consecutive day after the first 24-hour recall. Energy and nutrient intake 
distributions from the single 24-hour recall were thus adjusted by within-person variance 
obtained from the second 24-hour recall assessment and by interview weekday to estimate usual 
nutrient intake and to calculate the proportion of women with intakes below requirements. 
The Estimated Average Requirement (EAR) of carbohydrates and each micronutrient as 
recommended by the Institute of Medicine (IOM) for pregnant women was used as the cut-off 
point to assess adequacy of nutrient intake.208 The Estimated Energy Requirement (EER) for 
pregnant women during the second trimester was calculated for each participant using the age, 
weight and height at admission and according to the Dietary Reference Intake (DRI) formula for 
adult women.62 As data of physical activity was not collected the value for sedentary lifestyle 
was used conservatively. Energy intake obtained from the first 24-hour recall assessment was 
divided by the EER then normalized using PC-SIDE.159 The 80% of EER during pregnancy 
suggested by Goldberg was used to calculate the plausibility of energy intake.209 Protein 
adequacy was calculated using the EAR of 0.88 grams per kg of body weight, using weight at 20 
weeks´ gestation 62  
A specific questionnaire was also included to investigate supplement intake during pregnancy. 
Women were asked about frequency and dose of the supplements and medicines. Trial 
supplementation was not computed in the dietary assessment of this sub-study as it was the 
intervention being tested and not, otherwise, part of the diet of this group of women. 
5.4. Statistical Analysis 
Categorical values were described using percentages and numerical variables using means and 
standard deviations (SD). Statistical data analyses were performed using the SPSS 23.0 software 
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package (IBM, New York, NY, USA). Dietary intake variables were log transformed and tested 
for normality using the Anderson-Darling statistical test using the PC-SIDE software. The 
software performs three steps: adjustments for weekday; transformation to normality using 
power transformation; and estimation of within-person variance using an error measurement 
model. 
5.5. Ethics 
Ethical approval was obtained from appropriate national and institutional ethics review bodies 
as applicable for each study site, and all participants provided informed written consent. The 
study was approved by the Research Project Review Panel of the UNDP/UNFPA/ 
UNICEF/WHO/World Bank Special Programme of Research, Development and Research 
Training in Human Reproduction at the Department of Reproductive Health and Research of 
WHO, and the WHO Research Ethics Review Committee, Geneva, Switzerland. 
Data management procedures were compliant with good clinical practice (GCP).210 
5.6. Results 
A total of 2187 women were screened in South Africa and Zimbabwe during the sub-study period 
(March 2013 to March 2016) and 1101 (50.3%) were eligible and accepted to participate (Figure 
5.1). Of the 1101 participants randomised, 541 (49.1%) became pregnant of whom, 55 (10.0%) 
had a miscarriage or a pregnancy termination before 20 weeks´ gestation, 34 did not attend to the 
pregnancy visit at 20 weeks’ gestation, and 102 (18.8%) completed the visits at 20 weeks´ 
gestation outside the sub-study period. A total of 350 women were eligible for this sub-study, 
however 38 (10.8%) missed the dietary assessment interview. Thus, we present the results of 312 
women that completed the dietary assessment at the 20 weeks´ gestation visit. Of these women 
224 (71.8%) were from South Africa and 88 (28.2%) from Zimbabwe. Repeated dietary 
assessments were obtained from 107 (34.3%) women, 79 from South Africa and 28 from 
Zimbabwe. 
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Figure 5.1: Flow chart 
 
At the time of the assessment, women from South Africa had been in the study an average of 
12.5 (SD ±7.4) months and women from Zimbabwe 13.1 (SD ±7.4) months. Their 
inter-pregnancy interval was 24.5 (SD ± 22.5) months in South Africa and 30.3 (SD ±23.7) 
months in Zimbabwe (Table 5.1). 
  
Figure	1:	Flow	chart				 					 	
Analysis	
Follow-Up	
Pregnancy loss before study visit at 20 weeks n= 55 (10,0%)  		
Screened women (n= 2187)  
Randomized n=1101 
Enrolment	
  Ineligible/declined n = 1086 (49,7%) 
 
Not conceived during study n= 560 (50,9%) 
 
Conceived during study n= 541 
Study pregnancy visit at 20 weeks n= 350	
No dietary assessment at 20 weeks n= 38 (10,8%) 
Analysed n= 312 		
No visit at 20 weeks n= 34 (6,3%) 		
Pregnancy visit out of study period n=102 (18,8%) 
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Table 5.1: Participant Characteristics 
 All South Africa Zimbabwe 
 n= 312 % n=224 % n=88 % 
Age (years)       
Less than 20 1 0.3 0 0 1 1.1 
20 to less than 35 255 81.7 182 81.3 73 83 
35 and older 56 17.9 42 18.8 14 17.9 
Parity        
1 121 38.8 93 41.5 28 31.8 
2  111 35.6 79 35.3 32 36.4 
3 or more 79 25.3 51 22.8 28 31.8 
Missing 1 0.3 1 0.4 0 0 
       
Months in study from admission to 20 weeks´ gestation  
Mean (sd)  312 12.5 (7.4) 224 13.1 (7.4) 88 11.0 (7.4) 
Less than 6 month 94 30.1 60 26.8 34 38.6 
6 to less than 12 month 88 28.2 59 26.3 29 33.0 
12 to less than 24 month 97 31.1 79 35.3 18 20.5 
24 or more month 32 10.3 25 11.2 7 8.0 
Missing 1 0.3 1 0.4 0 0 
  
Months since last birth with PE to 20 weeks´ gestation  
Mean (sd) 312 24.5 (22.5) 224 30.3 (23.7) 88 27.4 (19.0) 
Less than 6 month 9 2.9 7 3.1 2 2.3 
6 to less than 12 month 54 17.3 39 17.4 15 17.0 
12 to less than 24 month 94 30.1 62 27.7 32 36.4 
24 or more month 135 43.3 102 45.5 33 37.5 
Missing 20 6.4 14 6.3 6 6.8 
       
Anthropometric variables       
Height at admission - mean (sd) 286 160.3 (6.4) 202 159.9 (6.4) 84 161.1 (6.4) 
Weight at admission - mean (sd) 302 76.1 (17.4) 217 78.9 (18.2) 85 69.0 (12.6) 
Weight at week 8 of gestation - mean (sd) 251 77.1 (16.9) 173 80.2 (17.7) 78 70.2 (12.4) 
Weight at week 20 of gestation - mean (sd) 300 80.2 (17.5) 215 83.5 (18.1) 85 71.9 (12.6) 
Weight at week 32 of gestation - mean (sd) 224 84.0 (17.0) 158 88.2 (17.5) 66 74.0 (10.1) 
Mean BMI at admission - mean (sd) 283 29.6 (6.3) 201 30.7 (6.6) 82 26.8 (4.5) 
       
Body Mass Index at admission       
Underweight (BMI < 18.5 kg/m2) 3 1.0 2 0.9 1 1.1 
Normal (18.5 BMI < 25 kg/m2) 62 19.9 34 15.2 28 31.8 
Overweight (25 BMI < 30 kg/m2) 95 30.4 62 27.7 33 37.5 
Obesity I (30 BMI 35 kg/m2) 75 24.0 58 25.9 17 19.3 
Obesity II (35 BMI 40 kg/m2) 32 10.3 30 13.4 2 2.3 
Obesity III (BMI >40 kg/m2) 16 5.1 15 6.7 1 1.1 
Missing 29 9.3 23 10.3 6 6.8 
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Clinical characteristics 
At recruitment, the mean age of women in this sub-study was 29.2 years (SD ± 5.2) in South 
Africa and 29.3 (SD ± 4.8) in Zimbabwe. Parity was three or more in about 25% of the women 
(22.8% and 31.8% in South Africa and Zimbabwe, respectively). The mean height was 159.9 cm 
(SD ±6.4) in South Africa and 161.1 cm (SD ±6.4) in Zimbabwe; and the mean weight before 
pregnancy was 78.9 kg (SD ±18.2) in South Africa and 69.0 kg (SD ±12.6) in Zimbabwe. The 
prevalence of overweight was 27.7% in South Africa and 37.5% in Zimbabwe while the 
prevalence of any degree of obesity was 46.0% in South Africa and 22.7% in Zimbabwe (Table 
5.1). In total, 73.7% and 60.2% women in South Africa and Zimbabwe, respectively entered the 
trial with BMI above normal. On the other hand, the prevalence of underweight was virtually 
non-existent in both countries.  
Gestational Weight Gain 
We found that women who were initially classified according to their BMI as normal weight had 
gained from 8 to 32 weeks’ gestation an average 8.9 kg (SD ± 4.4) in South Africa and 7.4 kg 
(SD ± 3.3) in Zimbabwe. Those classified as overweight had gained 7.8 kg (SD ± 4.5) in South 
Africa and 5.8 kg (SD ±3.8) in Zimbabwe and those classified as obese had gained 5.9 kg (SD ± 
6.2) in South Africa and 3.1 kg (SD ± 4.1) in Zimbabwe. 
Diet 
Macronutrients 
The average total daily energy intake was 1765.6 kcal (SD ±346.6) in South Africa and 1827.9 
(SD ±303.9) in Zimbabwe. Average daily carbohydrate, fat and protein intakes were 230.8 (SD 
± 57.5) grams, 59.1 (SD ± 6.4) grams and 54.7 (SD ±7.8) grams in South Africa and 213.6 (SD 
± 22.3) grams, 76.4 (SD ± 24.8) grams and 52.9 (SD ± 25.8) grams in Zimbabwe, respectively 
(Table 2). Most (54.4%) of total energy intake came from carbohydrates, 27.8% from fats and 
12.6% from proteins in South Africa while the percentages in Zimbabwe were 48.0%, 36.4% and 
11.3% respectively. 
Average daily intake of total sugars was 45.6 (SD ± 40.9) grams in South Africa and 34.5 (SD 
±26.0) grams in Zimbabwe representing 10.6% and 7.5% of the total energy intake. The majority 
of women in both countries had lower than recommended protein intake (71.1% for South Africa 
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and 98.3% for Zimbabwe) and a higher intake of carbohydrates (2.9% for South Africa and 0% 
for Zimbabwe) (Table 5.2). 
Table 5.2: Usual intake from foods and beverages, excluding supplements, estimated using 
repeated 24-hour recalls in 312 women and repeated in a sub-sample of 107 women, and 
percentage of women with usual intake below Estimated Average Requirement (EAR) 
Estimated Daily Usual Intake * 
 
South Africa 
 
Zimbabwe 
 
EAR¶ 
% women with intakes below 
EAR 
n= 224 n=88 South Africa Zimbabwe 
Energy (kcal) 1765.6 (346.6) 1827.9 (303.9) NA** NA NA 
EER Estimated Energy Requirement 
(%) 0.88 (0.20) 0.93 (0.14) 
0.8 
37.7 19.1  
Protein (g) 54.7 (7.8) 52.9 (25.8) § NA NA NA 
Protein (g/kg) 0.82 (0.43) 0.79 (0.04) 0.88 71.1 98.3  
Carbohydrates (g) 230.8 (57.5) 213.6 (22.3) 135 02.9 0.00 
Total Sugars (g) 45.4 (19.4) 35.4 (10.7) NA NA NA 
Fats (g) 59.1 (6.4) 76.4 (24.8) NA NA NA 
Calcium (mg) 441.0 (97.7) 360.5 (171.4) 800 99.9 97.6 
Iron (mg) 9.9 (5.3) 7.9 (1.7) 22 96.9 100.0 
Folate (mcg) 253.2 (69.1) 240.6 (46.2) 520 99.9 100.0 
Mg (mg) 239.6 (51.1) 262.5 (38.8) 290 83.9  77.3  
Zn (mg) 7.3 (1.7) 6.4 (1.6) 9.5 90.4 95.7 
Se (mcg) 37.9 (4.3) 37.5 (11.8) 49 99.1 83.7 
Riboflavin (mg) 1.3 (0.6) 0.8 (0.5) 1.2 54.0 84.0 
Niacin (mg) 13.0 (3.8) 13.0 (3.7) 14 63.8 64.9 
Vitamin C (mg) 82.4 (45.1) 109.80 (41.8)  70 46.6 15.6 
Vitamin E (mg) 10.1 (3.8) 26.4 (9.1) 12 73.5 03.7 
¶ EAR: Estimated average requirement 
* Usual intake was obtained using the IOWA methodology. 
** NA (Not Applicable) 
§ This value represents the mean of the first interview. 
 
Micronutrients 
Adjusted usual nutrient intakes (from food and beverages, excluding supplements) are presented 
in Table 5.2. Micronutrient inadequacy was highly prevalent in both countries. Almost all women 
in South Africa had inadequate intakes of folate (99.9% ), calcium (99.9% ), iron (96.9% ) and 
selenium (99.1% ), while the majority also had inadequate intakes of magnesium (96.9% ), zinc 
(90.4% ), niacin (63.8% ) and vitamin E (73.5% ). More than half of the women had inadequate 
intakes of riboflavin (54.0% ) while less than half had inadequate intake of vitamin C (46.6% ). 
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All women in Zimbabwe had inadequate dietary intakes of iron and folate (100.0% ); the majority 
also had inadequate intakes of calcium (97.6% ), magnesium (77.3% ), zinc (95.7% ), selenium 
(83.7% ) and riboflavin (84.0% ). The intake of vitamin C (15.6% ) and E (3.7% ) was however, 
adequate in the majority of women from Zimbabwe. (Table 5.2) 
Supplements 
In South Africa, 62.9% of women (141) reported taking 5 mg of folic acid supplements, 57.1 % 
(128) reported taking iron supplements with doses ranging between 75 to 400 mg; 24.1% (54) 
reported taking vitamin C with doses ranging between 100 to 250 mg daily and 9.8% (22) 
reported taking vitamin B complex. At 20 weeks of pregnancy, women reported taking these 
supplements for a mean period of 2.1 to 2.7 months. Other supplements reported include calcium 
gluconate, magnesium sulphate and copper sulphate. Most of the supplements were provided by 
the hospital. On the other hand, a total of 29 (12.9%) women reported taking multivitamins for a 
mean period of 1 to 2 months, which are not provided by the hospitals. 
In Zimbabwe, only one woman reported taking iron supplements during pregnancy. No other 
types of supplements intake were reported what so ever. 
5.7. Discussion 
This study shows that a high proportion of women whose previous pregnancy was complicated 
by pre-eclampsia in hospitals from South Africa and Zimbabwe started their subsequent 
pregnancy overweight or obese (73.7% in South Africa and 60.2% in Zimbabwe). In fact, obesity 
affected about 1 in 4 women in Zimbabwe, and as many as 1 in 2 women in South Africa were 
obese. Furthermore, at 20 weeks´ gestation more than 90% of these women had intakes of 
micronutrients, like iron, calcium, folate and zinc below requirements. 
Overweight and obesity problems have already been reported in these countries. The prevalence 
of overweight or obese women found in our study is higher than the 64% that has been reported 
for South Africa by the SANHANES-1 and the 54.9% and 25% that the WHO Global Database 
on Body Mass Index reports for South Africa in 2004 and Zimbabwe in 2006 respectively, but 
in line with other studies conducted in South Africa that reported 69%.31,211,212 The fact that we 
only included women who had a previous pregnancy complicated with pre-eclampsia could 
contribute to the higher overweight or obesity prevalence in our study population.46,168 A link 
between obesity and hypertensive disorders of pregnancy has been reported in the literature. A 
systematic review concluded that for every 5 to 7 kg/m2 increase in BMI, the risk of developing 
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pre-eclampsia doubles which confirms the relevance and critical importance of developing and 
implementing special efforts to control the BMI of these women before they become pregnant.213 
We found that women with normal BMIs’ at 8 weeks´ gestation, compared to those with higher 
BMI, gained more weight at 32 weeks, which is in accordance to recommendations.197 However, 
as we only assessed weight up to 32 weeks´ gestation and most gestational weight gain occurs 
after 20 weeks´ gestation, we would expect that many of these women would exceed the Institute 
of Medicine recommendations. In our study, women classified as normal weight gained from 8 
to 32 weeks’ gestation an average 8.9 kg (SD ± 4.4) in South Africa and 7.4 kg (SD ± 3.3) in 
Zimbabwe of the 11.5 to 16 kg recommended for this group. Those classified as overweight 
gained 7.8 kg (SD ± 4.5) in South Africa and 5.8 kg (SD ±3.8) in Zimbabwe of the 7 to 11.5 kg 
recommended for this group and those classified as obese gained 5.9 kg (SD ± 6.2) in South 
Africa and 3.1 kg (SD ± 4.1) in Zimbabwe of the 5 to 9 kg recommended for this group.4 
Programmes and interventions to reduce obesity before pregnancy and control weight gain during 
pregnancy would be advisable in view of the findings of this analysis. 
The energy intake we report is similar to those reported for women in the US National Health 
and Nutrition Survey in 2010-2011 where the prevalence of overweight and obesity are also 
higher than 70% 212,214 According to Goldberg, if the estimated usual intake is below 80% of the 
estimated average requirement for a person, this would imply underreporting. In our study this 
would imply 37.7% of underreporting in South Africa and 19.1% in Zimbabwe.209 Fat intake as 
a percentage of total energy was within the recommended range of 20 to 35% of total energy in 
South Africa (27.8%), but slightly higher than recommended in Zimbabwe (36.4%). The high fat 
intake in Zimbabwe was due to a higher intake of polyunsaturated fats. In both countries, 
carbohydrates and protein intake as a percentage of total energy were within the recommended 
ranges of 46-65% and 10-35% respectively.208 However, the intake of sugar in South Africa was 
slightly above the recommended maximum of 10% of total energy. Considering recommended 
grams of macronutrients, the women from both countries had mostly adequate total grams of 
carbohydrate intakes, but the majority had inadequate grams per kilograms of protein intake. It 
is thus important that interventions should focus on increasing the intake of affordable protein 
sources and decreasing sugar intake. 
The prevalence of inadequate micronutrient intake from food sources was high in both countries. 
For the most basic micronutrients like iron, calcium, folate and zinc, the percentage of women 
below requirements was above 90% in both countries. It is likely that underreporting of dietary 
intake by almost 40% of the women in South Africa may have contributed to the high prevalence 
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of inadequate intake. However, it must also be borne in mind that the consumption of energy-
dense foods such as sugar was higher than recommended and underreporting of energy-dense 
foods would not have affected micronutrient intake. Furthermore, similar to our results recent 
publications have also reported high prevalence of inadequate micronutrient intake in pregnant 
women that are not treated for other medical conditions and pregnant women with gestational 
diabetes mellitus attending public health care facilities in Cape Town. 125,207 
The most common supplements taken in South Africa were folic acid, ferrous sulphate, and 
vitamin C, all issued by the hospital. There is a policy in South Africa to supplement pregnant 
women with 5 mg of folic acid and 200 mg of ferrous sulphate (equivalent to 40 mg elemental 
iron) daily, which allowed those women taking the supplements to reach the recommendations.215 
The elemental iron supplementation provided by this policy is in accordance with the WHO 
guidelines for antenatal care, however folic acid supplementation is more than 10 times the 
recommended amount.4 On the other hand, vitamin C is not recommended, as there is no 
evidence of an impact on birth outcomes. In contrast, only one woman in Zimbabwe reported 
taking supplements and this may be due to the fact that there is no policy to provide supplements 
during pregnancy in Zimbabwe and very few women bought commercial supplements. The 
inadequate intakes are worrying as iron and folic acid supplementation are known to prevent 
anaemia, puerperal sepsis, low birth weight and preterm birth; folate to prevent neural tube 
defects, calcium supplementation in areas with low calcium intake in order to reduce risk of pre-
eclampsia; vitamin A in deficient areas to prevent night blindness. Regarding the diet a higher 
intake of vitamin E is usually related to higher intakes of oils and fats whereas vitamin C indicates 
an increased intake of fruits and vegetables.216,217 
 
Strengths 
Strengths of this study include the standardised procedures used throughout the trial in all sites. 
Women in this study had close follow up from the same research team before and during 
pregnancy. 
The 24-hour recall dietary assessment method used is subject to less recall bias than other dietary 
assessment methods, such as diet histories or food frequency checklists.157 Major advantages of 
using 24-hour recalls are that high literacy of the respondent is not required and that inter-
observer differences are minimised.156 On the other hand, food frequency questionnaires usually 
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require use of generic memory and higher numeracy skills in the population interviewed to 
quantify average food intakes over a period of time.158 
Limitations 
A main limitation in this sub-study is the limited generalizability of the findings as the study 
population were women with high risk of pre-eclampsia and they were women who had a 
previous hospital delivery. It has been shown that, obesity, hypertension and endothelial 
dysfunction are risk factors of PE. In this way, women in the CAP trial might have had an increase 
occurrence of these diseases compared to the general population and therefore different 
physiological changes. 202,203 Besides women with limited access to hospital delivery are not 
represented in this study. 
We did not use the same scales to measure weight across sites, as weight was not the main 
outcome of this trial. However, women were assessed with the same scale throughout the study 
at each participating site. 
We did not use any technique to corroborate energy intake, however under-reporting has been 
described in the literature in women especially in those with high BMI.218 
Food data from both countries was analysed using the SAMRC-Food composition database as 
there is not a local food composition database in Zimbabwe. There were a few cases where foods 
reported during the assessment were not found in the database, and they were added as the most 
similar item in terms of macronutrients and calcium content. Nevertheless, this was only in a few 
cases and we believe it cannot affect the main results of this sub-study. Besides, in Zimbabwe 
we used the same food composition database than in South Africa, which includes fortified foods 
by South African law 2003, this may have the prevalences of inadequate intake in Zimbabwe 
even higher for vitamin A, thiamine, riboflavin, niacin, pyridoxine, folic acid, iron and zinc. 
Although not having a database for Zimbabwe might be a limitation, it prevents showing 
differences that are related to errors of the food composition tables rather than of the nutrient 
intake.219 
The IOWA methodology to estimate usual intake requires at least 50 repeated interviews. We 
obtained repeated 24-hour recall for 107 women, however we obtained fewer than 50 repeated 
interviews for Zimbabwe so the estimation might not be as accurate as for South Africa. One of 
the limitation of the methodology used to estimate usual intake is that when duplicate recalls are 
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made in very few individuals the estimated intake of some micronutrients can be less accurate 
than that for macronutrients or those consumed more frequently.  
 
5.8. Conclusion 
We found a high prevalence of overweight and obesity and high prevalence of inadequate intakes 
of protein and micronutrients in pregnant women who had a previous pregnancy complicated 
with pre-eclampsia. Although this group is not representative of the general population of 
pregnant woman, taking into account the increasing prevalence of overweight and obesity 
worldwide among young age groups, the obesity and micronutrient inadequacy figures reported 
in this study are issues of concern that need to be addressed so that maternal and perinatal 
outcomes are improved.33,34 Noticing the differences found in both countries regarding BMI and 
nutrient intake it would be interesting to explore the reasons behind as it could help to tackle the 
problem. 
Supplement intakes during pregnancy seem to be essential for these groups of women to achieve 
requirements of key micronutrients. Policies should be reinforced and reviewed according to the 
most recent evidence. Pregnancy is a period when women may have more regular contacts with 
the health system and, if health care services were integrated for mothers and babies, these regular 
contacts could be maintained after delivery to improve maternal health.220 These opportunities 
could be used to deliver dietary and nutritional interventions to high-risk women to improve the 
outcomes of future pregnancies.221 Furthermore, taking into account that women with a history 
of pre-eclampsia are at higher risk of developing cardiovascular disease later in life, pregnancy 
and postnatal periods could be an ideal time for preventing future health complication from a 
young age. 
5.9. Further analysis to comply with the PhD proposal 
 
Preconceptional weight according to WHO BMI classification 
Preconceptionally women participating in the CAP trial had a mean height of 160.3 cm (SD 6.4), 
a mean weight of 76.1 kg (SD 17.4) and a mean BMI of 29.6 (6.3) (See table 5.1). According to 
BMI WHO classification only 1 % of women were underweight and only 19.9% were normal 
weight. The vast majority of women were overweight 30.4% or obese 48.7% (Table 5.1). 
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Women in South Africa had a higher mean weight and BMI than in Zimbabwe (p=0.001 for both 
weight and BMI) however the height and age were similar. 
Weight gain during pregnancy 
 
Mean weight at 8, 20 and 32 weeks was 77.1 (16.9), 80.2 (17.5) and 84.0 (17.0) respectively, 
however women in South Africa had a mean weight of approximately 10 kg more than in 
Zimbabwe throughout pregnancy (Table 5.2). 
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Calcium supplementation for weight reduction.  
6.1. Introduction 
Description of the condition  
The prevalence of overweight and obesity is increasing worldwide across different age 
groups.33,34 According to the World Health Organization (WHO), the prevalence of obesity 
doubled between 1980 and 2008 and it is increasing more rapidly in lower- and middle-income 
countries.36 In the adult population, obesity is currently more prevalent in women than in men; 
between 23% and 29% of women are obese in the European, Eastern Mediterranean and 
American regions.37 Obesity can lead to high blood pressure, heart disease, stroke, diabetes and 
insulin resistance.36 A systematic review of 23 trials reporting national data on adolescent obesity 
shows that in 21 countries the prevalence of overweight and obesity was higher than 20%.38 The 
prevalence of overweight and obesity in children has shown a remarkable increase over recent 
decades, representing a public health challenge as this prevalence tends to track into adult life.39,40 
A systematic review of the economic burden of obesity worldwide estimated that compared to 
normal weight individuals, those who are obese have 30% greater medical costs.53 Moreover, it 
has been estimated that every kilogram of weight gain during adulthood increases the risk of 
cardiovascular disease by 3.1% to 5.7%.52 
Description of the intervention  
Calcium is the most abundant mineral in the human body. It is available in estimated quantities 
of 1.2 kg. Ninety-nine per cent of calcium is found as calcium hydroxyapatite in the skeletal 
system and is essential for this system's creation, rigidity and maintenance.97 The remaining one 
per cent is distributed between the intra- and extracellular fluids where it is involved in the 
majority of the metabolic processes as well as in muscle contraction, nervous system 
transmission, enzymatic activation, and hormonal function.147 Calcium metabolism acts over the 
0.1% located in the extracellular fluid. Calcium serum levels are regulated by the parathyroid 
hormone, vitamin D, and calcitonin. All of these control calcium bowel absorption, its bone 
resorption and renal excretion.222 
Calcium requirements are high during all stages of life.147 Dietary recommendations for 
individuals over 19 years of age vary from 1000 mg to 1300 mg, depending on the reference 
guidelines.22,100 
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In most low- and middle-income countries, daily calcium intake is well below recommendations; 
however, low intakes are also observed in special age groups, such as adolescents, in high-income 
countries.106 Whereas calcium intake seems to be below 600 mg a day in low- and middle-income 
countries, reports from high-income countries show that the intake is above 900 mg a day 
depending on age groups.97 A review of studies reporting dietary intakes of pregnant women 
from low- and middle-income countries shows consistently low calcium intakes across Asian, 
African and Latin American countries.108 
Interventions, such as calcium supplementation or food fortification, have been used for many 
years as strategies to increase calcium intake. Calcium supplementation is currently 
recommended by the WHO during pregnancy for the improvement of maternal and infant 
outcomes.1 Calcium supplements are frequently consumed in high-income countries; however 
reports show that this is an uncommon practice in low- and middle-income countries.97 
There is some evidence of an inverse relationship between calcium intake and body weight.63 A 
systematic review found that among overweight or obese individuals, calcium supplementation 
compared to placebo produced a mean body weight loss of 0.7 kg (95% confidence interval (CI) 
-1 to -0.5).25 Six of the included trials had a duration of six months with a dose of 1000 mg of 
elemental calcium per day while one trial had a duration of 24 months with a dose of 1500 mg 
of elemental calcium per day. The clinical relevance of this reduction has been questioned. 
However, at a population level, a small effect could help prevent the observed global trends.186 
Adverse effects of the intervention 
According to the Institute of Medicine, calcium intake upper limits are between 2000 mg to 3000 
mg daily depending on the age group.22 
The following adverse events have been described for high calcium intakes: 
Cardiovascular diseases 
Several trials have shown an inverse association between calcium intake and blood pressure or 
hypertension.223 However, a secondary analysis of a trial designed to assess the effect of calcium 
supplementation on bone mineral density among postmenopausal women described a higher risk 
of self-reported myocardial infarction among those who received calcium supplements.83 The 
results of this secondary analysis have been questioned, as the change in risk was no longer 
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significant when the analysis was limited to data verified by hospital records.224 A recent review 
concluded that there is no firm evidence that calcium supplementation increases coronary heart 
disease or all-cause mortality risks in elderly women.85 The review highlights that self-reported 
myocardial infarction should not be used as the primary outcome in randomised controlled trials 
(RCTs) of calcium supplementation, as it can be confused with gastrointestinal symptoms. 
Gastrointestinal symptoms 
A review showed an increased rate of self-reported gastrointestinal events in participants 
receiving calcium compared with placebo (Risk Ratio (RR) 1.43 (1.28 to1.59).86 The 
gastrointestinal events reported were acute abdominal pain, indigestion and constipation. 
However, no relationship to the calcium salt formulation or dose was reported. 
Nephrolithiasis 
There is some controversy as to whether increasing calcium intake reduces or increases the risk 
of kidney stone formation. One proposed explanation is that the effect depends on the basal 
dietary calcium intake. Calcium in the intestine binds to potential stone formation factors such 
as oxalates, which restrict its absorption and reduce the risk of stone formation.147 However, after 
this binding is saturated, higher calcium intakes do not produce further benefits. One RCT of 
calcium supplementation of 1000 mg a day combined with vitamin D showed an increased risk 
of kidney stones in the intervention group, however intakes in this group were higher than 
calcium recommended intakes as baseline mean calcium intake was 1148 mg ± 654 mg a day.225 
Another RCT evaluating men with a history of kidney stones, allocated to receive either a high 
or low calcium diet, showed a 50% decrease in the recurrence of kidney stone formation.226 
Calcium supplements and iron absorption  
There have been concerns related to the effects of calcium supplements on iron absorption based 
on short term studies reporting that calcium supplements inhibit iron absorption by 28% to 55% 
depending on the dose, type of salt used, time of supplementation and if the food contained hem 
or non-hem iron.88 However, evidence shows no effect on iron status of prolonged calcium 
supplementation taken at the same time or separate of meals.89–94 A study of infants supplemented 
with calcium glycerophosphate or placebo found no difference in iron status at 4 and 9 months, 
mean change in serum ferritin was -24.5 to -46.6 μg/L in both intervention and placebo groups 
respectively.227 Another study that supplemented adolescent girls with 1 g of calcium citrate 
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malate/day for 4 years did not find difference in iron status; serum ferritin average concentrations 
in the supplemented group at baseline and years 1, 2, 3, and 4 were 29.1 ± 1.3, 31.1 ± 1.5, 31.1 
± 1.6, 30.6 ± 2.0, and 29.6 ± 1.9 μg/L, respectively; and in the placebo group, concentrations 
were 29.3 ± 1.4, 33.8 ± 1.7, 32.3 ± 1.4, 30.9 ± 1.5, and 29.5 ± 1.6 μg/L, respectively (p = 0.88, 
0.23, 0.56, 0.88, and 0.96 for baseline and years 1, 2, 3, and 4, respectively).228 Similarly, another 
study of 113 adolescent girls supplemented with 500 mg of calcium/day as calcium carbonate 
found no differences on iron status markers. At one year hemoglobin was 136 g/L in the 
supplemented group and 134 g/L in the placebo group (p=0.31); ferritin was 25.4 μg/L in the 
supplemented group and 26.1 μg/L in the placebo group (p = 0.73).93 
A study that supplemented post-partum women with 500 mg of calcium/day as calcium carbonate 
found that those supplemented had a mean serum ferritin of 28.4 mg/L and 27.5 mg/L in the 
placebo group (p > 0.5).92 A study in 24 healthy individuals also showed that supplementation 
with 1200 mg of calcium/day, as calcium carbonate had no significant effect on hemoglobin or 
hematocrit at 6 months. Mean hemoglobin at 6 months was 136 g/L in the calcium group 
compared to 139 ± 4 in the control group and 0.416 ± 0.013 in the calcium group compared to 
0.424 ± 0.009 in the control group.229 
With this evidence it has also been recommended that pregnant women take calcium supplements 
together with iron and folic acid to improve adherence.230 This recommendation is in line with 
that of Molgaard et al. where public health recommendations should be based on long term 
studies and not in short term studies that are mainly to study the mechanisms. 93  
How the intervention might work  
Three mechanisms by which calcium could affect body weight have been postulated. The first is 
linked to the regulation of the parathyroid hormone that is required to maintain calcium 
concentrations in extracellular fluids.64,65 Serum calcium is tightly regulated and small reductions 
stimulate parathyroid hormone and 1-25 vitamin D secretion to produce an increase of calcium 
resorption from the bones, reabsorption from the kidneys, and absorption in the intestine. 
However, high levels of parathyroid hormone and 1-25 vitamin D also stimulate calcium influx 
into different cell types.63 In the adipocyte, this increase of intracellular calcium stimulates fatty 
acid synthetase and lipogenesis.65 Low calcium diets have also been linked to insulin resistance 
and high blood pressure through similar collateral effects of increased parathyroid levels.147 A 
second postulated mechanism is related to appetite regulation. Higher calcium intakes have been 
linked to an increase of glucagon-like peptide-1 that reduces appetite.73 A third mechanism is 
associated with the reduction of fatty acid absorption in the intestine. Higher calcium intakes 
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could bind to bile acids or to fatty acids impairing their absorption and decreasing available 
energy.70,71 
Why it is important to do this review  
A decline in calcium intake has been observed with an increase in population weight gain.24,190,192 
On a population level, a small decrease in body weight could help reverse the trend of increased 
weight gain. Two systematic reviews on the effect of calcium supplementation on weight have 
been conducted in 2006 and 2011. The first systematic review found that calcium 
supplementation compared to placebo reduces weight by 0.7 kg (95% CI 0.5 to 1.25) in 
overweight or obese people, however of the seven included studies five did not assess quality of 
evidence.25 The other systematic review reported that calcium supplementation compared to 
placebo reduces weight by 0.4 kg (CI 0.3 to 1.1) in the general population, however studies where 
participants had a calcium intake of less than 300 mg of calcium a day or where published before 
2002 were excluded.231 These reviews had a comprehensive search, however the trials had a 
duration of at least 6 months and did not included pregnant women. Several trials have been 
published since these reviews, at least two studies with a shorter intervention period. Besides, 
the Cochrane library of systematic reviews recommends that reviews are updated every 2 
years.232 In our review, we included trials with overweight and obese individuals. 
6.2. Objectives  
To assess the effects of calcium supplementation for weight reduction in overweight or obese 
people. All randomised controlled trials reporting the effect of calcium supplementation on 
overweight and obese individuals including pregnant participants with duration of at least 2 
months were included. 
6.3. Methods  
Criteria for considering studies for this review  
Types of studies  
We included randomised controlled trials (RCTs) assessing the effect of calcium compared with 
placebo or control in which the intervention had a minimum duration of two months as specified 
in the review protocol.233  
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Types of participants  
We included overweight or obese participants of any age or gender. We also included pregnant 
women. 
We classified participants as being overweight or obese using the body mass index (BMI), which 
is a person's weight divided by the square of the person's height (kg/m2). 
Diagnostic criteria for overweight and obesity 
Adults: overweight BMI ≥ 25 to < 29.9, obesity BMI >30.173 
Children and adolescents: we accepted validated classifications for overweight or obese children 
or adolescents such as the World Health Organization (WHO) child growth standards for 0 to 60 
months, WHO growth references for school aged children and adolescents using BMI for age 
16,179, the International Obesity Task Force child BMI cut offs that are derived from BMI centiles 
at 18 years, and BMI z-scores. 
Types of interventions 
We investigated the following comparisons of intervention versus control/comparator. 
Intervention 
(a) Oral calcium supplementation 
(b) Calcium food or beverage fortification 
Comparator 
• Placebo compared with (a) or (b) 
• Non-calcium fortified food or beverage compared with (b) 
Calcium fortification could include salt of calcium carbonate, sulphate, citrate, citrate malate, 
chloride, hydroxyapatite, phosphate, acetate, lactate, glycerophosphate, gluconate, oxide or 
hydroxide. Calcium content in these salts varies from 9% to 70%.128 
Concomitant interventions had to be the same in both the intervention and comparator groups to 
establish fair comparisons. 
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Minimum duration of intervention 
We only considered RCTs in which the intervention had a minimum duration of two months. 
Minimum duration of follow-up 
We did not specify a minimum duration for follow up. 
Specific exclusion criteria 
We excluded trials of participants with chronic illnesses that affect calcium absorption or 
metabolism, such as lactose intolerance, inflammatory bowel disease (Crohn’s disease, ulcerative 
colitis) or bariatric surgery patients.234 
Types of outcome measures  
We did not exclude trials because one or several of our primary or secondary outcome measures 
were not reported in the publication. In case none of our primary or secondary outcomes was 
reported, we excluded the trial. 
Primary outcomes  
• Body weight. 
• Health-related quality of life. 
• Adverse events. 
Secondary outcomes  
• Anthropometric measures other than body weight. 
• All-cause mortality. 
• Morbidity. 
• Socioeconomic effects. 
Method of outcome measurement 
• Body weight (kg) measured at month 2, 6, 12 or more. 
• Health-related quality of life: evaluated by a validated instrument such as the Center for 
Disease Control and Prevention health-related quality of life questionnaire and measured 
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at month 2, 6, 12 or more. Health-related quality of life refers to a multi-dimensional 
concept that includes domains related to physical, mental, emotional, and social 
functioning. It focuses on the impact health status has on quality of life rather than direct 
measures of population health or causes of death and morbidity, which is included in the 
secondary outcome. 
• Adverse events: defined as total incidence of adverse events occurring at any time after 
initiation of the intervention. Specific adverse events will be specified as incidence of: 
o Hypercalcaemia: defined as the proportion of participants who have a serum 
calcium level above the upper limit of 10 mg/dL.  
o Hypercalciuria: defined as the proportion of participants who have a 24-hour urine 
collection of calcium > 250 mg in women and > 300 mg in men 235or > 4 mg/kg 
for men and women.236  
o Nephrolithiasis: defined as the proportion of participants who experience a kidney 
stone clinically or radiologically. 
o Coronary heart disease (CHD): including myocardial infarction, angina pectoris 
and acute coronary syndrome, and chronic CHD verified by clinical review, 
hospital record, or death certificate. 
o Secondary hyperparathyroidism: assessed by parathyroid hormone levels above 
the upper limit of 65 pg/mL.237 
o Anaemia: measured by serum haemoglobin levels below 110 g/L in children 6 to 
59 months of age and pregnant women; 115 g/L in children 5 to 11 years of age; 
120 g/L in children 12 to 14 years of age and non-pregnant women and 130 g/L 
in men.238 
o Gastrointestinal symptoms: defined as the proportion of participants who 
experience constipation, anorexia, nausea, vomiting, or epigastric pain. 
• Anthropometric measures other than body weight: defined as body mass index (BMI) and 
waist circumference at month 2, 6, 12 or more. 
• All-cause mortality: defined as death from any cause, occurring at any time after initiation 
of the intervention. 
• Morbidity: defined as diabetes, CHD or stroke diagnosed at any time after initiation of 
the intervention. 
• Socioeconomic effects: such as direct costs defined as admission/readmission rates, 
average length of stay, visits to general practitioner, accident/emergency visits, 
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medication consumption at month 2, 6, 12 or more; indirect costs: defined as resources 
lost due to illness by the participant or their family member at month 2, 6, 12 or more. 
Timing of outcome measurement 
For body weight, health-related quality of life, anthropometric measures other than body weight 
and socioeconomic effects at month 2, 6, 12 or more. For all other outcomes measures: any time 
after participants were randomised to the intervention/comparator groups. 
Search methods for identification of studies  
Electronic searches  
We searched the following sources from inception of each database to the specified date and 
placed no restrictions on the language of publication. 
• Cochrane Central Register of Controlled Trials (CENTRAL) 
• MEDLINE 
• Embase. 
• LILACS 
• ClinicalTrials.gov 
• World Health Organization (WHO) International Clinical Trials Registry Platform 
(ICTRP) Search Portal (http://apps.who.int/trialsearch/). 
We continuously applied a MEDLINE (Ovid SP) email alert service established by the Cochrane 
Metabolic and Endocrine Disorders (CMED) to identify newly published trials using the same 
search strategy as described for MEDLINE (Table 6.1). After supplying the final review draft for 
editorial approval, the CMED Group performed a complete updated search on all databases 
available at the editorial office and send the results to the review authors. Should we identified 
new trials for inclusion, we would have evaluated these, incorporate the findings into our review, 
and resubmitted another Cochrane Review draft.239 
Table 6.1: Electronic Search Strategies 
Cochrane Central Register of Controlled Trials (Cochrane Register of Studies Online) 
1. MESH DESCRIPTOR Calcium Compounds EXPLODE ALL TREES 
2. MESH DESCRIPTOR Calcium 
3. calcium:TI,AB,KY 
4. #1 OR #2 OR #3 
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5. MESH DESCRIPTOR Obesity EXPLODE ALL TREES 
6. MESH DESCRIPTOR Weight Loss 
7. MESH DESCRIPTOR Overweight 
8. (obes* or overweight):TI,AB,KY 
9. (weight ADJ (reduction? or loss?? or control or management)):TI,AB,KY 
10. body weight:TI 
11. body mass index:TI 
12. BMI:TI 
13. #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 
14. #4 AND #13 
MEDLINE (Ovid SP) 
1. exp Calcium Compounds/ 
2. Calcium/ 
3. calcium.tw. 
4. or/1-3 
5. exp Obesity/ 
6. Weight Loss/ 
7. Overweight/ 
8. (obes* or overweight).tw. 
9. (weight adj (reduction? or loss?? or control or management)).tw. 
10. body weight.ti. 
11. body mass index.ti. 
12. BMI.ti. 
13. or/5-12 
14. 4 and 13 
[15-25: Cochrane Handbook 2008 RCT filter - sensitivity max. version] 
15. randomized controlled trial.pt. 
16. controlled clinical trial.pt. 
17. randomi?ed.ab. 
18. placebo.ab. 
19. drug therapy.fs. 
20. randomly.ab. 
21. trial.ab. 
22. groups.ab. 
23. or/15-22 
24. exp animals/ not humans/ 
25. 23 not 24 
26. 14 and 25 
[27: Wong 2006a – systematic reviews filter – Spec version] 
27. cochrane database of systematic reviews.jn. or search*.tw. or meta analysis.pt. or medline.tw. or systematic 
review.tw. 
28. 14 and 27 
29. 26 or 28 
Embase (Ovid SP) 
1. calcium.tw. 
2. exp obesity/ 
3. weight reduction/ 
4. (obes* or overweight).tw. 
5. (weight adj (reduction? or loss?? or control or management)).tw. 
6. body weight.ti. 
7. body mass index.ti. 
8. BMI.ti. 
9. or/2-8 
10. 1 and 9 
[11: Wong 2006b "sound treatment studies" filter - SDSSGS version]  
11. random*.tw. or clinical trial*.mp. or exp treatment outcome/ 
12. 10 and 11 
LILACS (iAHx) 
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(MH:"Calcium Compounds" OR MH:"Calcium" OR calcium OR calcio) AND (MH:"Obesity" OR MH:"Weight 
Loss" OR MH:"Overweight" OR obes$ OR overweight OR sobrepeso OR "weight reduction" OR "weight loss" 
OR "weight control" OR "weight management" OR peso OR masa OR massa OR IMC) 
+ Filter "Controlled Clinical Trial" 
International Clinical Trials Registry Platform (ICTRP) Search Portal (Standard search) 
overweight* AND calcium OR 
obes* AND calcium OR 
weight reduction AND calcium OR 
weight loss AND calcium OR 
weight control AND calcium OR 
weight management AND calcium 
ClinicalTrials.gov (Advanced search) 
Search Terms: obese OR obesity OR overweight OR "weight loss" OR "weight reduction" OR "weight control" 
OR "weight management" 
Interventions: calcium 
If we detected additional relevant keywords during any electronic or other searches, we would 
have modified the electronic search strategies to incorporate these terms and documented the 
changes. 
Searching other resources  
We tried to identify other potentially eligible trials or ancillary publications by searching the 
reference lists of included trials, systematic reviews, meta-analyses and health technology 
assessment reports. In addition we contacted authors of included trials to identify additional 
information on the retrieved trials and, if further trials exist, trials that we may have missed. 
Data collection and analysis  
Selection of studies  
Two review authors (Gabriela Cormick and Janetta Harbron) independently scanned the abstract, 
title, or both, of every record we retrieved in the literature searches, to determine which trials we 
should assess further. We obtained the full-text of all potentially relevant records. We resolved 
any disagreements through consensus or by recourse to a third reviewer. If we could not resolve 
a disagreement, we planned to categorise the trial as a 'study awaiting classification' and we 
planned to contact the trial authors for clarification. We presented an adapted Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram to shows the process 
of trial selection.240 
Data extraction and management  
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For trials that fulfilled the inclusion criteria, two review authors (Gabriela Cormick and Janetta 
Harbron) independently extracted key participant and intervention characteristics. We reported 
data on efficacy outcomes and adverse events using standard data extraction sheets from the 
CMED Group. We resolved any disagreements by discussion or, if required, by consultation with 
a third reviewer.  
We emailed all authors of included trials to enquire whether they were willing to answer 
questions regarding their trials. We thereafter sought relevant missing information on the trial 
from the primary author(s) of the article, if required. 
Dealing with duplicate and companion publications 
In the event of duplicate publications, companion documents or multiple reports of a primary 
trial, we maximised the information yield by collating all available data and used the most 
complete dataset aggregated across all known publications. We listed duplicate publications, 
companion documents, multiple reports of a primary trial and trial documents of included trials 
(such as trial registry information) as secondary references under the study identifier (ID) of the 
included trial. Furthermore, we also listed duplicate publications, companion documents, 
multiple reports of a trial and trial documents of excluded trials (such as trial registry information) 
as secondary references under the study ID of the excluded trial. 
Data from clinical trial registers 
In case data of included trials are available as study results in clinical trial registers such as 
ClinicalTrials.gov or similar sources, we made full use of this information and extract data. If 
there was also a full publication of the trial, we collated and critically appraised all available data. 
If an included trial was marked as a completed study in a clinical trial register but no additional 
information (study results, publication or both) is available, we added the references of the trial. 
Assessment of risk of bias in included studies  
Two review authors (Gabriela Cormick and Janetta Harbron) independently assessed the risk of 
bias of each included trial. We resolved any disagreements by consensus, or by consultation with 
a third reviewer. In cases of disagreement, we consulted the rest of the group and made a 
judgement based on consensus. If adequate information was not available from trial authors, trial 
protocols or both we contacted trial authors for missing data on 'Risk of bias' items. 
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We used the Cochrane 'Risk of bias' assessment tool assigning assessments of low, high or 
unclear risk of bias.181,241 We evaluated individual bias items as described in the Cochrane 
Handbook for Systematic Reviews of Interventions according to the criteria and associated 
categorisations contained therein.181,241 
Summary assessment of risk of bias 
We presented a 'Risk of bias' graph and a 'Risk of bias' summary Figure 6.1. 
We distinguished between self-reported, investigator-assessed and adjudicated outcome 
measures. 
We considered the following outcomes as self-reported. 
• Adverse events 
• Health-related quality of life 
• Body weigh as measured by participants 
• Anthropometric measures other than body weight 
• Socioeconomic effects 
We considered the following outcomes as investigator-assessed. 
• Body weight 
• Adverse events 
• Anthropometric measures other than body weight 
• All-cause mortality 
• Morbidity 
• Socioeconomic effects 
Risk of bias for a trial across outcomes: some risk of bias domains like selection bias (sequence 
generation and allocation sequence concealment) affect the risk of bias across all outcome 
measures in a trial. In case of high risk of selection bias, all endpoints investigated in the 
associated trial were marked as 'high' risk. Otherwise, we did not perform a summary assessment 
of the risk of bias across all outcomes for a trial. 
Risk of bias for each outcome within a trial and across domains: we assessed the risk of bias 
for each outcome measure including all of the entries relevant to that outcome, i.e. both trial-level 
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entries and outcome-specific entries. 'Low' risk of bias is defined as low risk of bias for all key 
domains, 'unclear' risk of bias as unclear risk of bias for one or more key domains and 'high' risk 
of bias as high risk of bias for one or more key domains. 
Risk of bias for an outcome across trials and across domains: these are our main summary 
assessments that were incorporated in our judgements about the quality of evidence in the 
'Summary of findings' tables. 'Low' risk of bias is defined as most information coming from trials 
at low risk of bias, 'unclear' risk of bias as most information coming from trials at low or unclear 
risk of bias and 'high' risk of bias as a sufficient proportion of information coming from trials at 
high risk of bias. 
Measures of treatment effect  
Dichotomous data 
When at least two trials are available for a comparison and a given outcome, we expressed 
dichotomous data as odds ratio (OR) or risk ratio (RR) with 95% confidence interval (CI). 
Continuous data 
We calculate mean differences (when trials use the same measure) or standardised mean 
differences (SMDs) (when trials use different measurement scales) and 95% CIs for continuous 
outcome measures. When necessary, we calculated effect estimates from P values, t statistics or 
other available statistics. For those studies, which provide only change scores, we performed 
separate analyses to those studies, which provide only final values. We combined both values 
using the generic inverse variance method.181 
Dealing with missing data  
If possible, we obtained missing data from trial authors and carefully evaluated important 
numerical data such as screened, randomly-assigned participants as well as intention-to-treat, and 
as-treated and per-protocol populations. We investigated attrition rates (e.g. drop-outs, losses to 
follow-up, withdrawals), and we critically appraised issues concerning missing data and 
imputation methods (e.g. last observation carried forward). 
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In trials where the standard deviation (SD) of the outcome was not available at follow-up, or 
cannot be recreated, we standardised by the average of the pooled baseline SD from those trials 
in which this information was reported. 
Where means and SDs for outcomes have not been reported and we did not received the needed 
information from trial authors, we imputed these values by estimating the mean and variance 
from the median, range, and the size of the sample.242 
We investigated the impact of imputation on meta-analyses by performing sensitivity analyses, 
and we reported per outcome which trials were included with imputed SDs. 
Assessment of heterogeneity  
We identified heterogeneity (inconsistency) by visually inspecting the forest plots and by using 
a standard Chi² test with a significance level of α = 0.1. In view of the low power of this test, we 
also considered the I² statistic, which quantifies inconsistency across trials to assess the impact 
of heterogeneity on the meta-analysis; where an I² statistic ≥ 75% indicates a considerable level 
of heterogeneity.182–184 
When we found heterogeneity, we would have attempted to determine possible reasons for it by 
examining individual trial and subgroup characteristics. 
Assessment of reporting biases  
As we included 10 or more trials investigating a particular outcome, we used funnel plots to 
assess small-trial effects. Several explanations may account for funnel plot asymmetry, including 
true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias 
of small trials) and publication bias. We therefore interpreted results carefully.243 
Data synthesis  
We planned to undertake (or display) a meta-analysis only if participants, interventions, 
comparisons and outcomes are judged to be sufficiently similar to ensure an answer that is 
clinically meaningful. Unless good evidence shows homogeneous effects across trials, we 
primarily summarised low risk of bias data using a random-effects model.244 We interpreted 
random-effects meta-analyses with due consideration to the whole distribution of effects, ideally 
by presenting a prediction interval.245,246 A prediction interval needs at least four trials to be 
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calculated and specifies a predicted range for the true treatment effect in an individual trial.247 
For rare events such as event rates below 1% we used Peto's odds ratio method, provided that 
there was no substantial imbalance between intervention and comparator group sizes and 
intervention effects are not exceptionally large. In addition, we also performed statistical analyses 
according to the statistical guidelines presented in the Cochrane Handbook for Systematic 
Reviews of Interventions.248 
Subgroup analysis and investigation of heterogeneity  
We expected the following characteristics to introduce clinical heterogeneity, and planned to 
carry out the following subgroup analyses with investigation of interactions. 
• Menopausal status: pre- and post-menopausal women. 
• Age: children, adults, older adults. 
• Sex. 
• BMI: obese, overweight. 
• Physical activity: sedentary or active. 
• Calcium supplementation: low dose ≤ 500 mg, moderate dose 500 to 1000 mg, high dose 
≥ 1000 mg. 
• Baseline energy intake: restricted energy intake or not. 
• Pregnancy status. 
• Type of diet as co-intervention. 
Sensitivity analysis  
When applicable we planned to perform sensitivity analyses to explore the influence of the 
following factors on effect sizes: 
• Published trials. 
• Taking into account risk of bias, as specified in the Assessment of risk of bias in included 
studies section. 
• Very long or large trials to establish the extent to which they dominate the results. 
Certainty of evidence 
We included a 'Checklist to aid consistency and reproducibility of GRADE assessments' (Table 
6.3), to help with standardisation of the 'Summary of findings' (Table 6.4).249 We presented 
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results for the outcomes as described in the Types of outcome measures section above. If 
meta-analysis was not possible, we presented the results in a narrative format in the 'Summary 
of findings' table. We justified all decisions to downgrade the quality of trials using footnotes, 
and we made comments to aid the reader's understanding of the Cochrane Review where 
necessary. 
We presented the overall certainty of evidence for each outcome specified under Types of 
outcome measures: 'Summary of findings' (Table 6.4) according to the GRADE approach, which 
takes into account issues related not only to internal validity (risk of bias, inconsistency, 
imprecision, publication bias) but also to external validity, such as directness of results. Two 
review authors independently rated the certainty of evidence for each outcome. Differences in 
assessment were solved by discussion or consultation with a third researcher. 
Summary of findings table 
We presented a summary of the evidence in a 'Summary of findings' (Table 6.4). This provided 
key information about the best estimate of the magnitude of the effect, in relative terms and as 
absolute differences, for each relevant comparison of alternative management strategies, 
numbers of participants and trials addressing each important outcome and a rating of overall 
confidence in effect estimates for each outcome. We created the 'Summary of findings' table 
based on the methods described in the Cochrane Handbook for Systematic Reviews of 
Interventions (250) using Review Manager (RevMan 5.3) table editor. 251 We will report the 
following outcomes, listed according to priority.  
• Body weight 
• Health-related quality of life 
• Adverse events 
• All-cause mortality 
• Morbidity 
• Socioeconomic effects. 
6.4. Results 
The search strategy generated 883 hits after duplicates were removed. After screening of titles 
and abstracts 144 papers remained to evaluate for formal inclusion and exclusion criteria. 
Seventeen randomised controlled trials (RCTs) reported in 26 articles fulfilled the inclusion 
criteria and were included in the review (See Figure 6.1). We also identified eight ongoing trials. 
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Figure 6.1: Prisma Diagram Flow of Screened and included studies 
 
 
 
We identified two main comparisons: fifteen trials compared calcium versus placebo (Asemi 
2015; Li 2010; Menon 2009; Palacios 2009; Ricci 1998; Shalileh 2010; Shapses 2001; Shapses 
2004; Shidfar 2011; Tabesh 2015; Wang 2009; Wagner 2007; Yanovski 2009; Zemel 2004; 
Zemel 2009) 252–264 265 and two trials compared a high and a low dose of calcium 
supplementation, participants in the controlled group received calcium and placebo in order to 
achieve a lower dose (Riedt 2005; Riedt 2007).266,267 None of the trails included assessed food 
fortification. 
Six trials had no co-intervention (Asemi 2015; Li 2010; Palacios 2009; Shidfar 2011; Wang 
2009; Yanovski 2009)252–254,258,263, eleven trials had a weight reduction co-intervention - two 
trials had diet counselling (Ricci 1998; Shapses 2001)259,261, five trials a 500 kcal/day restriction 
diet (Menon 2009; Shalileh 2010; Shapses 2004; Zemel 2004; Zemel 2009) 255–257,260,262, one trial 
had a 500 kcal restriction diet plus physical activity (Wagner 2007) 268, two trials a diet of no 
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more than 1200 to 1500 kcal a day (Riedt 2005; Riedt 2007) 266,267 and one had vitamin D as co-
intervention (Tabesh 2015)264. 
Overview of trial populations 
1255 participants were randomised in total, with 961 participants finishing their respective study, 
76.2% of participants finishing the trial in the intervention and 77.0% in the controlled groups. 
Individual sample size ranging from 15 (Menon 2009) to 335 (Yanovski 2009) 268. 
Trial design 
All seventeen RCTs had a parallel and a superiority design. Only one study was performed in 
four different sites (Zemel 2009256), three studies reporting having one site (Wagner 2007; Wang 
2009; Yanovski 2009254,265,268) and for the rest of the studies the information was missing. 
 
Four of seventeen trials were double-blinded for participants and personnel (Li 2010, Palacios 
2009, Tabesh 2015; Wang 2009253,258,264,269) and thirteen did not report blinding for participants 
and personnel. Two of seventeen trials (Palacios 2009, Wang 2009; Yanovski 2009254,258) 
reported blinding for outcome assessors. 
 
Trials were published from year 1998 to year 2015. Only eight trials reported the run-in period, 
and for these trials the earliest recruitment started during the year 2000 (Riedt 2005)266 and the 
latest recruitment finished in 2014 (Shapses 2004262) (See Table 6.2). 
 
The duration of the trial intervention ranged between 8 weeks to 24 months. None of the studies 
assessed the effect after finishing the intervention; therefore the follow-up period was the same 
as the intervention period. None of the trials reported anticipated termination of the trial. 
Settings 
Out of the seventeen included trials, nine were performed in the USA (Ricci 1998; Riedt 2005; 
Riedt 2007; Shapses 2001; Shapses 2004; Wagner 2007; Yanovski 2009; Zemel 2004; Zemel 
2009) 65,254,259,261,262,266–268,270, four in Iran (Asemi 2015; Shalileh 2010; Shidfar 2011; Tabesh 
2015) 252,260,263,264, one in Brasil (Menon 2009) 257, two in China (Li 2010; Wang 2009) 253,265 and 
one in Puerto Rico (Palacios 2009)258. 
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Table 6.2: Characteristics of included studies 
Trial ID Intervention(s) and 
comparator(s) (in mg of 
elemental calcium) 
Trial 
Duration 
Countr
y 
Age Body weight BMI 
(mean years (SD)) (mean kg (SD)) (mean kg/m² 
(SD)) 
Tabesh 2015 I: 1000 mg as calcium carbonate 8 weeks Iran 53.7 (5.7) 76.1 (8.8) 30.4 (4.2) 
C: placebo 
  
51 (6.1) 77.4 (10.5) 30.3 (3.8) 
Asemi 2015 I: 1000 mg as calcium carbonate 8 weeks  Iran 25 (6.7) 71.5 (11.9) 28.3 (4.7) 
C: placebo 
  
24.3 (5.2) 71.9 (13.8) 27.5 (5.2) 
Shidfar 2011 I: 1250 mg as calcium carbonate 8 weeks  Iran 35.1 (4.8) 81.4 (7.7) 27.5 (1.6) 
C: placebo 
  
33.8 (4.8) 85.6 (8) 27.9 (1.8) 
Shalileh 2010 I: 1000 mg as calcium carbonate 24 weeks Iran 36.6 (7.8) 77.7 (16.9) 29.7 (3.9) 
C: placebo 
  
36.6 (8) 76.3 (8.2) 29.8 (3.3) 
Li 2010 I: 162 mg as calcium carbonate 26 weeks China 41.6 (9) 77.5 (8) 30.5 (2.5) 
C: placebo 
  
41.2 (6.8) 80.8 (9.7) 31.1 (2.7) 
Menon 2009 I: 400 mg as calcium carbonate 3 months Brasil — 80 (1) 34 (5) 
C: placebo 
  
— 87 (9) 34 (4) 
Palacios 2009 I: 600 mg as calcium carbonate 21 weeks  Puerto 
Rico 
35.3 (2.2) 115.2 (5.6) 38.5 (1.9) 
C: placebo — 
 
39.5 (2.2) 104.9 (4.5) 36.7 (1.6) 
Yanovski 
2009 
I: 1500 mg as calcium carbonate 24 months  USA 38.9 (10.5) 94.5 (20.5) 33.2 (6.8) 
 
C: placebo 
  
38.7 (10.4) 94 (20.5) 33.6 (6.8) 
Zemel 2009 I: 900 mg as calcium carbonate 12 weeks  USA 26.2 (4.8) 82.7 (14.8) 29.9 (2.6) 
 
C: placebo 
  
25.3 (4.9) 80.1 (12.4) 29.4 (2.7) 
Wagner 2007 I1: 800 mg as calcium phosphate 12 weeks  USA 41.6 (1.6) 196.7 (8.9) 33.4 (1.4) 
 
I2: 800 mg as calcium lactate — 
 
40.2 (1.8) 196.2 (5.8) 33.3 (0.7) 
 
C: placebo — 
 
36 (2.2) 190.7 (11.3) 32.4 (1.5) 
Riedt 2007 I: 1000 mg as calcium citrate 6 months USA 38 (6.4)  73.2 (4.4) 27.7 (2.1)  
 
C: 200 mg as calcium citrate 
  
38 (6.4) 71.4 (6.7) 27.7 (2.1)  
Riedt 2005 I: 1000 mg as calcium citrate 6 months  USA 61.3 (6.7) 71.3 (6.4) 26.9 (2.1) 
 
C: 200 mg as calcium citrate 
  
61.6 (6.4) 73.8 (6.9) 27.2 (1.7) 
Zemel 2004 I: 800 mg as calcium carbonate 24 weeks USA 46 (8)  99.8 (4.5) 35 (4.1)  
 
C: placebo 
  
46 (8)  103.1 (6.1) 35 (4.1)  
Shapses 2004 I: 1000 mg as calcium citrate 
malate or calcium citrate 
25 weeks USA PostM 61.6 (8.6) / 
PreM 40.4 (5.4) 
PostM 84.1 (9.4) / 
PreM 93.7 (13.6) 
PostM 32.1 (3.5) / 
PreM 33.9 (3.9)  
C: placebo 
  
PostM 57 (8.2) / 
PreM 41.5 (6.8) 
PostM 89.4 (10.3) / 
PreM 93.5 (14.3) 
PostM 32.8 (4.2) / 
PreM 34.7 (5.9) 
Shapses 2001 I: 1000 mg as calcium citrate 
malate 
6 months  USA 40.4 (5.8) 94.9 (14.9) 34 (3.9) 
 
C: placebo 
  
40.4 (5.8)  93.8 (13) 34.5 (3.4) 
Ricci 1998 I: 1000 mg as calcium citrate 
malate 
 
6 months USA 58.3 (9.1) 88.5 (12.9) 33.2 (4.6) 
 
C: placebo 
  
58.3 (9.1)  88.0 (9.9) 32.9 (4.5) 
I= intervention. C= comparison, PostM= postmenopausal , PreM premenopausal 
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Participants 
A total of 369 participants were from low- and middle-income countries from Latin America and 
Asia and 879 were from the USA. There were no studies from Africa, Europe or Oceania. No 
ethnic groups were identified in the studies. 
 
All seventeen studies included adults and older adults participants ranging from 18 to 80 years, 
however one trial did not specify the age of participants (Menon 2009)257. Ten trials included 
only women (Asemi 2015; Li 2010; Menon 2009; Ricci 1998; Riedt 2005; Riedt 2007; Shapses 
2001; Shapses 2004; Wagner 2007; Wang 2009)252,253,257,259,261,262,265–268, six trials included men 
and women (Palacios 2009; Shalileh 2010; Tabesh 2015; Yanovski 2009; Zemel 2004; Zemel 
2009)65,254,258,260,264,270 and one included only men (Shidfar 2011)263. Of the ten trials including 
only women; three were specifically in premenopausal women (Riedt 2007; Shapses 2001; 
Wagner 2007) 261,267,268 two were specifically about postmenopausal women (Ricci 1998; Riedt 
2005) 259,266; two in pre and postmenopausal women (Shapses 2004; Wang 2009)262,265 and the 
remaining three did not specify (Asemi 2015; Li 2010; Menon 2009)252,253,257. 
 
Four of seventeen trials reported co morbidities. One included women with polycystic ovarian 
syndrome and who were vitamin D deficient (Asemi 2015)252, one calcium stone formers (Menon 
2009)257, one included type 2 diabetic subjects (Tabesh 2015)264 and one study included 
participants with increased risk for cardiovascular disease (Wang 2009)265. Major exclusion 
criteria of participants in the included trials were taking supplements or any medication for a 
chronic disease, having cardiovascular or renal disease, having a recent weight change. 
Diagnosis 
All participants included in the trial were classified as overweight or obese. Three trials included 
overweight participants with BMI between 25 to less than 30 kg/m2. 
Interventions 
One of seventeen trials reported studying the participants before start of the trial.256 
All interventions were supplements taken orally. Daily dose of elemental calcium ranged from 
0.162 to 1.5 grams. Most frequent dose was 1 gram/day that was used in eight out of sixteen 
studies. 
Out of the 17 included studies, eleven studies used calcium carbonate as the intervention salt 
(Asemi 2015; Menon 2009; Palacios 2009; Shalileh 2010; Shapses 2001; Shidfar 2011; Tabesh 
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2015; Wang 2009; Yanovski 2009; Zemel 2004; Zemel 2009)252,254,270,256–258,260,261,263–265, two 
used citrate (Riedt 2005; Riedt 2007)266,267, one calcium citrate or calcium citrate malate (Shapses 
2004)262, one study calcium citrate malate (Ricci 1998)259, one study used calcium lactate and 
calcium phosphate (Wagner 2007)268. In one trial (Li 2010)253 it was not specified the salt used. 
All seventeen trials used placebo. However, two trials compared a high and a low dose of calcium 
supplementation, to achieve a lower dose participants in the controlled group received , one with 
calcium and the other one with placebo (Riedt 2005; Riedt 2007). 266,267  
Outcomes 
Eight of seventeen trials explicitly stated a primary outcome in the publication (Asemi 2015; Li 
2010; Menon 2009; Palacios 2009; Shalileh 2010, Shapses 2004; Wang 2009; Yanovski 
2009)252–254,257,258,260,262,265. Most commonly defined primary outcomes in publications were body 
weight and fat mass (Li 2010; Menon 2009; Palacios 2009; Shapses 2004; Yanovski 
2009)253,254,257,258,262. 
Only three trials had the protocol registered (Asemi 2015; Tabesh 2015; Yanovski 2009)252,254,264. 
Two trials (Asemi 2015; Yanovski 2009)254,271 were registered before starting recruitment and 
reported primary outcomes stated in the protocol. One trial was registered days after starting 
recruitment and their stated main outcome in the publication is their secondary outcome of their 
published protocol. 
 
Primary outcomes 
 
Fifteen of seventeen trials provided body weight as endpoint measurement (Li 2010; Menon 
2009; Palacios 2009; Ricci 1998; Riedt 2005; Riedt 2007; Shalileh 2010; Shapses 2004; Tabesh 
2015; Wagner 2007; Yanovski 2009; Zemel 2004; Zemel 2009)253–260,262,264,266–268. One trial 
provided BMI that is a secondary outcome in our systematic review (Shidfar 2011)263. None of 
the trials reported health-related quality of life or adverse events as endpoints. 
One study did not report any of the primary outcomes of this review (Wang 2009)265. 
Secondary outcomes 
Three trails reported waist circumference (Asemi 2015; Menon 2009; Tabesh 2015)252,257,264. 
Five trials reported BMI (Asemi 2015; Menon 2009; Shapses 2001; Tabesh 2015; Yanovski 
2009)252,254,257,261,264. 
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None of the trials investigated all-cause mortality, morbidity/complications or socioeconomic 
effects. 
Excluded studies  
After evaluation of the full publication, we excluded 109 full-text articles. The main reasons for 
exclusion were design not being an RCT, a wrong intervention or duration of less than 2 months.  
Risk of bias in included studies 
Each trial was assessed for the following seven domains: (1) random sequence generation, (2) 
allocation concealment, (3) blinding of participants and personnel, (4) blinding of outcome 
assessment, (5) incomplete outcome data, (6) selective reporting and (7) other bias (See Figure 
6.2 and Figure 6.3). 
No studies were judged to have a low risk of bias in all seven domains. One study reported to 
have low risk of bias for six domains (Yanovski 2009)254 and another study reported to have low 
risk of bias for 5 domains (Palacios 2009258). Two studies were judged to have a low risk of bias 
in four domains (Asemi 2015, Li 2010)252,253. One study was judged to have a low risk of bias in 
three domains (Tabesh 2015)264. Four studies were judged to have a low risk of bias in two 
domains (Shidfar 2011, Menon 2009, Shapses 2004, Zemel 2004)257,262,263,270. Two studies were 
judged to have a low risk of bias in one domain: Riedt 2005, Riedt 2007.266,267 Five studies had 
no domain judged as low risk of bias (Ricci 1998, Shalileh 2010, Shapses 2001, Wagner 2007, 
Zemel 2009)256,259–261,268. 
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Figure 6.2: Risk of bias summary: review authors' judgements about each risk of bias item for each included study. 
 
 
 
For Palacios 2009, much information was gathered from correspondence with the author.258 
For the following domains, the studies were assessed both on a study level and an endpoint level 
(primary outcome) individually: blinding of participants and personnel, blinding of outcome 
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assessment and incomplete outcome data. Wang 2009 was only assessed on study level, as it did 
not report any primary or secondary outcomes for this review.265 The rest of the sixteen studies 
were assessed for the primary outcome, body weight. The following five studies Asemi 2015; 
Menon 2009; Shapses 2001; Tabesh 2015; Yanovski 2009 were assessed for the outcome BMI 
(secondary outcome: anthropometric measures other than body weight for this 
review).252,254,257,261,264 
Allocation (selection bias)  
The following six studies were judged to have a low risk of selection bias by adequately 
describing the generation of random sequence: Asemi 2015, Li 2010, Shapses 2004, Shidfar 
2011, Wang 2009; Yanovski 2009.252–254,262,263,265 The following eleven studies were judged to 
have an unclear risk of bias due to insufficient information: Menon 2009, Palacios 2009, Ricci 
1998, Riedt 2005, Riedt 2007, Shalileh 2010, Shapses 2001, Tabesh 2015, Wagner 2007, Zemel 
2004 and Zemel 2009.189,256–261,264,266–268 
Blinding (performance bias and detection bias)  
Only four of seventeen trials reported being double-blinded for participants and personnel (Li 
2010, Palacios 2009, Tabesh 2015, Yanovski 2009)253,254,258,264. Only two of seventeen trials 
(Palacios 2009, Yanovski 2009)254,258 reported blinding for outcome assessors. 
Incomplete outcome data (attrition bias)  
Percentage of attrition rates (range) are described in all trials with losses to follow-up; three of 
seventeen trials reported intention-to-treat analysis (Asemi 2015; Yanovski 2009; Zemel 
2009)252,254,256, one of seventeen trials had no loss to follow-up (Menon 2009257). Seven of 
seventeen trials (Asemi 2015; Li 2010; Palacios 2009; Ricci 1998; Riedt 2007; Shalileh 2010; 
Shidfar 2011)252,253,258–260,263,267 had loss to follow-up and a detailed description of reasons for 
participants' withdrawals. 
 
Ten of seventeen trials (Palacios 2009; Ricci 1998; Riedt 2005; Riedt 2007; Shalileh 2010; 
Shapses 2001; Shapses 2004; Wagner 2007; Zemel 2004; Zemel 2009)255,256,258–262,266–268 had 
attrition rates with possible impact on body weight and BMI outcomes, specially Ricci 1998; 
Riedt 2005 that excluded women of the analysis for not losing weight.259,266 
Selective reporting (reporting bias)  
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Only three trials had the protocol registered (Asemi 2015; Tabesh 2015; Yanovski 2009)252,254,264. 
Two trials (Asemi 2015; Yanovski 2009)252,254 were registered before staring recruitment and 
reported primary outcomes stated in the protocol. One trial was registered days after starting 
recruitment and the stated main outcome in the publication the secondary outcome of the 
published protocol. 
Other potential sources of bias  
Three studies reported that baseline characteristics including anthropometric measurements and 
gender were different between allocation groups (Shalileh 2010; Shapses 2004; Wagner 
2007)260,262,268 and three studies did not report this baseline measurements for which they were 
classified as unclear risk (Ricci 1998; Shapses 2001; Zemel 2009)256,259,261.  
Figure 6.3: Risk of bias graph: review authors' judgements about each risk of bias item presented as 
percentages across all included studies 
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Table 6.3: Checklist to aid consistency and reproducibility of GRADE assessments 
 
Body weight 
Trial limitations 
(risk of bias)a 
Was random sequence generation used (i.e. no potential for selection bias)? Unclear 
Was allocation concealment used (i.e. no potential for selection bias)? Unclear 
Was there blinding of participants and personnel (i.e. no potential for performance bias) 
or outcome not likely to be influenced by lack of blinding? 
Unclear 
Was there blinding of outcome assessment (i.e. no potential for detection bias) or was 
outcome measurement not likely to be influenced by lack of blinding? 
Unclear 
Was an objective outcome used? Yes 
Were more than 80% of participants enrolled in trials included in the analysis (i.e. no 
potential reporting bias)?e 
No (↓) 
Were data reported consistently for the outcome of interest (i.e. no potential selective 
reporting)? 
Yes 
No other biases reported (i.e. no potential of other bias)? No (↓) 
Did the trials end up as scheduled (i.e. not stopped early)? Yes 
Inconsistencyb Point estimates did not vary widely? Yes 
To what extent did confidence intervals overlap (substantial: all confidence intervals 
overlap at least one of the included studies point estimate; 
some: confidence intervals overlap but not all overlap at least one point estimate; no: at 
least one outlier: where the confidence interval of some 
of the studies do not overlap with those of most included studies)? 
Substantial  
Was the direction of effect consistent? Yes 
What was the magnitude of statistical heterogeneity (as measured by I²) - low (I²<40%), 
moderate (I² 40%-60%), high I²>60%)? 
Low 
Was the test for heterogeneity statistically significant (0.1)? No 
Indirectness Were the populations in included studies applicable to the decision context? Yes 
Were the interventions in the included studies applicable to the decision context? Yes 
Was the included outcome not a surrogate outcome? Yes 
Was the outcome timeframe sufficient? Sufficient 
Were the conclusions based on direct comparisons? Yes 
Imprecisionc Was the confidence interval for the pooled estimate not consistent with benefit and harm? Yes 
What is the magnitude of the median sample size (high: 300 participants, intermediate: 
100-300 participants, low: <100 participants)?e 
Low (↓) 
What was the magnitude of the number of included studies (large: >10 studies, moderate: 
5-10 studies, small: <5 studies)?e 
Large 
Was the outcome a common event (e.g. occurs more than 1/100)? N/A 
Publication biasd Was a comprehensive search conducted? Yes 
Was grey literature searched? No (↓) 
Were no restrictions applied to study selection on the basis of language? Yes 
There was no industry influence on studies included in the review? Yes 
There was no evidence of funnel plot asymmetry? Yes 
There was no discrepancy in findings between published and unpublished trials? Yes 
a Questions on risk of bias are answered in relation to the majority of the aggregated evidence in the meta-analysis rather than to individual 
trials 
b Questions on inconsistency are primarily based on visual assessment of forest plots and the statistical quantification of heterogeneity based on 
I² 
c When judging the width of the confidence interval it is recommended to use a clinical decision threshold to assess whether the imprecision is 
clinically meaningful 
d Questions address comprehensiveness of the search strategy, industry influence, funnel plot asymmetry and discrepancies between published 
and unpublished trials 
e Depends on the context of the systematic review area 
(↓): key item for potential downgrading the quality of the evidence (GRADE) as shown in the footnotes of the 'Summary of findings' table(s); 
GRADE: Grading of Recommendations Assessment, Development and Evaluation; N/A: not applicable 
 
The quality of the evidence is Moderate as shown analysed by the GRADE methodology and 
shown in the Summary of findings table (Table 6.4). There was a downgrade as one of the four 
points, quality for methodological limitations, was unclear for some items in several studies 
(Figure 6.2 and 6.3). However the results of the meta-analysis were consistent, the confidence 
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intervals were precise, the body weight and BMI outcomes were directly measured and there was 
no evidence of publication bias (Figure 6.4 to Figure 6.13). 
Table 6.4: Summary of findings table 
Outcomes Relative effect 
(95% CI) 
No of 
participants 
(trials) 
Quality of 
the 
evidence 
(GRADE) 
 
Assumed risk Corresponding risk 
Control Calcium 
Body weight (kg) 
Follow-up: 8 weeks 
to 24 months 
The mean body 
weight change 
ranged across control 
groups from -8.8 to 
7.0 kg 
The mean body weight 
change ranged across 
intervention groups 
from -9.0 to 5.5 kg 
MD -0.33 kg in 
the intervention 
group; 95% 
CI -0.57 to -0.09 
705 (11) ⊕⊕⊕⊝1 
Moderate 
 
 
Health-related 
quality of life 
No trials reported health-related quality of life 
Adverse events One trial reported 
foot surgery in a 
participant who 
received placebo. 254 
One trial reported "2 
women that withdrew 
the study for health 
problems.252  
3 women discontinued 
the study "2 for 
constipation and one 
for cancer".262  
  
⊕⊝⊝⊝ 
very low  
All-cause 
mortality 
No trials reported all-cause mortality 
Morbidity No trials reported morbidity 
Socioeconomic 
effects  
No trials reported socioeconomic effects 
The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group 
and the relative effect of the intervention (and its 95% CI). 
CI: confidence interval; MD: mean difference; RR: risk ratio; BMI: body mass index 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect 
and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect 
and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
1 Downgraded due to serious methodological limitations as most risk of bias domains were uncertain. 
Effects of interventions 
The summary of the results are presented in Table 6.4: Summary of findings and Table 6.3 
consistency and reproducibility of GRADE assessments. 
Primary outcomes 
Body weight 
Fifteen trials (Asemi 2015; Li 2010; Menon 2009; Palacios 2009; Ricci 1998; Riedt 2005; Riedt 
2007; Shalileh 2010; Shapses 2001; Shapses 2004; Tabesh 2015; Wagner 2007; Yanovski 2009; 
Zemel 2004; Zemel 2009)189,252–254,256,257,259–262,264,266–268 provided data for body weight. 
 
 
120 
 
  
Including all studies in a random-effects meta-analyses, calcium supplementation compared to 
placebo reduces body weight (Mean Difference (MD) -0.33 kg, 95% CI -0.57 to -0.09); (p < 
0.007) with no considerable heterogeneity detected between the studies; I2 = 10%; 819 
participants; 15 studies) (Figure 6.4).  
Figure 6.4: Oral calcium supplementation versus placebo: Primary Outcome: Body weight in kg. Random 
effect 
 
We found no studies assessing beverage fortification versus placebo or beverage fortification 
versus non-calcium fortified food. 
Health-related quality of life 
None of the included trials reported health related quality of life. 
Adverse events 
None of the included trials reported adverse events. 
Secondary outcomes 
Anthropometric measures other than body weight 
BMI 
Nine trials (Asemi 2015; Menon 2009; Palacios 2009; Ricci 1998; Shapses 2001; Shapses 2004; 
Shidfar 2011; Tabesh 2015; Yanovski 2009)252,254,257–259,261–264 provided data for BMI. Including 
all studies in a random-effects meta-analyses, calcium supplementation compared to placebo 
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reduces BMI (MD -0.17, 95% CI -0.21 to -0.13); p < 0.00001 with no heterogeneity detected 
between the studies; I² = 0%; 695 participants; 10 studies).  
Figure 6.6: Oral calcium supplementation versus placebo: Outcome: Body Mass Index (BMI). Random effect 
 
All-cause mortality 
None of the included trials reported this outcome. 
Morbidity 
None of the included trials reported this outcome. 
Socioeconomic effects 
None of the included trials reported this outcome. 
Calcium food or beverage fortification versus placebo 
We did not include any study measuring food or beverage fortification vs placebo. 
Calcium food or beverage fortification versus non-calcium fortified food or beverage 
We did not include any study measuring food or beverage fortification vs none-fortified food or 
beverage. 
Subgroup analyses 
We did not perform pregnancy status or age subgroup analyses because there were not enough 
studies to estimate effects. 
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• Gender: Nine trials included only women (Asemi 2015; Li 2010; Menon 2009; Ricci 
1998; Riedt 2005; Riedt 2007; Shapses 2001; Shapses 2004; Wagner 
2007252,253,257,259,261,262,266–268), six trials included men and women (Palacios 2009; 
Shalileh 2010; Tabesh 2015; Yanovski 2009; Zemel 2004; Zemel 2009254–256,258,260,264) 
and one included only men, however the study only reported BMI (Shidfar 2011263). The 
studies including men and women showed a reduction of calcium supplementation 
compared to placebo in body weight of (MD -0.43 kg, 95% CI -0.54 to -0.33), however 
the evidence including only women was no strong (MD -0.25 kg, 95% CI -0.74 to 0.25). 
Figure 6.7: Oral calcium supplementation versus placebo: Outcome: Body weight by gender. Random effect 
 
 
• Menopausal status: pre- and post-menopausal women. Eleven trials included only 
women; three were specifically in premenopausal women (Riedt 2007; Shapses 2001; 
Wagner 2007)261,267,268 two were specifically about postmenopausal women (Ricci 
1998; Riedt 2005)259,266; one in pre and postmenopausal women (Shapses 2004)262 
and the remaining four did not specify (Asemi 2015; Li 2010; Menon 2009; Palacios 
2009)253,257,258,271. The meta-analysis of only those studies reporting post-menopausal 
status shows no effect of calcium supplementation on body weight (MD 0.26, 95% 
CI -1.07 to 1.59) p = 0.70, nor if these studies are analysed by pre-menopausal women 
(MD -0.28, 95% CI -1.57 to 1.00) p = 0.66). 
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Figure 6.8: Oral calcium supplementation versus placebo: Outcome: Body weight by menopausal status 
 
• Basal BMI: Three trials included only overweight participants (Riedt 2005; Riedt 2007; 
Shidfar 2011)263,266,267 and four trials only included obese participants; (Palacios 2009; Li 
2010; Shapses 2001; Zemel 2004)253,255,258,261. Nine trails included participants that were 
overweight or obese (Asemi 2015; Menon 2009; Ricci 1998; Shapses 2004; Wagner 
2007; Shalileh 2010; Tabesh 2015; Yanovski 2009; Zemel 
2009)252,254,256,257,259,260,262,264,268. There is no effect of calcium supplementation in the 
meta-analysis of those trials including only overweight (MD 0.03, 95% CI -2.32 to 2.38) 
p = 0.98 or obese subjects (MD -1.35, 95% CI -4.20 to 1.50) p = 0.35. 
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Figure 6.9: Oral calcium supplementation versus placebo: Outcome: Body weight by BMI status 
 
• Calcium supplementation: low dose ≤ 500 mg, moderate dose 500 to 1000 mg, high dose 
≥ 1000 mg (Figure 6.10). Most frequent dose was 1 gram/day that was used in eight out 
of sixteen studies (Asemi 2015; Ricci 1998; Riedt 2005; Riedt 2007; Shalileh 2010; 
Shapses 2001; Shapses 2004; Tabesh 2015)252,259–262,264,266,267. Two studies used higher 
doses, one 1.25 grams/day (Shidfar 2011)263 and one 1.5 grams/day (Yanovski 2009)254. 
Two trials used 0.8 grams/day (Wagner 2007; Zemel 2004)268,270; one 0.9 grams/day 
(Zemel 2009)256 and one 0.6 grams/day (Palacios 2009258). Two studies used doses less 
than 0.5 grams/day; Menon 2009 257 used 0.4 and Li 2010 253 used 0.162 grams a day. 
Those studies with doses of more than 500 mg a day showed a statistical significant 
evidence favouring calcium supplementation as compared to placebo (MD -0.35 kg, 95% 
CI -0.54 to -0.16); p = 0.0003 and those studies with doses of 500 mg a day or less showed 
a no statistically significant effect in the same direction (MD -2.05 kg, 95% CI -4.36 to 
0.26); p = 0.08. 
 
 
125 
 
  
Figure 6.10: Oral calcium supplementation versus placebo: Outcome: Body weight by intervention dose 
 
• Type of co-intervention: A subgroup analysis, as specified in the protocol for this review, 
was conducted to assess the effect that the presence or absence of a co-intervention may 
have on weight loss. Four trials did not have a co-intervention (Asemi 2015; Li 2010; 
Palacios 2009; Yanovski 2009)252–254,258, and eleven studies had a co-intervention for both 
the calcium and placebo groups. Only one had as co-intervention vitamin D and therefore 
excluded from this subgroup meta-analysis. Studies without co-intervention or with co-
intervention showed a no statistically significant effect favouring calcium. The mean 
difference for those without co-intervention was MD -0.29, (95% CI -1.42 to 0.84); p= 
0.62 with moderate heterogeneity I² = 36% and for those with energy restriction or diet 
counselling was MD -0.17, (95% CI -0.55 to 0.21); p= 0.38; with no heterogeneity I² = 
0%. There was no difference in the effect of calcium in body weight according to the 
presence or absence of co-intervention. 
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Figure 6.11: Oral calcium supplementation versus placebo: Outcome: Body weight by type of co-intervention 
 
Sensitivity analyses 
We performed sensitivity analyses for the following factors: 
• Publication status: all trials were published 
• Very long or large trials to establish the extent to which they dominate the results. There 
was a significant effect in the short duration trials of less than 6 months (MD -0.43 kg, 
95% CI -0.54 to -0.33; p < 0.000) with no considerable heterogeneity detected between 
the studies (I2 = 0%; 9 studies) that was not seen in those lasting 6 months or more 
(MD -0.21 kg, 95% CI -0.85 to 0.43; p = 0.53) with higher heterogeneity detected 
between the studies (I2 = 25%; 6 studies). However there was only one very long trial 
lasting 24 month that did not find an effect of calcium supplementation compared to 
placebo on body weight (difference, 0.02 kg [95% CI, -1.64 to 1.69 kg]; p = 0.98), the 
rest of studies included had a duration of 6 months or less. 
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Figure 6.12: Oral calcium supplementation versus placebo: Outcome: Body weight by study duration 
 
• There were two large trials with a 100 participants or more (Shapses 2001; Yanovski 
2009)254,261 that provided a no statistically significant effect (MD -0.16 kg, 95% CI -1.27; 
p = 0.78) with no heterogeneity detected between the studies (I2 = 0%; 2 studies), whereas 
those with less than a 100 participants provided a marginal effect (MD -0.31 kg, 95% 
CI -0.61, -0.00; p = 0.05) with no considerable heterogeneity detected between the studies 
(I2 = 18%; 13 studies). 
Assessment of reporting bias 
As there were more than 10 trials included we performed the funnel plot and found no evidence 
of publication bias. 
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Figure 6.13: Funnel plot of comparison: Oral calcium supplementation versus placebo, outcome: Body weight 
(kg) 
 
 
Ongoing trials 
We found eight ongoing RCTs. All had a parallel design. The estimated sample sizes were 10 to 
400 participants. Six studies use a supplement dose of 1000 mg of calcium or more 272–277, one 
study uses enriched foods with calcium without stating the amount of calcium 278 and one a dose 
of 700 mg a day 279. 
The primary outcomes in these studies are body weight or body mass index for five studies 273,276–
279; fat oxidation or lipid metabolism in one study 275, insulin resistance in one study 274 and blood 
pressure in one study 272. Three trials did not report recruitment status 272–274 and five 275–279 have 
completed recruitment. 
6.5. Discussion 
The systematic review included seventeen studies of which fifteen provided data for the primary 
outcome body weight. Body weight was reduced with the intervention of calcium 
supplementation compared to placebo (Mean Difference (MD) -0.33 kg, 95% CI -0.57 to -0.09); 
(p=0.007); 819 participants; 15 studies). The BMI was also reduced with calcium 
supplementation compared to placebo (MD -0.17, 95% CI -0.21 to -0.13); p < 0.00001; 695 
participants; 10 studies).  
 
The random effect model is recommended to be used in those meta-analysis where the objective, 
as it was in our study, is to show an effect that is extended to other population groups beyond the 
ones included in the meta-analysis. The random model is generalizable as it assumes the effect 
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might vary according to different population groups, it assumes the effect of the included studies 
in the meta-analysis and some hypothetical variation.280 The random effect size is a summary of 
different effect sizes. The random effect size is a summary of different effect sizes. On the other 
hand, the fixed effect model assumes that there is only one effect size, independent of the 
population group, and the difference in the included studies is only due to errors in estimating 
the true effect size.245  
However if the number of included studies is very small the heterogeneity might not be detected 
correctly.281 
All included trials used placebo as comparator, there were no articles measuring food or beverage 
fortification. None of the included articles reported primary outcomes health-related quality of 
life or adverse events or secondary outcomes waist circumference, all-cause mortality, morbidity 
or socioeconomic effects. 
 
Most studies were performed in the USA (n= 879), where it is known that the dietary calcium 
intakes are higher and close to recommendations.107 There were seven studies with 369 
participants performed outside the USA, four of which were in Iran. All trials were performed in 
adult population and most were performed in women, only one trial was performed in men. There 
were no studies including children, pregnant women or older adults. 
 
There was an unclear risk of bias, only four studies reported blinding for participants and 
personnel. Most studies had unclear risk in selection, performance and reporting bias. Ten trials 
had low attrition rates with possible impact on body weight and BMI outcomes.  
 
All the subgroup analysis performed per protocol showed results in favour of calcium 
supplementation compared to placebo in the reduction of body weight. However in some 
subgroups such as those studies including men and women, overweight and obese participants 
combined or with an intervention of more than 500 mg of elemental calcium the evidence was 
stronger. On the other hand, there was no statistically significant effect on subgroups such as 
trials with co-intervention or without co-interventions and those with a duration of 6 months or 
more. Finally, there were no enough studies to truly show if there was an effect on subgroups 
such as pre-menopausal or post-menopausal women, doses of 500 mg or less and those with 100 
participants or more. 
 
 
 
130 
 
  
There is a moderate evidence of calcium supplementation compared to placebo in the reduction 
of body weight shown by the GRADE assessment as the results of the meta-analysis were 
consistent, the confidence interval were precise, body weight was directly measured and there 
was no evidence of publication bias. 
 
6.6. Conclusion 
There is a moderate evidence of the effect of calcium supplementation as compared to placebo 
in the reduction of body weight as shown by the random effect meta-analysis (MD -0.33 kg, 95% 
CI -0.57 to -0.09); (p=0.007); 819 participants; 15 studies) with no considerable heterogeneity 
detected between the studies; (I2 = 10%; 819 participants; 15 studies). 
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Chapter 7 - Integrated discussion, conclusions and recommendations 
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7.1. Integrated discussion  
 
The prevalence of overweight and obesity is increasing worldwide in different age groups.33–35 
According to the WHO, the prevalence of obesity doubled between 1980 and 2008 and it is 
increasing more rapidly in LMICs.36 In LMICs, obesity prevalence is higher in women than in 
men for whom the impact of obesity is more deleterious.51 In South Africa and Zimbabwe the 
prevalence of overweight and obesity in women doubles that of men.42,45–47 
Nutritional status and dietary intake before and during pregnancy, and weight gain during 
pregnancy are the main factors influencing pregnancy outcomes and early child health. Being 
overweight or obese at the beginning of pregnancy increases the risk of developing complications 
such as pre-eclampsia, gestational diabetes mellitus, gestational hypertension, depression, foetal 
macrosomia, stillbirth, preterm birth, birth by caesarean section and infant mortality.8–13 
Excessive weight gain during pregnancy and failure to return to pre-pregnancy body weight have 
also consequences later in life, as it increases the risk of obesity and cardiovascular disease.14 
Optimal weight management before and during pregnancy is thus of utmost importance for 
optimal health of the mother and offspring. Although numerous weight loss treatment options 
exist, the multifactorial causes of obesity can only be addressed with a broad approach and it is 
likely that strategies at population level are necessary to curb the current trends in obesity 
prevalence. 
A systematic review in 2011 showed that calcium supplementation may play a role in weight 
management, however the studies included had a short intervention period of around 6 months 
and the effect during pregnancy was not assessed. 25 Although the effect found was small, at a 
population level it could help to prevent the observed global trends in obesity. 26 More recent 
studies have emerged lately and warranted new meta-analyses including different age population 
group and in different life stages. Furthermore, it has also been reported that calcium intake of 
women from LMICs is low.107 However, there are limited number of studies from African 
countries reporting dietary intake of the population.  
This PhD thesis therefore aims to evaluate the effect of calcium intake on body weight and to 
investigate the pre-pregnancy weight status, weight gain during pregnancy and adequacy of 
dietary intake of pregnant women participating in the randomised placebo controlled Calcium 
and Pre-eclampsia (CAP) trial. The thesis involved an intervention study to evaluate the effect 
of calcium supplementation before and during pregnancy, a systematic review of randomised 
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control trials evaluating the effect of calcium supplementation on body weight of different age 
population groups and in different life stages and a descriptive study to assess nutritional status 
before and during pregnancy and dietary intake of women at mid-pregnancy. 
 
Results of aim 1 
The results of the CAP trial showed that supplementation with 500 mg of elemental calcium from 
before pregnancy until 20 weeks´ gestation as compared to placebo had no effect on weight 
change of non-pregnant or pregnant women who had history of pre-eclampsia. Although the 
calcium group had a smaller increase in body weight than the placebo group at week 8 (1.1 kg 
(SD ± 5.5) vs 1.5 kg (SD ± 6.1)), at week 20 (3.9 kg (SD ±6.0) vs 4.0 kg (SD ±7.0)) and at week 
32 (7.7 kg (SD ±6.6) vs 8.3 kg (SD ±7.3)) gestation, none of these differences were statistically 
significant. In obese women those receiving calcium supplementation had a smaller increase in 
body weight than those who received placebo, however this smaller increase was not statistically 
significant. In this trial all women received 1500 mg of elemental calcium from 20 weeks´ 
gestation until the end of pregnancy as recommended by the WHO. 
At 20 weeks´ gestation women randomised to receive calcium supplements or placebo had 
similar energy and calcium intakes. Women of different age or parity had, at 20 weeks´ gestation, 
similar energy intake, however calcium intakes were lower in older pregnant women. These 
results disregard some postulated mechanisms related to a decrease in appetite and thus energy 
intake in women consuming calcium supplements. 
The results of the CAP trial also showed no difference on the infant´s birth weight between those 
infants born to mothers randomised to calcium 2670 grams (SD ±1021) and those to placebo 
2686 grams (SD ±846) (p=0.897). The lack of differences between the birthweight of infants 
born to mothers that received calcium supplementation and those that received placebo before 
and in the first half of pregnancy discards any concern about the effect of calcium 
supplementation on birthweight. 
This is the first study assessing the effect of calcium supplementation before and during 
pregnancy. The results are robust as they are from a randomised controlled trial that followed 
women from before conception until the end of pregnancy. Even though there was no statistically 
significant effect, the results were all in the same direction, implying consistency and that there 
could be an effect if the study had a larger sample size. Unfortunately, the study had a fixed 
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sample size that was powered to detect a 40% reduction in pre-eclampsia. Before starting the 
analysis, it was known that the sample size of the CAP trial would only detect a body weight 
change of 1.2 kg or higher.  
Furthermore, it is also likely that a higher calcium dose could have had a higher effect as later 
shown in the systematic review that included non-pregnant adults with higher calcium dosages 
of more than 1000 mg. 
The evidence of this study can be included in a systematic review and meta-analysis to increase 
the power, and provide novel insights on the effect of calcium in the body weight of pregnant 
women. 
Results of aim 2 
The prevalence of overweight and obesity found in the CAP trial population is alarming, with 
figures reaching 73.7% in South Africa and 60.2% in Zimbabwe. This together with the 
micronutrient inadequacy at 20 weeks´ pregnancy, show a very poor nutritional status of women 
that are on high risk of pre-eclampsia and have the possibility of falling pregnant again. For the 
most basic micronutrients like iron, calcium, folate and zinc, the percentage of women below 
requirements was above 90%. 
Women with normal BMIs at 8 weeks´ gestation, compared to those with overweight or obese 
BMIs, gained more weight at 32 weeks, which is in accordance to recommendations. However, 
weight was only assessed up to 32 weeks´ gestation and most gestational weight gain occurs after 
20 weeks´ gestation, therefore it was expected that many of these women would exceed the 
Institute of Medicine recommendations for optimal weight gain during pregnancy. Programmes 
and interventions to reduce obesity before pregnancy and controlling weight gain during 
pregnancy would be advisable in view of the findings of this analysis. 
Previous studies have shown that obese populations have micronutrient deficiencies and that 
overweight and obese individuals showed lower blood concentrations of vitamins and minerals 
compared to non-overweight or obese individuals specially vitamin A, E, D, C, zinc, iron, 
selenium and calcium.282 The lower blood concentrations of vitamins and minerals found in 
overweight or obese populations could be due to higher amounts of micronutrients required to 
compensate for the extra tissue metabolism or to lower micronutrient intake.283,284 It has been 
suggested that overweight and obese individuals could have higher micronutrient 
requirements.282,285 Even more, these micronutrient deficiencies may be impairing weight loss, 
as some of these micronutrients are required for lipid metabolism.192,286–288 In this way, the 
 
 
136 
 
  
micronutrient deficiency could be contributing to weight gain and development of metabolic 
problems that, in the case of pregnancy, could also program the foetus to obesity.289,290 The CAP 
trial participants reported a rather low energy intake and overall dietary micronutrient inadequacy 
or the results could possibly be due to underreporting. However we did not measure nutrient 
status to determine nutrient deficiencies suggested in previous studies. It must be borne in mind 
that the dietary reference intake values used to evaluate micronutrient inadequacy are set for 
healthy individuals with a healthy body weight.99 Individuals with one or more diseases may 
have different nutrient requirements. As there are no dietary reference intake values available for 
non-healthy individuals, I used the ones available. The CAP trial participants had history of 
pre-eclampsia and a high prevalence of overweight and obesity so recommendations for this 
special group could be different. 
 
Preconceptional care becomes of extreme importance for this population group in order to 
improve women´s health and that of their children. 
 
Results of aim 3 
The systematic review and meta-analysis of calcium supplementation on body weight indicated 
that there is evidence of the effect of calcium supplementation as compared to placebo in 
reducing body weight as shown by the random effect meta-analysis (MD -0.33 kg, 95% CI -0.57 
to -0.09); (p=0.007); 819 participants; 15 studies) with no considerable heterogeneity detected 
between the studies; (I2 = 10%; 819 participants; 15 studies). There was also a significant effect 
of calcium supplementation compared to placebo in reducing BMI (MD -0.17, 95% CI -0.21 
to -0.13); p < 0.00001; 695 participants; 10 studies). 
The subgroup analysis showed that there was a statistically significant effect when trials of men 
and/or women or trials of overweight and obese participants were combined in the meta–analysis. 
There was a statistically significant effect in those trials with an intervention of more than 500 
mg of elemental calcium. 
 
The evidence was moderate according to the GRADE approach that has four levels of evidence: 
high, moderate, low and very low. The moderate evidence means that although there is evidence 
from randomised control trials and the true effect is likely to be close to the estimated effect, this 
evidence has important methodological limitations.250 
The CAP trial sub-analysis in chapter 4 shows that calcium supplementation compared to placebo 
does not have an effect in reducing 1.2 kg body weight in women with history of pre-eclampsia 
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in the last hospital delivery. However the CAP trial sample size did not provide the power to 
detect smaller effects. On the other hand, the meta-analysis of chapter 6 had the power to detect 
smaller differences as it included pooled data of fifteen trials with 705 participants. The total 
mean difference effect size of calcium supplementation versus placebo observed in the 
meta-analysis was -0.33 kg (95% CI -0.57 to -0.09) and represents an estimate of the true effect. 
Despite the number of studies on calcium supplementation during pregnancy, this thesis reports 
on the first study that investigates the effect calcium supplementation on body weight of pregnant 
women. There were no studies in children or adolescents. These results warrant further 
investigation especially on the effect of calcium supplementation on weight management of 
pregnant women. 
 
The evidence of this systematic review on the effect of calcium supplementation on body weight, 
together with previous evidence of calcium supplementation in decreasing blood pressure, 
pre-eclampsia and cholesterol plus the fact that there is a low calcium intake in many regions of 
the world points to the direction of the need to improve dietary calcium, reach adequate intakes 
and reduce the risk of these prevalent diseases that are part of the metabolic syndrome.23,67,77,107 
 
 
7.2. Final comments of the Thesis 
 
Strengths 
• The data used in this thesis for the first and second aims comes from a well-designed 
randomised controlled trial as shown by the similarity of women randomised to calcium 
or placebo. This reflects that any differences found in outcomes between the two groups 
can be attributed to the intervention. 
• The dietary assessment questionnaires were adapted for this study and the fieldworkers 
were well-trained. I supervised and maintained regular contact with each of them. 
• The systematic review was performed using the Cochrane methodology and in 
communication with the Cochrane Metabolic and Endocrine Disorders Group. 
 
Limitations 
The population of the CAP trial involve women with a history of PE. It is thus possible that the 
nutritional status and dietary intake may be different in women without a history of PE. Women 
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with history of PE, as the CAP trial women, have a higher risk of recurrent PE and of developing 
hypertension later in life.291 Furthermore, it has been shown that, obesity, hypertension and 
endothelial dysfunction are risk factors of PE. In this way, women in the CAP trial might have 
had an increase occurrence of these diseases compared to the general population and therefore 
the physiology of calcium in weight changes may be different. 202,203 
 
The data of the CAP trial had the limitation of a small sample size for the analysis of the effect 
of calcium supplementation on body weight; therefore the analysis was not powered to detect an 
effect smaller than 1.2 kg. Besides the trial was designed to evaluate pre-eclampsia and not to 
evaluate weight, however weight was included in the original protocol and thus provided the 
opportunity to conduct this sub-study. Furthermore, all women independently of the group they 
were allocated to (calcium supplementation or placebo); received calcium supplements with a 
total of 1500 mg per day after 20 weeks´ gestation. This could have dwindled the effect of the 
CAP trial intervention -calcium supplementation with a low dose of 500 mg per day- as both 
groups received calcium supplements at a high dose for almost half of their pregnancy. The same 
constrain was seen in the CAP trial primary and secondary outcomes, where the effect of calcium 
supplementation on pre-eclampsia and blood pressure did not reach statistical significance.170 
 
Data collection for the CAP trial in Argentina started later than in South Africa and Zimbabwe, 
consequently, the final sample of Argentina was very small. In this way, although the data 
collected in Argentina contributed to the main findings in body weight, it was not possible to 
describe the dietary intake of the participants of Argentina separately. 
 
The combined effect of dietary calcium plus calcium supplements on weight change could not 
be determined since dietary intake was only evaluated once at 20 weeks´ gestation while 
supplements were taken from admission to the end of the trial. 
 
7.3. Final conclusions 
 
The results of this thesis show that the majority of women participating in the CAP trial were 
overweight or obese before starting a new pregnancy and additionally these women had 
inadequate intakes of micronutrients during pregnancy. The intake of calcium supplements with 
a dose of 500 mg a day had no significant effect on the body weight of these women before 
pregnancy nor during pregnancy. Although the calcium group had a smaller increase in body 
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weight at weeks 8, 20 and 31 of pregnancy, specifically in the group that started pregnancy 
overweight or obese, these differences were no statistically significant. 
 
The results of the systematic review and meta-analysis are very consistent in showing an effect 
of calcium supplementation in the reduction of body weight and BMI in adults including 
non-pregnant women of fertile age and men. However, there were no studies on children and the 
only study in pregnant women was the one of the CAP trial of this thesis. 
 
7.4. Recommendations 
 
 
The following recommendations were formulated based on the findings of this research: 
• The weight status and dietary intake of women of child bearing age in South Africa and 
Zimbabwe should receive urgent attention. Preconceptional care needs to be put in place 
so as to advise body weight management during the inter-pregnancy interval to prevent 
the adverse effects of overweight and obesity. The health system needs to follow women 
in the postpartum period, especially those that have finalised a high-risk pregnancy so as 
to aid them to control their weight and monitor a healthy diet and improve maternal and 
perinatal outcomes. 
 
• Due to the high proportion of women with inadequate micronutrient intake, there is also 
a need to approach the problem from a public health perspective rather than individually. 
Strategies to increase the consumption of healthy foods such as tax reduction and food 
fortification should be a priority in low and middle-income countries.  
 
• At this stage calcium supplementation for weight management should not be 
recommended for pregnant women. However, further research is necessary in this regard 
as this was the first study to investigate this. 
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• Before making clinical recommendations on the effect of calcium supplementation in 
reducing body weight further studies are needed to assess diversity of doses within 
different population groups and in combination with lifestyle treatment. 
7.5. Recommendations for future research studies 
 
There is a need to further explore the tendency of a lower body weight gain reduction shown in 
pregnant women in this thesis. There is also a need to update the evidence with future studies so 
as to see if the larger effects shown in animal studies can be replicated in humans. The 
recommendations for future research derived from the findings of this thesis are: 
 
• More research is required to explore barriers and facilitators on the acceptability of nutritional 
counselling on healthy eating and physical activity interventions in pre-gestational and 
pregnant women of LMICs. Most of the evidence of interventions such as nutritional 
counselling on healthy eating and physical activity come from HICs and less is known about 
the real effects in LMICs. 126 
 
• There is a need to develop strategies to follow up women to provide nutritional counselling 
on healthy eating after their pregnancy so as to obtain a better health and nutritional status 
before facing a new pregnancy. Information from this thesis shows that even after a high risk 
pregnancy women lose interaction with the health system and start a new pregnancy in poor 
health and nutritional conditions.  
 
• Evidence of the poor nutritional conditions of women in LMICs from one side the epidemic 
of obesity and in the other side the poor intake of micronutrient and minerals implies that 
broad scale interventions should be developed and tested. 
 
 
• Further RCTs that investigate effect of calcium supplementation on weight management of 
pregnant women with larger doses than 500 mg of elemental calcium during pregnancy. 
However, as 1.5 g of elemental calcium is already recommended to pregnant women from 
mid-pregnancy, a new RCT design should contemplate this. Thus a new RCT design should 
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be comparing lower to higher doses. Another option would be testing the effect of a calcium-
fortified food including some measures of nutrient status. 
 
• Further basic and experimental studies in laboratory animals and humans should be 
developed to better understand the mechanisms involved in the relationship between calcium 
intake and weight.  
 
The recommendations for future research derived from the literature of this thesis are: 
 
• Basic and experimental studies to explore if there is a modelling effect of calcium intake 
during pregnancy on the weight of the progeny in short and long-term basis. These studies 
would be a major contribution to assess if maternal diet could have a role on the progeny and 
would derive in strategies to improve maternal diet. 
 
• There is a need to further investigate the role of micronutrients in obesity as inadequate intake 
of micronutrients may impair weight reduction. There is also a need to establish micronutrient 
recommended dietary intake values for obese individuals as the currently available 
recommended dietary intake values are for healthy individuals, and the needs for obese 
individuals might be different. 
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              SCREENING FORM         V2 (01 Nov 2012)  
                             
 
Center number                 Screening number       
 
                            
 
                          N Y 
 
1.  Date of interview:  Day  Month  Year    13. Is she willing to give consent?        
                          1   2  
 
                
NEW 
              
 
                              
 
ELIGIBILITY CRITERIA - Section 1: Unchangeable   14.a. Does she have hypertension now       
 
           N Y   AND urine protein 1+ or more?  1   2  
 
2. Did she have pre-eclampsia          If she has hypertension (ie she is       
 
(high blood pressure and protein 1  2   on antihypersives or her BP is                   
 
in urine during pregnancy)          >140mmHg systolic or >90 mmHg diastolic),   
 
and no term pregnancy          but her urine protein is < 1+, the answer is “No”. 
 
without pre-eclamsia afterwards?                     
 
                If any response (Q9-Q14a) falls in a shaded box, 
 
3. DELETED             she is not eligible at this visit but her status might 
 
                change in future. Arrange a suitable date for a new 
 
                assessment, and go to Q19.          
 
4. Is she pregnant?             If not, continue - she is eligible.       
 
Check pregnancy test if unsure. 1  2                                       
 
                NEW               
 
                       
5. Has she been diagnosed          14.b. Is she on anti-hypertension treatment?    
 
with urinary stones?        1  2   1=No 2=Yes                                      
 
6. Has she been diagnosed 
         
15. Is she eligible? 
            
 
                     
 
with persistent renal disease? 1  2   1=No 2=Yes              
                  
                If "No", end questionnaire.          
 
7. Has she been diagnosed          If "Yes", randomize in ALEA.       
 
with parathyroid disease?     1  2                                           
 
                16. Randomization  Day  Month  Year   
 
8. Does she have a serious medical      date:               
 
condition (e.g. cancer) which would 1  2                                       
 
prevent her from participating in study?      17. Subject number:             
 
Women with HIV may participate.      (generated in ALEA)             
 
If any response (Q1-Q8) falls in a shaded box, she 
  
18. First supplement pack 
         
 
           
 
is not eligible for recruitment. Go to Q15 and    number given:             
 
end questionnaire.             AFTER RANDOMIZATION, GO TO ADMISSION   
 
                FORM and end questionnaire.          
 
ELIGIBILITY CRITERIA - Section 2: Modifiable                   
 
           N Y   19. Date of next  Day  Month  Year   
 
9. Is she in a sexual relationship?      assessment:              
 
           1  2                  
 
                
 
10. Is she using reliable contraception?      Investigator's name:  Investigator's signature:   
 
(pill, injection, IUD or 100% condom) 1  2                   
                     
                  
 
11. Is she younger than 18 years of age?      Date form completed:  Day  Month  Year    
           1  2                  
 
12. Is she already taking calcium 
                        
 
                        
 
supplementation?        1  2   OPEN CLINICA DATA ENTRY SIGN & DATE:                  
 
                1st data entry:             
 
                2nd data entry:             
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                ADMISSION FORM           
V1 (10 Oct 
2011) 
 
                                 
 
Center number        Subject number       Screening number       
 
                                  
 
                   CURRENT VISIT             
 
1. Date of admission: Day Month   Year   14.  a) Do you have any serious health       
 
                      problems?             
 
                      1= No  2= Yes             
 
BASELINE INFORMATION                If "No", go to Q15.          
 
                    b) If "Yes", which of the following does the woman 
 
2. Age: 
                
have? 
                
        (years)                        
 
                      1= No  2= Yes             
 
3. Parity (previous pregnancies >24 weeks):             i. Heart disease       
 
                        ii. Kidney/bladder disease   
 
4. Date of last birth Day Month  Year         iii. Diabetes          
 
 complicated                    iv. Severe headaches   
 
 by pre-eclampsia                    v. Epilepsy/Convulsions   
 
 or eclampsia:     Don't know          vi. Other          
 
                      If "No" in "vi. Other", go to Q15. 
 
PREVIOUS PREGNANCY COMPLICATIONS    c) Specify "Other":        ICD-10 code 
 
(Most recent pregnancy complicated                        .   
 
by eclampsia or pre-eclampsia)                           
 
                  15. Blood pressure:             
 
5. Is previous hospital record available?         a) Systolic:     (mmHg)     
 
 1= No 2= Yes                                  
 
                    b) Diastolic:     (mmHg)     
 
6. Onset of pre-eclampsia:    (weeks)                        
 
 (99 if unknown)              16. Weight (999 if not measured):  (kg)    
 
7. Highest blood pressure (999 if unknown) 
      
17. Height (999 if not measured): 
     
 
         (cm)    
 
 a) Systolic:    (mmHg)                            
 
                  18. First day of last  Day  Month   Year  
 
 b) Diastolic:    (mmHg)          menstrual period:              
 
                                  
 
8. Eclampsia:                             Unsure  
 
 1= No 2= Yes  9= Unsure                           
 
                  19. Urine sample collected:          
 
9. HELLP Syndrome:                1= No 2= Yes             
 
 1= No 2= Yes  9= Unsure                           
 
                  20. Date of next visit:  Day  Month   Year  
 
10. Labour induction or caesarean section (CS):                        
 
 1= No  2= CS   3= Induction                           
 
 4= Both  9= Unsure             REMARKS:                
 
                
 
11. Gestational age at birth:    (weeks)     Investigator's name:  Investigator's signature: 
 
 (completed weeks; 99 if unsure)                           
 
                         
 
12. ICU admission (mother):             Date form completed:  Day  Month   Year  
 
 1= No 2= Yes                                  
 
                                      
 
13. Baby born alive:               OPEN CLINICA DATA ENTRY SIGN & DATE: 
 
 1= No 2= Yes               1st data entry:             
 
                   2nd data entry:             
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              PRE-PREGNANCY VISIT (Every 12 Weeks)       
V1 (10 Oct 
2011) 
 
Center number 
        
Subject number 
     
Screening number 
      
 
                   
 
                               
 
1. PPV form number: 
           
7. Number of antihypertensive medicines 
     
 
                
 
                      being taken: (9 if unsure)          
 
2. Date of visit:   Day Month   Year                       
 
                     8. Blood pressure (999 if not measured)      
 
                      a) Systolic:     (mmHg)     
 
HEALTH VISIT                                   
 
3. a) Does the woman have any serious health      b) Diastolic:     (mmHg)     
 
   problems?                               
 
   1= No   2= Yes            9. First day of last  Day  Month   Year  
 
   If "No", go to Q4.             menstrual period:              
 
 b) If "Yes", which of the following does she have?                      
 
                                    
   1= No   2= Yes                          Unsure   
 
       i. High blood pressure                        
 
       ii. Heart disease         SUPPLEMENTATION             
 
       iii. Kidney/bladder disease                        
 
       iv. Diabetes        10.  a) Old supplement bottle returned?      
 
       v. Severe headaches        1= No 2= Yes             
 
       vi. Epilepsy/Convulsions        If "No", go to Q10d.          
 
       vii. Other                               
 
   If "No" in "vii. Other", go to Q4.    b) Old supplement bottle          
 
 c) Specify "Other":     ICD-10 code      number returned by the woman:      
 
                .                        
 
                      c) Number of tablets returned:      
 
4. Is she pregnant?               Go to Q11.             
 
 1= No   2= Yes                               
 
 If "Yes", go to Q7.             d) If not returned, estimate number of      
 
                                  
 
If "Unsure", please check pregnancy test. 
     
tablets taken since last visit: 
      
           
 
                        (99 if unable to estimate)          
 
5. Is she having regular sexual intercourse?                        
 
 1= No 2= Yes           11. Does she continue in the study?      
 
                      1=No 2=Yes             
 
6. a) Is she using condoms?             If "No", fill in EOS form and end questionnaire. 
 
   1= Never  2= Sometimes  3= Always                      
 
                    12. New supplement bottle number:        
 
 b) Is she using other contraception?                        
 
   1= No            4= IUD  13. Date of next visit  Day  Month   Year  
 
   2= Depot (DMPA or nur-isterate)   5= Other    (in 12 weeks):              
 
   3= Oral contraceptives                               
 
   If "No", go to Q7.            Investigator's name:  Investigator's signature: 
 
                           
 
 c) Is she planning to stop contraception                        
 
   in the future?            Date form completed:  Day  Month   Year  
 
   1= No   2= Yes 9= Unsure                      
 
   If "No" or "Unsure", go to Q7.                            
 
                     OPEN CLINICA DATA ENTRY SIGN & DATE: 
 
 d) When, approximately, does (months)      1st data entry:             
 
   she want to stop contraception?         2nd data entry:             
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        DURING PREGNANCY VISIT ( <8, 8, 20 and 32 weeks)  V1 (10 Oct 2011) 
 
Center number 
       
Subject number 
     
Screening number 
     
 
                 
 
                             
 
                                      
 
Hospital record             6.  Number of antihypertensive medicines   
 
number (9 if not known):               being taken:            
 
                     (9 if unknown)            
 
1. Type of DPV form:                                
 
1= less than 8 weeks      7.  Are you taking routine calcium      
 
2= 8 weeks                   supplementation (apart from trial tablets)? 
 
3= 20 weeks                   1= No 2= Yes            
 
4= 32 weeks                                   
 
             8.  Blood pressure (999 if not measured):   
 
2. Date of visit:   Day Month  Year    a) Systolic:     (mmHg)    
 
                     
b) Diastolic: 
        
 
                         (mmHg)    
 
INFORMATION FROM ANTENATAL CARD SINCE                  
 
LAST TRIAL VISIT      9.  Proteinuria on dipstick:         
 
                     0= 0 2= ++     9= Not done 
 
3. Highest blood pressure (999 if unknown):          1= + 3= +++            
 
a) Systolic      (mmHg)                            
 
            10.  Weight (999 if not measured): (kg)    
 
b) Diastolic      (mmHg)                            
 
            11.  If visit at 8 weeks,  Day Month  Year  
 
4. Highest proteinuria on dipstick: 
         
date of last 
 
             
                     
 
0= 0  2= ++   9= Unknown          normal menstrual            
 
1= +  3= +++                period:           Unsure   
 
          
 
CURRENT VISIT      12.  First ultrasound report (record only once): 
 
                     a) Date:     Day Month  Year  
 
5.  a) Do you have any serious health                           
 
 problems?                                
 
 1= No 2= Yes                           Not done   
 
 If "No", go to Q6.                If "Not done", go to Q13.      
 
b) If "Yes", which of the following does the woman b) Gestational age at time of ultrasound: 
 
                                 
 have?                          weeks   days   
 
 1= No 2= Yes                                
 
    i. High blood pressure    13.  If visit at 8 weeks, best clinical estimate 
 
                                      
    
ii. Heart disease 
         
of gestational age: 
            
                        
 
    iii. Kidney/bladder disease            weeks   days   
 
    vi. Diabetes                           
 
    v. Severe headaches    14.  If visit at 20 weeks, estimated dietary 
 
    
vi. Epilepsy/Convulsions 
         
calcium intake: 
 
            
                        
 
    vii. Other               (9999 if unknown)    (mg/day)      
 
 If "No" in "vii. Other", go to Q6.                           
 
            
15. 
 
If visit at 20 or 32 weeks, urine 
     
 
                  
 
c) Specify "Other": 
              
sample collected: 
            
                         
 
          ICD-10 code 1= No 2= Yes            
  
.  
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         DELIVERY/END OF PREGNANCY FORM  V1 (10 Oct 2011) 
 
                         
 
Center number        Subject number    Screening number      
 
                      
 
Hospital record 
               
b) Reason for induced labour: 
     
 
                    
 
number (9 if not known):              1= Hypertensive disorder      
 
                  2= Other medical condition      
 
INFORMATION FROM ANTENATAL CARD SINCE    3= APH      
 
LAST TRIAL VISIT PLUS HOSPITAL RECORD    4= PROM      
 
                  5= Fetal distress      
 
1. Highest blood pressure (999 if unknown):    6= Other      
 
a) Systolic  (mmHg)          If not "Other", go to Q8a.      
   
c) Specify other reason for induced labor: 
b) Diastolic     (mmHg)           ICD-10 code 
 
                   .  
 
2. Highest proteinuria on dipstick:              
 
0= 0 2= ++   9= Unknown     8.  a) Final mode of delivery:        
 
1= + 3= +++            1= Vaginal        
 
              2= Assisted (vacuum or forceps) 
 
3. Number of antihypertensive medicines      3= Caesarean section before labour 
 
taken: (9 if unsure)           4= Caesarean section in labour 
 
              5= Laparotomy for ectopic pregnancy 
 
4. First ultrasound report (record only once):      6= Medical or surgical procedures for 
 
a) Date:  Day Month   Year   miscarriage or abortion 
 
              7= Other        
 
              If "Vaginal", go to Q9.        
 
       Not done    If "Laparotomy", go to Q16. 
 
If "Not done", go to Q5.              
 
             b) Reason for intervention:  
 
b) Gestational age at time of ultrasound:      1= Hypertensive disorder 
 
   weeks    days    2= Other medical condition 
 
              3= APH        
 
              4= PROM        
 
5. Best clinical estimate of gestational age      5= Fetal distress        
 
at delivery/end of pregnancy:      6= Poor progress of labour 
 
   weeks    days    7= Woman's request        
 
              8= Other        
 
BIRTH OUTCOME           If not "Other", go to Q9. 
 
6. Date of birth, 
     
c) Specify other reason for intervention: 
 
 Day Month   Year  
 
miscarriage or                 ICD-10 code 
 
abortion:                   .  
 
       Unknown            
 
             9. Total number of births:        
 
7.  a) Onset of Labour:          If more than one baby, complete ABO form(s). 
 
1= Spontaneous                   
 
2= Induced          10. Pregnancy outcome:        
 
3= No Labour          1= Live birth 4= Macerated stillbirth 
 
If not "Induced", go to Q8a.     2= Miscarriage 5= Termination of 
 
             3= Fresh stillbirth  pregnancy 
 
             If "Miscarriage", "Fresh/Macerated stillbirth" 
 
             or "Termination", go to Q16. 
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          DELIVERY/END OF PREGNANCY FORM    V1 (10 Oct 2011) 
 
Center number 
      
Subject number 
    
Screening number 
     
 
               
 
                           
 
11. Birthweight: 
     
(g) 
     
21. Cardiac arrest: 
           
 
                     
 
(9999 if not measured)         1= No 2= Yes            
 
12. Apgar score at 5 min: 
                      
 
                      
 
              22. Pre-eclampsia?            
 
13. NICU admission > 24h:         1= No 2= Yes            
 
1= No2= Yes                       
 
              23. Eclampsia?            
 
14.  a) Any baby complications:         1= No 2= Yes            
 
 1= No  2= Yes 3= Died  If "No" in both Q22 and Q23, go to Q37. 
 
 If "No" or "Died", go to Q15.                 
 
               FOR WOMEN WITH PRE-ECLAMPSIA/ECLAMPSIA 
 
b) If "Yes", specify baby complications:                 
 
 
1= No 
 
2= Yes 
      
24. Date of first 
         
       Day  Month  Year  
 
   i. Birth asphyxia         diagnosis of            
 
   ii. Encephalopathy     hypertension:            
 
   iii. Respiratory complications        Not diagnosed or unknown   
 
   iv. IVH                       
 
   v. Sepsis       25. Date of first Day  Month  Year  
 
   vi. NEC         diagnosis of            
 
   vii. Anomalies         pre-eclampsia/            
 
   viii. Other         eclampsia: Not diagnosed or unknown   
   
If "No" in "viii. Other", go to Q15.  
              26. Laboratory urine protein:         
 c) Specify "Other":             (9999 if not done)  a)   (mg/l)     
          ICD-10 code                
            .        b)  (mg/24h)     
                         
15. Baby discharge  Day Month  Year 27. Laboratory urine protein/creatinine  .   
 or death date:              ratio: (9.99 if not done)         
                             
MOTHER OUTCOME          28. Highest Creatinine level:   (µmol/l)     
                 (9999 if not done)           
16. Placental abruption:                         
 1= No 2= Yes          29. Lowest platelet count:     (1000/µl)    
                 (999 if not done)           
17. ICU admission >24h:                         
 1= No 2= Yes          30. a) Highest Urate:   (mmol/l)   .   
                 (99.99 if not done)           
18. Cerebrovascular accident:           If "not done", go to Q31.     
 1= No 2= Yes                         
                 b) Date of  Day  Month  Year 
19. Pulmonary oedema:             urate test:            
 1= No 2= Yes                         
                         Unknown  
20. Ventilation > 24 hours:                       
 1= No 2= Yes                          
 
 
169 
 
  
  
      A65750 - Long Term Calcium Supplementation in Women   DEL 
 
         at High Risk of Pre-Eclampsia   page 3/3 
 
        DELIVERY/END OF PREGNANCY FORM  V1 (10 Oct 2011) 
 
                       
 
Center number      Subject number     Screening number      
 
                      
 
31. Highest ALT: 
   
(U/l) 
                
 
                   
 
 (999 if not done)                      
 
32. Highest AST: 
                
 
   (U/l)                
 
 (999 if not done)                      
 
33. Highest LDH: 
   
(U/l) 
                 
 
                    
 
 (9999 if not done)                   
 
                  
 
34. If eclampsia, number of convulsions:              
 
 (9 if unknown)                      
 
35. HELLP Syndrome: 
                  
 
                  
 
 1= No2= Yes                   
 
36. Use of MgSO4: 
                     
 
                     
 
 1= No  3= Treatment        
 
 2= Prophylaxis  9= Unknown        
 
                 
 
37. a) Any other maternal complications? 
              
 
              
 
 1= No 2= Yes 3= Died        
 
 If "No", go to Q38.                   
 
 If "Died", fill in Serious Adverse        
   
Event form and go to Q38. 
 
b) If "Yes", please specify other maternal 
complications:  
       ICD-10 codes 
 
          .  
 
         
 
          .  
 
38. Mother's discharge 
       
 
Day Month   Year 
 
or death date:           
  
 
Unknown  
 
REMARKS:   
Investigator's name:  Investigator's signature: 
 
Date form completed: 
         
 
Day Month  Year 
 
          
  
 
OPEN CLINICA DATA ENTRY SIGN & DATE:  
1st data entry:   
2nd data entry:  
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               ADVERSE EVENT REPORT          
V1 (10 Oct 
2011) 
 
                                     
 
Center number           Subject number       Screening number       
 
                                      
 
Hospital record 
                
12. Measures taken: 
              
 
                              
 
number (9 if not known):              a) Study drug:               
 
                        1= No change               
 
1. AER report number:                  2= Study drug stopped           
 
                        3= Not applicable               
 
2. Date event first  Day Month   Year                          
 
 notified to                   b) Participation in the study:           
 
 investigator:                     1= Continuing               
 
                       2= Discontinued or released from the study 
 
3. Date of report:  Day Month   Year                          
 
                    13.  a) Was the adverse event related to the     
 
                        study treatment?               
 
4. Description of event:                1= Not related   4= Probably     
 
           ICD-10 codes      2= Unlikely   5= Highly probably 
 
 a)            .         3= Possibly   9= Not assessable 
 
                        If "Not related" or "Unlikely", go to Q14. 
 
 
b) 
                                    
 
            .                           
 
                      b) If "Not assessable", explain:     
 
                                  
5. Date of onset:  Day Month   Year                          
 
                                          
 
6. Date ended: 
             
c) If "Possibly", "Probably" or "Highly 
    
 
   Day Month   Year         
 
                                     
                        Probably", is the adverse event unexpected? 
 
                        
1= No 
 
2= Yes 
               
                                      
 
            Not ended                           
 
                     Report all Unexpected Adverse Events to WHO 
 
7. Duration:     hours    mins      immediately (Dr Ana Pilar Betran,     
 
 (if less than 24 hours)             Tel +41.22.791.4205, Fax +41.22.791.4171,     
 
                    email: betrana@who.int)           
 
8. Frequency:                                       
 
 1= Intermittent 2= Continuous         14. Is the adverse event a Serious     
 
                      Adverse Event?               
 
9. Severity:                   1= No 2= Yes               
 
 1= Mild 2= Moderate   3= Severe    If "Yes", complete SAE form.     
 
                               
 
10. a) Treatment to manage event:          REMARKS:                 
 
  1= No 2= Yes                                  
 
  If "No", go to Q11.                                 
 
                     Please sign, scan and upload form to Open Clinica. 
 
 b) Treatment provided:     ICPM codes   Investigator's name:   Investigator's signature: 
 
             -                             
 
                    
Date form completed: 
            
 
             -         Day  Month  Year  
 
11. Current status or outcome: 
                                 
 
                                 
 
 1= Resolved      4= Sequelae   OPEN CLINICA DATA ENTRY SIGN & DATE: 
 
 2= Partially resolved 5= Death   1st data entry:                 
 
 3= Not yet resolved               2nd data entry:                 
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           SERIOUS ADVERSE EVENT REPORT    V1 (10 Oct 2011) 
 
Center number 
        
Subject number 
     
Screening number 
     
 
                  
 
                              
 
Hospital record 
               
10. Hospitalization (or prolongation of 
     
 
                    
 
number (9 if not known):               hospitalization)         
 
                   1= No 2= Yes         
 
1. SAE report number:                              
 
                 11. Treatment given to manage the event: 
 
2. Date event first  Day Month  Year                ICPM codes 
 
 notified to                            -     
 
 investigator:                                 
 
                                  
 
                             -     
 
3. Date of report:  Day Month  Year                 
 
                 12.  a) Current status or outcome:      
 
                     1= Resolved 4= Sequelae   
 
SUBJECT                    2= Partially resolved 5= Death      
 
                     3= Not yet resolved         
 
4. Weight:         (kg)           If answer is not "Death", go to Q13a. 
 
5. a) Previous intolerance to medication: 
        
b) If "Death", date 
       
 
        Day Month  Year  
 
 
1= No 2= Yes 
 
9 = Unknown 
          
of death: 
 
           
                      
   
If "No" or "Unknown", go to Q6.  
                c) Cause of death:  
 
 b) Specify medication:               ICD-10 codes  
 
          ICPM codes         .   
 
          -                
 
                      .   
 
          -                
 
                d) Autopsy performed:  
 
ADVERSE EVENT              1= No 2= Yes   
 
                
 
6. Description of event:             CASE SUMMARY  
 
         ICD-10 codes             
 
 a)          .   13.  a) Clinical description:  
 
 
b)  
                   
 
         .             
 
                      
 
7. Date of onset:  Day Month   Year             
 
                          
 
           
 
8. Date ended:  Day Month   Year   b) Relevant medical history:  
 
                          
 
                      
 
         Not ended             
 
9. Duration: 
 
hours 
   
mins 
              
 
                  
 
 (if less than 24 hours)                       
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              TELEPHONE FOLLOW UP (6 weeks after delivery)    
V1 (10 Oct 
2011) 
 
                                      
 
Center number           Subject number        Screening number      
 
                                   
 
Hospital record 
                   
b) If "Yes", which of the following does 
 
                   
 
                                     
number (9 if not known):                  the baby have?            
 
                          1=No 2=Yes            
 
1. Date of     Day Month   Year          i. Chest problems      
 
telephone contact:                      ii. Feeding problems   
 
                             iii. Floppy baby      
 
2.  a) Does the mother have any health           iv. Convulsions      
 
  problems?                     v. Other         
 
  1=No 2=Yes  3=Died             If "No" in "v. Other", go to Q4.      
 
  If "No", go to Q3.                                 
 
  If "Died", go to Q2d.              c) Specify "Other":            
 
                                    ICD-10 code 
 
b) If "Yes", which of the following does the woman                   .   
 
  
have? 
 
                                      
                                       
 
  1=No 2=Yes                  Go to Q4.              
 
      i. High blood pressure                         
 
      ii. Heart disease           d) If baby has died:            
 
      
iii. Kidney/bladder disease 
       
i) Date of 
 
         
             Day  Month  Year  
 
      iv. Depression              baby's              
 
      v. CNS disease (e.g. stroke)         death:              
 
      vi. Other                                
 
  If "No" in "vi. Other", go to Q3a.      ii) Specify cause of baby's death: 
 
                                   ICD-10 codes 
 
c) Specify "Other":                               .   
 
               ICD-10 code                      
 
                 .                      .   
 
  Go to Q3a.                  If baby has died, end questionnaire. 
 
d) If mother has died: 
            
4. What feeding method is baby using? 
     
 
                 
 
                             
  i) Date of  Day Month   Year     1= Breastfeeding only         
 
   mother's                  2= Formula feeding only         
 
   death:                    3= Mixed breast and formula feeding      
 
                   
 
  ii) Specify cause of mother's death:   REMARKS:              
 
              ICD-10 codes                     
 
                 .                         
 
                                       
 
                 .                         
 
                       Investigator's name:  Investigator's signature: 
 
                     
 
3.  a) Does the baby have any serious health                         
 
  
problems? 
              
Date form completed: 
         
                Day  Month  Year  
 
  
1=No 2=Yes 
 
3=Died 
                            
 
                               
 
  If "No", go to Q4.                                  
 
  If "Died", go to Q3d.             OPEN CLINICA DATA ENTRY SIGN & DATE: 
 
                       1st data entry:              
 
                       2nd data entry:              
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     ADDITIONAL BIRTH OUTCOME   page 1/1 
 
     (repeat for each baby in addition to first)  V1 (10 Oct 2011) 
 
                   
 
Center number     Subject number     Screening number      
 
                   
 
1. Birth order: 
              
 
              
  
 
2. Pregnancy outcome:   
1= Infant alive  
2= Miscarriage   
3= Fresh stillbirth  
4= Macerated stillbirth   
5= Termination of pregnancy  
If "Miscarriage", "Fresh/Macerated stillbirth",   
or "Termination", end questionnaire.  
 
3. Birthweight: (g)     
 
 (9999 if not measured)      
 
4. Apgar score at 5 min: 
     
 
     
 
5. NICU admission >24h: 
     
 
     
 
 1= No 2= Yes      
 
6. a) Any baby complications: 
     
 
     
 
 1= No 2= Yes 3= Died 
   
If "No" or "Died", go to Q7. 
 
b) If "Yes", describe baby complications:  
1= No 2= Yes   
i. Birth asphyxia  
ii. Encephalopathy  
iii. Respiratory complications  
iv. IVH  
v. Sepsis  
vi. NEC  
vii. Anomalies  
viii. Other  
If "No" in "viii. Other", go to Q7. 
 
 c) Specify "Other":                        
        ICD-10 code               
          .               
                         
 7.  Baby discharge Day Month  Year   Investigator's name:  Investigator's signature: 
 or death date:                        
                          
 REMARKS:            Date form completed: Day Month  Year  
                          
                          
              OPEN CLINICA DATA ENTRY SIGN & DATE: 
              1st data entry:            
              2nd data entry:             
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            END OF STUDY FORM   V1 (10 Oct 2011) 
 
                         
 
Center number         Subject number     Screening number      
 
                     
 
1. Date of end 
                      
 
 Day Month  Year             
 
of study:                       
 
2.  a) Status of subject: 
                     
 
                     
 
1= Completed study with pregnancy                
 
2= Completed study without pregnancy        
 
3= Discontinued while pregnant                
 
4= Discontinued while not pregnant                
 
5= Lost to follow-up                    
  
 
If "Completed study with pregnancy",  
"Completed study without pregnancy"  
or "Lost to follow-up", end questionnaire.  
 
b) If "Discontinued", what is main reason:  
1= Medical reasons  
2= Personal reasons  
 
REMARKS:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Investigator's name:  Investigator's signature: 
 
Date form completed: 
         
 
Day Month  Year 
 
          
  
 
OPEN CLINICA DATA ENTRY SIGN & DATE:  
1st data entry:   
2nd data entry: 
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          A65750 - Long Term Calcium Supplementation in Women         
 
              at High Risk of Pre-Eclampsia        UNV 
 
              UNSCHEDULED VISIT FORM       page 1/1 
 
              (not related to end of pregnancy)       
V1 (10 Oct 
2011) 
 
                                   
 
Center number          Subject number       Screening number      
 
                              
 
Hospital record 
               
10. a) Treatment given at this visit? 
     
 
                    
 
number (9 if not known):               1= No  2= Yes            
 
                      If "No", go to Q11.         
 
1. UNV form number:                b) Specify treatment given:    ICPM codes 
 
                                  -     
 
2. Date of visit:  Day  Month  Year                       
 
                                       
 
                                  -     
 
3. Was this visit scheduled by doctor: 
      
11. a) Is subject hospitalized? 
        
 
              
 
1= No 2= Yes                  1= No  2= Yes            
 
                      If "No", go to Q12.         
 
4.  a) Main reasons for this visit:         b) If "Yes", specify main reasons: ICD-10 codes 
 
 
1= Needs tablets 
                              
                            .   
 
 2= Other                                  
 
 
If "Needs tablets", go to Q12. 
                        
 
                        .   
 
                  
 
b) Specify "Other" reason:   ICD-10 codes   SUPPLEMENTATION            
 
              .     12. a) Old supplement bottle returned?      
 
                       1= No  2= Yes            
 
              .         If "No", go to Q12d.         
 
                     b) Old supplement bottle         
 
5. Blood pressure (999 if not measured):           number returned by the woman:      
 
a) Systolic     (mmHg)           (88888 if routine calcium)         
 
                     c) Number of tablets returned:      
 
b) Diastolic     (mmHg)           Go to Q13.            
 
                     d) If not returned, estimate number of    
 
                                  
6. Proteinuria on dipstick: 
              
tablets taken since last visit: 
      
                   
 
0= 0 1= +   2= ++ 3= +++ 9= Not done      (99 if unable to estimate)         
 
                      
 
7. Date of last  Day  Month  Year   13. Does she continue in the study?      
 
menstrual period:                 1=No 2=Yes            
 
                     If "No", fill in EOS form and end questionnaire. 
 
            Unsure                         
 
8.  a) Is she pregnant?              14. New supplement bottle number:       
 
 1= No  2= Yes             (99999 if not issued; 88888 if routine calcium) 
 
 If "No", go to Q10.                               
 
b) Has ultrasound been done?       15. Date of next trial  Day  Month  Year  
 
 1= No  2= Yes             visit:                
 
 If "No", go to Q9.                               
 
c) Date of  Day  Month  Year     Investigator's name:  Investigator's signature: 
 
 ultrasound:                                   
 
                  
 
d) Gestational age at time            Date form completed:  Day  Month  Year  
 
 of ultrasound:  weeks    days                        
 
         
 
9. Best clinical estimate of gestational        OPEN CLINICA DATA ENTRY SIGN & DATE: 
 
age at this visit:  weeks    days     1st data entry:            
 
                    2nd data entry:            
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